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ABSTRACT OF DISSERATION 
 
 
 
LIPID SIGNALING IN BRAIN AGING AND ALZHEIMER’S DISEASE: 
PHARMACOLOGICALLY TARGETING CHOLESTEROL SYNTHESIS, 
TRANSPORT AND METABOLISM 
 
The role cholesterol plays in the brain has long been underappreciated even though the 
brain contains a disproportionately high percentage of body cholesterol. Recent studies 
have found a link between the dysregulation of lipid metabolism and the risk of acquiring 
Alzheimer’s disease (AD) as well as a predisposition to cognitive decline.  The goal of 
these studies was to elucidate the possible role lipid metabolism plays in pathological and 
normal brain aging by pharmacologically manipulating lipid metabolism and determining 
effects on key hippocampal biomarkers of AD and age-related cognitive decline.  One 
series of experiments used an agonist (TO901317) to the liver X receptor (LXR) in two 
transgenic AD mouse models. Chronic LXR activation reduced AD associated pathology 
and improved cognitive performance in AD mouse models. However, long-term 
potentiation (LTP) was not enhanced and peripheral side effects were observed. In 
another series of experiments the effects of chronically inhibiting cholesterol synthesis on 
cognitive aging in rats was determined.  Animals were treated with either of two 
commonly prescribed statins, simvastatin or atorvastatin.  Simvastatin, the more 
lipophilic statin, increased LTP and reduced the duration of the afterhyperpolarization 
(AHP).  In addition, simvastatin upregulated key genes of the cholesterol synthesis 
pathway in the hippocampus as revealed by microarray analyses, but was associated with 
impaired performance in the Morris Water Maze, a hippocampal dependent task.  
Atorvastatin, a less lipophilic statin, reduced the AHP, but did not affect LTP or cognitive 
performance. Atorvastatin modulated a very different set of genes and reduced brain 
cholesterol more than simvastatin.  These results suggest that manipulation of cholesterol 
metabolism selectively modulates key aspects of AD and brain aging. 
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Chapter One: Introduction 
Rationale 
As the brain ages various changes occur, some of which may increase the 
propensity to develop Alzheimer’s disease (AD).  Further, it is likely that many cellular 
and molecular alterations are in fact shared in both normal and pathological aging, and 
understandably, these alterations correlate with cognitive decline present in both states. 
Recently, focus has been drawn to the role lipids, specifically cholesterol, play in both 
aging and AD. This attention is overdue, given the disproportionate amount of cholesterol 
that is concentrated in the central nervous system.  Given the importance of cholesterol in 
the brain, dysregulation of cholesterol metabolism may be detrimental to normal 
cognitive function and may play a role in the etiology of AD.   
Most of the cholesterol in the brain is concentrated in myelin (Barztokis et al. 
2004), which makes up the white matter.  In both humans and monkeys, there is a 
decrease in white matter as the brain ages, most of this being attributed to a reduction in 
myelin (Peters et al. 2009).  Cholesterol levels also seem to increase in the exofacial layer 
of cellular membranes in mice, which leads to the loss of fluidity (Igbavboa et al., 1996), 
which if occurring in the  synapse may cause a “hardening of the synapse”, therefore 
effecting synaptic communication.  
Whether high or low cholesterol serum levels are detrimental or beneficial to 
brain function is still unclear. Recent epidemiological results suggest that low levels of 
serum cholesterol in the elderly (>65 years of age) is actually a frailty marker, and is 
indicative of increased chances of experiencing cognitive decline (van den Kommer et 
al., 2009).  Yet, high cholesterol at midlife is associated with impaired cognitive function 
several decades later (Solomon et al., 2007; Solomon et al., 2009).  Thus, as with most 
biological processes, either too little or too much is not optimal.  In addition, the studies 
in humans also indicate that progressive changes in cholesterol requirements with age 
may alter brain cholesterol dynamics and homeostasis.  
The first links between cholesterol and AD pathology were observed more than a 
decade ago, when it was observed that non-demented patients with cardiovascular disease 
and hypercholesterolemia, had significantly greater numbers of senile plaques in their 
2 
 
brains, one of the pathological hallmarks of the disease (Sparks et al., 1996). This 
suggested that peripheral cholesterol levels may be having a direct effect on the brain.  In 
fact, high cholesterol diets can induce the formation of greater numbers of senile plaques 
in the brains of rabbits (Sparks et al. 1995). In humans, high peripheral levels of 
cholesterol have been associated with increased risk of AD; conversely, using drugs that 
lower serum cholesterol levels are thought to reduce AD risk (Jick et al., 2000; Wolozin 
et al., 2000; Pappolla et al., 2003; Wolozin et al., 2007).  Similarly,  in mouse models of 
AD, cholesterol-lowering drugs have been shown to reduce AD-associated pathology 
(Refolo et al., 2001; Petanceska et al., 2002). 
Rodent animal models have great utility in studies of brain aging.  Many of the 
same changes occurring in humans are also experienced by aging animals or can be 
modeled through genetic manipulation.  Thus, some common changes believed to 
underlie normal aging include increased inflammation, glial reactivity, and decreased 
mitochondrial function (Norris et al., 2005; Wyss-Coray, 2006; Gibson et al., 2008).  In 
studies of AD, aspects of the pathology are modeled in transgenic mice that are 
engineered to carry those familial mutations that cause amyloidogenesis (Oddo et al., 
2003; Jankowsky et al., 2004). Therefore, many insights can be gleaned from studying 
aging changes in animals, in particular how therapeutic interventions can be used to 
attenuate or ameliorate these alterations in brain function.   
An issue increasingly recognized as being a critical factor in studies of aging is 
determining when the aging process begins to occur.  In rat models, a temporal decline in 
cognition begins at midlife, at approximately 12 months of age, as measured by  
performance in the Morris water maze, a spatial memory paradigm (Blalock et al., 2003). 
This is the same time point in which electrophysiological biomarkers of brain aging also 
begin to emerge (Gant et al., 2006; Lynch et al., 2006).  This reflects cognitive changes 
that occur at approximately the same time in  humans (midlife) as well (Park et al., 2002).  
Microarray studies in rats have revealed alterations in lipid metabolism that 
coincide with cognitive decline at midlife (Rowe et al. 2007, Kadish et al. 2009).  Many 
genes involved in lipid catabolism, cholesterol trafficking and myelinogenesis were 
found to be upregulated.  This coincides with increased staining of SOAT1 within the 
hippocampus of aging animals, indicating upregulation of processes involved in 
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cholesterol esterification and cholesterol storage.  Cholesterol levels within the normal 
brain are tightly controlled and most of this is in the form of free cholesterol (Dietschy 
2009).  Therefore, a shift toward esterification and storage marks a divergence in 
metabolism. 
One interpretation of the age-related change in hippocampal gene expression 
across the lifespan is that it points to a more generalized shift occurring in metabolism as 
the brain ages. Genes involved in lipid and protein catabolism, as well as lysosomal 
activity, are upregulated at midlife, pointing toward an increase in the endocytosis of 
materials from the extracellular space (Kadish et al. 2009).  In addition to these gene 
pathways, a parallel increase in expression of genes involved in immune responses is 
seen (Blalock et al., 2003; McGeer and McGeer, 2004).  Along with the signals for 
increased myelinogenesis, these may act together to degrade and remyelinate axons, a 
process  known to continue throughout aging  (Peters, 2009). The degeneration of myelin 
may result in increased extracellular debris, especially if it is a result of inflammatory 
degradation via activated microglia.  Endocytosis of the myelin debris may cause a shift 
in the brain to utilize more free fatty acids and amino acids as its major fuel source.  
Given the high concentration of cholesterol in myelin, degradation of myelin would also 
lead to an increased uptake of free cholesterol, leading to cellular excess within astrocytes 
of the brain.  This is corroborated by the increase in the cholesterol acyltransferase, 
SOAT, as mentioned above, which esterifies cholesterol thus enabling it for storage 
within vesicles.   Because cholesterol levels in the brain are so finely regulated, any 
excess in levels directly affects cholesterol synthesis, degradation and efflux (Dietschy,  
2009).  
As excess cholesterol accumulates in the cell, turnover increases, and cholesterol 
is catabolized to 24-S-hydroxycholesterol, an endogenous ligand of the liver X receptor 
(LXR).  LXR regulates mechanisms directly involved with the efflux of cholesterol out of 
the cell.  This is accomplished by driving the expression of a number of cholesterol 
trafficking genes including Apoe (Apolipoprotein E) and the transcription factor Srebp 
(sterol regulatory element binding transcription factor), similar to that seen in aging brain 
(Repa et al., 2002; Repa and Mangelsdorf, 2002). The beta isoform of LXR has also been 
found to upregulated in the aging brain (Rowe et al., 2007).  The upregulation of this key 
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regulator of cholesterol efflux as well as genes involved in cholesterol trafficking suggest 
a potential compensatory reaction to excess cholesterol in the cell.   
If these phenomena observed in the aging brain are compensatory in some way, 
pharmacological approaches that could increase cholesterol removal from the cell or 
decrease synthesis may help maintain an appropriate brain cholesterol concentration.  In  
support of this notion are studies showing that potent LXR agonists that drive cholesterol 
efflux from cells reduce Aβ pathologies and improve memory (Koldamova et al. 2007, 
Jiang et al. 2008).     
These observations suggest that cholesterol dysregulation may underlie some of 
the cognitive deficits present as a function of age and AD.  Yet, very little is known about 
cholesterol dysregulation in the brain.  Much of our knowledge about cholesterol’s role in 
AD as well as normal aging is circumstantial in nature and very speculative. Given the 
increasing evidence pointing to cholesterol dysregulation as an important factor, answers 
to the following questions appear to be especially important: Does cholesterol 
dysregulation play a role in AD and brain aging?  Is part of the dysregulation attributed 
to excess cholesterol in the brain?  Is it possible to pharmacologically intervene by 
targeting cholesterol metabolism through increasing cholesterol trafficking or directly 
inhibiting its synthesis? Are the observed brain aging changes compensatory? 
The goal of this dissertation has been to elucidate the role lipid metabolism plays 
in normal and pathological brain aging.  This goal has been driven by two main 
hypotheses: 1). Chronically activating the liver X receptor (LXR), which in turn drives 
the expression of genes involved in cholesterol metabolism, transport, and efflux will 
reduce pathology and cognitive deficits associated with Alzheimer’s disease (AD) as 
modeled in mice, and 2). Chronically inhibiting cholesterol synthesis in mid-aged rats, 
when many signs of  aging begin to appear, will attenuate the appearance of cognitive 
deficits and associated electrophysiological correlates later in life.  
 To test the first hypothesis, a potent LXR agonist was administered chronically to 
two different transgenic AD mouse models, which were then assessed using a 
multidisciplinary approach including memory paradigms, electrophysiological measures, 
brain pathology assessment, and extensive microarray analysis.  To test the second 
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hypothesis, we chronically treated mid-aged Fischer 344 rats with two different HMG-
CoA reductase inhibitors (statins) and used similar techniques as  above. 
 
 The following literature review presents pertinent background information on 
various topics relevant to the work presented as well as justification for why this type of 
research is necessary.  The novel findings presented subsequently have implications in 
both the treatment of AD and the aging population as well, especially in the large part of 
the populace that currently take statins to reduce the risk of heart attack and stroke. 
Cholesterol: Structure and Origin 
Cholesterol is essential for life as it provides integrity to plasma membranes due 
to the rigidity inherent to its molecular structure. Perhaps surprising to most is that 
dietary cholesterol is not essential in order to have adequate amounts within the tissues of 
our bodies.  Every cell has the capacity to make as much cholesterol as it needs and the 
body has various mechanisms to deal with levels that may not be optimal. Yet, 
hypercholesterolemia is still present in a large section of the population.  The CDC 
reports that approximately 20% and 50% of the population have cholesterol levels greater 
than 240mg/dL and 200mg/dL, respectively (www.cdc.gov).  This is attributed to either 
genetic variations leading to an increased synthesis or, the excess intake of lipid-rich 
dietary sources, with dietary factors playing a greater role. It is no surprise then that 
prescribing drugs to treat dyslipidemia is common practice around the world.  
 Cholesterol, as alluded to above, has two distinct origins, endogenous and 
exogenous. The central regulatory organ for both pools is the liver.  Ingested cholesterol, 
as well as triacylglycerols (TAG), are absorbed in the intestine and are shuttled to the 
liver by chylomicrons containing Apolipoprotein B (ApoB), Apolipoprotein E (ApoE), 
and Apolipoprotein C-II.  Upon reaching the plasma, some of the triglycerides associated 
with the chylomicrons are converted to free fatty acids by extracellular lipases.  The 
remaining TAG as well as cholesterol is then delivered to the liver.  Excess lipids are 
either stored or disbursed about the body.  Various mechanisms are in place for the 
transport of both TAGs and cholesterol to extrahepatic tissues. The majority of TAGs are 
shuttled from the liver to peripheral tissues by very low-density lipoproteins (VLDL), 
whereas cholesterol is predominantly shuttled by low-density lipoproteins (LDL). The 
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cholesterol contained within LDL is both free and in the form of cholesteryl esters (CE), 
formed via an action of acyl-CoA-cholesterol acyl transferase (ACAT) that transfers a 
fatty acid onto the cholesterol making it more hydrophobic, and typically less toxic to the 
cell.   
Besides cholesterol and CE, the LDL is also composed of ApoB, which allow for 
their absorption into cells via the large family of LDL receptors (LDLR).  After binding 
to LDLR, the complex is endocytosed and digested by lysosomes within cells and broken 
down into its components, which include amino acids, CE and free cholesterol. 
Cholesterol, specifically, is able to then participate in the regulation of cholesterol 
synthesis pathways in extrahepatic tissues (Goldstein and Brown, 2009). 
 Endogenous cholesterol is synthesized in the liver and in extrahepatic tissues, 
from acetyl Co-A (much like other lipids), yet the structure of cholesterol is quite 
different from other lipids that typically contain long chain fatty acids (Figure 1.1).   
Cholesterol consists of a nucleus of four fused rings that create a relatively planar and, 
thus, rigid structure.  The molecule has a polar moiety at C3, which gives it its 
amphipathic nature. These characteristics make it perfectly suitable to provide structural 
integrity to membranes.   
The cholesterol synthesis pathway (Figure 1.2) is quite complex and involves a 
great many enzymes that produce a whole range of different metabolites that act to 
regulate the pathway itself.  Many of these metabolites act as precursors to a variety of 
other isoprenoid molecules that play important roles in the prenylation of many small G-
proteins.  Cholesterol also plays the role of precursor molecule in that it is further 
processed to produce steroid hormones, essential vitamins as well as bile acids that allow 
for the digestion of dietary lipids.  Figure 1.2 shows some of the major reaction products 
within the cholesterol synthesis pathway including key enzymes involved in their 
catalysis.  
 
A. B. 
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Figure 1.1: Chemical structure of cholesterol and cholesteryl.  A.  Cholesterol is 
composed of four fused rings which make up its non-polar, hydrophobic body. A 
hydroxyl group is bonded to C3 and acts to create a polar head giving the molecule its 
amphipathic nature.  B. Cholesteryl esters have their hydroxyl group replaced by a 
fatty acid making the molecule more hydrophobic and typically less toxic to the cell.  
Figure 1.2: Cholesterol synthesis pathway.  Key molecules within the cholesterol 
synthesis pathway are represented along with several enzymes that produce them.  
Acetyl-CoA is quickly converted to HmG-CoA by HmG-CoA synthase.  The action of 
the next enzyme in the pathway, HmG-CoA reductase, is considered rate-limiting.  
HmG-CoA reductase inhibitors, commonly known as statins, act to inhibit the actions 
of this enzyme, which leads to the subsequent reduction of several reaction products.  
Besides cholesterol, several other essential molecules are created as a result of this 
pathway including the production of isoprenoids from cholesterol precursors.  Finally, 
further cholesterol modification leads to the production of steroid hormones, essential 
vitamins and bile acids.  
 
8 
 
The General Nature of Cholesterol of the Nervous System 
The brain comprises 25% of the body’s total cholesterol pool, but is only 2% of 
the body’s total weight and essentially all the cholesterol that is found in the brain is 
synthesized there (Dietschy and Turley, 2001; Dietschy, 2009).  Brain cholesterol is at a 
concentration of 15-20 g/kg of tissue weight, is mostly unesterified and predominantly 
concentrated within the myelin that serves to insulate neuronal axons and, thus, increase 
the efficiency of their electrical signaling. Unlike in other tissues, brain cholesterol has a 
slow turnover rate, with a flux rate of only 0.9% of that normally seen across the entire 
body, which translates into a half-life of 4-6 months in the rat brain and 6-12 months in a 
human (Dietschy and Turley, 2004; Vance et al., 2005; Vaya and Schipper, 2007).  It is 
important to note that that total flux rates of cholesterol in humans, primates, and rodents 
differ considerably, with rodents having a much higher metabolic rate and thus a faster 
turnover rate of cholesterol.  Given that various animal models are used in the study of 
cognition it is important to consider these differences since the effects of specific drugs 
that modulate or directly inhibit metabolic processes involved in cholesterol synthesis 
and transport may differ given the length and dose of treatment with various animal 
species.  What remains true for all of these mammals is that, considering the rate of 
peripheral cholesterol catabolism, the turnover rate of cholesterol in the brain is still 
disproportionately low (Dietschy and Turley, 2001, 2004).  
As briefly mentioned above, the cholesterol that is incorporated into the plasma 
membranes of neurons and glia is produced de novo within the brain (Dietschy and 
Turley, 2001) and its level is tightly controlled.  Even in models of peripheral nerve 
regeneration, the cholesterol utilized for the regeneration of damaged sciatic nerves is 
synthesized locally.  There is a direct correlation between the rate of cholesterol synthesis 
and the accumulation of cholesterol within the regenerating nerve (Jurevics et al., 1998) 
and this synthesis is independent of dietary cholesterol (Jurevics and Morell, 1994).  
Similar to damaged sciatic nerves, exogenous cholesterol has little to no effect on the 
brain.  Isotopically labeled exogenous cholesterol does not enter the brain during 
development, and the accumulation of sterols during this time closely correlates with 
their synthesis (Jurevics and Morell, 1995).  Levels of myelin basic protein and 
cerebroside also correlate with cholesterol synthesis and accumulation, suggesting a 
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sophisticated level of coordination of mechanisms involved in lipid and protein formation 
during myelination, remeylination and axonal outgrowth.  
Regulation of Brain Cholesterol Levels.  Cholesterol levels in the brain are tightly 
regulated, and even during hypercholesterolemic conditions when plasma cholesterol 
levels are high, brain cholesterol levels are not altered (Edmond et al., 1991), unlike 
peripheral tissues which often display lipid accumulation.  Cholesterol in the periphery is 
typically transported via lipoproteins and is endocytosed by cells upon binding to LDLR.  
There is no strong evidence to support that this type of transport occurs across the blood 
brain barrier. Mice lacking LDLR show no difference in brain cholesterol levels and 
studies in sheep show no detectable uptake of LDL from the periphery to the brain 
(Osono et al., 1995; Turley et al., 1996).  There also seem to be few molecules that are 
rate-limiting and capable of significantly altering cholesterol levels in the brain, apart 
from perhaps a complete inhibition of HMG-CoA reductase.  Various knockout mice 
lacking specific proteins that play vital roles in cholesterol metabolism in the periphery 
(ABCA1, ApoE, ApoA1, LDLR, and SRB1, Cyp46a) show little change in overall 
cholesterol levels within the brain.  However, the absence of certain molecules can lead 
to changes in cholesterol synthesis rates.  For instance, mice lacking the cytochrome p450 
Cyp46a, also known as cholesterol 24-hydroxylase, show a reduction in synthesis.  
Cyp46a is almost exclusively found in the brain and produces the primary metabolite of 
brain cholesterol, 24(S)-hydroxycholesterol (24-OH-Chol), an oxysterol.  Thus, Cyp46a 
is involved directly in cholesterol turnover. Reductions in cholesterol breakdown (e.g., 
with inhibition of Cyp46a) are accompanied by reductions in brain cholesterol synthesis 
(Lund et al., 2003) and, therefore, cholesterol levels are maintained (Quan et al., 2003).  
Together, these findings suggest a series of finely regulated feedback pathways 
controlling overall cholesterol levels in the CNS.  
Interestingly though, mice lacking the Niemann-Pick disease, Type C1 (Npc1) 
gene show significant decreases in CNS cholesterol synthesis as well as overall 
concentrations within tissues. People with Niemann-Pick disease Type C1 have lower 
levels of the protein leading to a decreased ability to process cholesterol as it is 
endocytosed, leading to endosomal accumulation of cholesterol.  NPC1 is associated with 
progressive neurodegeneration ending in adolescent mortality.  Histological examination 
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shows an accumulation of cholesterol and other lipids in late endosomes of peripheral 
tissues (Ikonen and Hölttä-Vuori, 2004), whereas in the brain, cholesterol accumulation is 
absent while demyelination and neuronal death are both observed (Higashi et al., 1993; 
Takikita et al., 2004).  
Removal of Excess Brain Cholesterol.  Yet cholesterol levels can become 
excessive in the brain.  Free cholesterol, if allowed to accumulate, is toxic to cells 
because of its amphipathic nature (Dietschy 2009).  Unlike other tissues, the mechanism 
by which cholesterol is removed in the brain differs somewhat because of the presence of 
the blood brain barrier (BBB).  As briefly discussed above, much of the excess 
cholesterol must first be converted to an oxysterol by Cyp46 before it is able to exit 
through the BBB.  This enzyme is highly expressed in the brain relative to other regions 
of the body with higher levels of expression in the cerebrum and specifically in neurons 
(Dietschy and Turley, 2001; Lund et al., 2003; Xie et al., 2003; Vance et al., 2005).  
Much of  Cyp46’s synthesis occurs early in life during the formation of axons and their 
myelination (Vance et al., 2005).  Given the high level of Cyp46 expression in the brain, 
it would stand to reason that the amount of 24(S)-hydroxycholesterol (24-OH-Chol), the 
oxysterol metabolite of the enzyme’s activity, would be higher in the brain than any other 
tissue of the body.  This is in fact the case with the absolute concentration of this 
metabolite observed to be 3.8-4.8ng/mg in the cerebellum and 8.6-15.1 ng/mg in the 
cerebrum.  This accounts for 80% of the body’s total pool of 24-OH-Chol (Lutjohann et 
al., 1996).  The 24-OH-Chol has a flux rate of 6.4 ±1.8 mg/24hrs across the brain.  This 
mirrors the rate of uptake of this metabolite by the liver at 7.6 mg/24 hours, again 
confirming that production of this particular metabolite takes place predominantly in the 
brain (Bjorkhem et al., 1998).  Cholesterol can also be removed to a much lesser extent 
by apolipoproteins that are transported to the CSF (Pitas et al., 1987b; Pitas et al., 1987a; 
Vaya and Schipper, 2007).  The transport and efflux of cholesterol is discussed further 
below. 
Whereas 24-OH-Chol mostly moves unidirectionally from the brain to the 
plasma, other oxysterols enter into the brain from circulating plasma, perhaps acting as 
signaling molecules from the periphery.  27-OH-Chol is one oxysterol able to flux across 
the BBB from the plasma and is later metabolized to 7α-hydroxyl-3-oxo-4 cholestenoic 
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acid, which is then fluxed back out of the brain (Heverin et al., 2005; Meaney et al., 
2007).   Given that 27-OH-Chol does not remain in the brain, but is in fact metabolized 
for removal may suggest that the brain is able to utilize the molecule to sense peripheral 
levels of oxysterols.  
24-OH-Chol itself plays a vital role in the cholesterol homeostasis of  neurons in 
that high levels of this particular metabolite can actually attenuate the expression of 
enzymes critical in the production of cholesterol by activating the liver x receptor (LXR), 
for which it is a ligand (Wang et al., 2008).  A more detailed discussion of the role of 
LXR will follow, but briefly LXR activation leads to the expression of a whole host of 
genes, involved in reverse cholesterol efflux as well as enzymes that participate in 
various aspects of lipid metabolism.  
Cholesterol Transport in the CNS  
 Most of what is known about cholesterol transport comes from studies in the 
periphery.  As briefly reviewed above, peripheral transport of cholesterol involves the 
movement of cholesterol along with other lipid species within lipoprotein particles like 
high-density lipoproteins (HDL), very low density lipoproteins (VLDL) and low-density 
lipoproteins (LDL) (Goldstein and Brown, 2009).  Various apolipoproteins associate with 
these lipoproteins that carry cholesterol from the GI to peripheral tissues or from 
peripheral tissues to the liver in a process known as reverse cholesterol transport, 
referring to the movement of cholesterol from peripheral tissues to the liver.  These 
lipoprotein/apolipoprotein complexes associate with receptors in the large LDLR family 
allowing for the endocytosis of the lipid molecules in the respective tissue. Cholesterol 
transport in the brain, though not dependent on outside sources, still occurs and utilizes 
similar mechanisms to move cholesterol and other lipids throughout the CNS.  ApoE 
along with ApoA1 are thought to be the major apolipoproteins expressed in the CNS 
(Rebeck et al., 2006) and are contained within HDL-like lipoproteins.  These nascent 
lipoproteins are produced by astrocytes, are discoidal in shape and are generally lipid-
poor when first released from the cell indicating their readiness to collect cholesterol 
from other tissues (LaDu et al., 1998).   
ApoE is the most studied CNS apolipoprotein due to its role in Alzheimer’s 
disease as well as stroke and ischemic events (Poirier, 1996; Horsburgh et al., 1999; 
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McColl et al., 2007). There are three different ApoE isoforms found in the human 
population, differing only in presence or absence of one or two amino acids (ApoE 2: 
Cys-112, 158; ApoE 3: Cys-112, Arg-158; ApoE 4: Arg-112, Arg-158) at specific 
locations (Rebeck et al., 1998).  The CNS highly expresses ApoE and several different 
LDLR family members are found on the surface of both neurons and astrocytes ApoE 
will bind to LDLR, VLDR, low density-related protein (LRP) and apolipoprotein 
receptor 2 (APOER2) (Rebeck et al., 2006). There is evidence that cholesterol may be 
recycled, as well, under conditions of damage by being gathered by apolipoproteins and 
redistributed to cellular membranes. The large number of lipoprotein receptors in the 
brain, most likely allow for a redundancy in the recycling pathway in case of an 
interruption (Dietschy and Turley, 2001), and facilitates scavenging of free cholesterol 
from the intercellular space.   
The HDL-like lipoproteins, secreted from astrocytes, are in a different state from 
those found in the CSF, suggesting that perhaps the HDL-like particles derived from 
astrocytes may act to shuttle cholesterol within the CNS (LaDu et al., 1998; Rebeck et al., 
1998). ApoE is physically associated with astrocytes, especially those below the pia 
mater and along large blood vessels and less so with neurons and microglia (Boyles et al., 
1985). The formation of synapses and neurite outgrowth are promoted by ApoE-
associated cholesterol from surrounding astrocytes (Mauch et al., 2001). The utilization 
of ApoE molecules may help to explain how axons of sympathetic neurons that do not 
synthesize cholesterol themselves, are able to incorporate cholesterol within their 
membranes, especially during periods of elongation (Vance et al., 1994; de Chaves et al., 
1997).   
As indicated above, axonal growth and elongation are dependent on the synthesis 
and the proper transport and allocation of cholesterol. In cultured neurons, blocking 
synthesis via an HMG-CoA reductase inhibitor stopped axonal elongation after only 2.7 
days (Pfrieger, 2003a).  This growth was rescued though with the addition of either 
mevalonic acid or an exogenous source of cholesterol, namely lipidated lipoproteins. But 
neurons in culture are in early stages of development relatively speaking, and mature 
neurons in vivo act much differently and are more intimately associated with surrounding 
glia.  It has been suggested that neurons, in a proposed attempt to conserve energy, 
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outsources cholesterol synthesis to astrocytes (Pfrieger, 2003b).  The amount of 
cholesterol needed later in life is not as great as during development (Bjorkhem and 
Meaney, 2004) at which time a neuron supplies most of its own cholesterol.  As the 
neurons mature, the rate of synthesis drops and the axon terminus would be more 
dependent on cholesterol supplied from neighboring astrocytes (Pfrieger, 2003a).  The 
needed cholesterol would be most likely delivered by apolipoproteins like ApoE.  
Disruption of Cholesterol Synthesis: In the CNS and Periphery 
The rate-limiting step in the production of cholesterol is the enzymatic activity of 
HMG-CoA reductase.  The enzyme is regulated by cholesterol itself, with high levels 
triggering mechanisms that suppress synthesis and reduce cholesterol levels.  The 
feedback is dependent on the products of the mevalonic pathways as opposed to actual 
regulation by cholesterol itself (Kita et al., 1980; Corsini et al., 1995).  These products 
lead to actions resulting in the binding of HMG-CoA reductase to insulting induced gene 
1 (INSIG1) and INSIG2 leading to its degradation, reduction of sterol regulatory 
element-binding protein (SREBP) activity, and revving up LXR activation which in turn 
increases the production of bile acids, the last step in reverse cholesterol transport 
(Goldstein and Brown, 1990; Corsini et al., 1995; Dietschy, 2009).  
Cholesterol synthesis can be pharmacologically inhibited by blocking HMG-CoA 
reductase activity, typically with the use of a class of drugs collectively called statins.  
Statins were originally derived from fungal metabolites that competitively inhibit HMG-
CoA reductase (Endo et al., 1976).  The earliest statins, compactin (mevastatin) and 
mevinolin (lovastatin) have Ki of 10
-9
M, indicating an affinity to the enzyme in the 
nanomolar range, which is 10
4
-10
5
  times greater than the affinity of the endogenous 
substrate (HMG-CoA) which binds at the 30 uM range (Corsini et al., 1995).  The statin 
inhibits the enzyme by mimicking HMG-CoA via its lactone segment and blocking 
enzyme activity by directly binding within the substrate binding pocket (Schachter, 
2005).    
 These early statins were able to lower serum cholesterol levels in a number of 
mammals.  Surprisingly, the statins are unable to reduce serum cholesterol levels in rats 
(Endo, 1988) which should be noted given the data that will be presented below. To 
compensate for the potent inhibition of HMG-CoA reductase, there is a 200 fold increase 
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in reductase protein within a few hours of exposure (Liscum et al., 1983; Goldstein and 
Brown, 1990).  Long-term effects of statins in rodents have not been thoroughly 
elucidated. Statin use increases the expression of LDLR on hepatocytes leading to a 
reduction in circulating LDL levels.  They also increase HDL and decrease triglycerides.    
The original targets for statins were peripheral, in that they were intended to block 
cholesterol synthesis in the liver, which then increases the clearance of LDL from the 
plasma and thus act to help prevent atherosclerosis.  
Given the importance of cholesterol in the brain and the role that statins play in 
reducing synthesis and quantities in the periphery, it is no wonder that there were 
questions to whether statins could in fact get across the BBB and whether or not the 
presence of the compound would confer an effect on the CNS. The effects of specific 
statins on the CNS are potentially dependent on their unique chemical structures which in 
turn determine their relative lipophilicity. Two commonly prescribed statins that are 
taken in two distinct forms are simvastatin and atorvastatin.  The maximal dose for both 
in humans for LDL reduction is 80 mg/day.  Simvastatin is thought to be brain penetrant 
whereas atorvastatin is not (Wood, 1999).  The difference in lipophilicity is due in part to 
the chemical attributes of different functional groups of the respective drugs. Simvastatin, 
a modified version of lovastatin, which is a direct fungal derivative, is delivered in its 
lactone form, whereas atorvastatin, a completely synthetic statin, is delivered in its acid 
form (Hamelin and Turgeon, 1998; Schachter, 2005).  Both are metabolized by Cyp3a4 
and have a rather low bioavailability at 5 and 12%, respectively, when taken orally.  The 
lactone form of simvastatin must first be hydrolyzed into its acid form, before it can 
actively inhibit HMG-CoA reductase, by a non-specific carboxyesterase in a reversible 
reaction (Tubic-Grozdanis et al., 2008).  The lactone form of simvastatin has been found 
in circulating plasma and is three times more lipophilic than its acid form (Hamelin and 
Turgeon, 1998; Schachter, 2005).  Atorvastatin’s bioavailability, already rather low, can 
actually be reduced further when taken with food (Lennernas, 2003). The Cmax (the 
maximum concentration of the drug in plasma after its administration) for Simvastatin 
and Atorvastatin are 10-34 ng/ml and 27-66 ng/ml respectively (Corsini et al., 1999). 
Studies using BBB models utilizing bovine brain capillary endothelial cells 
(BCEC) found that the lactone form of simvastatin and lovastatin are much more 
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permeable then the their acid forms.  Simvastatin had a permeability coefficient of 4.76 in 
the lactone form, whereas it only showed a coefficient of 0.193 in the acid form.   The 
acid form is able to cross the BCEC model though, and appeared to do so in a passive 
from, most likely via a monocarboxylic acid carrier that requires no energy (Tsuji et al., 
1993; Saheki et al., 1994).  Given that simvastatin is taken in the lactone form, and the 
lactone form is found within the plasma, it would stand to reason that simvastatin would 
be more likely to enter the CNS than would a statin that is delivered in an acid form and 
is generally less lipophilic.  
There is evidence that statins are able to reduce cholesterol synthesis in the brain, 
but very little to indicate that such a reduction does anything to overall cholesterol levels 
in the CNS.  In a rather short-term study, 10 days of treatment in mice with simvastatin 
was unable to reduce cholesterol levels in the striatum as measured with GC/MS (Selley, 
2005). Yet, longer studies also fail to show any real effect on cholesterol levels. After 
four weeks of high-dose treatment with both pravastatin and simvastatin, two distinctly 
different statins in regards to their lipophilicty, cholesterol synthesis was be reduced in 
the brains of guinea pigs, but there was not a significant effect on cholesterol levels.  
Pravastatin is considered hydrophilic and is thought to be unable to pass through the 
BBB, yet it still had an effect on cholesterol synthesis despite a perceived inability to pass 
through the BBB (Lutjohann et al., 2004). This particular effect of statins on cholesterol 
synthesis in the brain was corroborated in a later study in which very high doses of  
simvastatin (100 mg/kg)  given to mice for approximately one month again showed no 
effect on cholesterol levels or the major cholesterol metabolite 24S-OH-CHOL in whole 
brain homogenates, but again, decreased cholesterol synthesis  (Mok et al., 2006).   
Though reports in the current literature of pharmacologically reducing cholesterol 
levels in the CNS are rare, benefits of using drugs that target cholesterol synthesis within 
the brain may have benefits independent of grossly reducing overall levels, and there is 
ample evidence that statins are able to confer positive effects in the CNS.  In several 
studies involving traumatic brain injury (TBI), statins were found to beneficial in 
reducing TBI-associated deficits. Both simvastatin and atorvastatin are able to improve 
performance on the rotorod paradigm after TBI as well as reduce hippocampal 
degeneration and improve cerebral blood flow (Wang et al., 2007).  Atorvastatin and 
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simvastatin are also able to improve performance on the Morris water maze in rodents 
(Lu et al., 2007; Wang et al., 2007).  In another study with a shorter term of treatment, 
simvastatin improved rotorod performance in TBI animals as well as lowered mRNA 
levels of toll-like receptor 4 (TLR4), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), interleukin 1β (IL-1β), tumor necrosis factor –alpha (TNFα), 
interleukin-6 (IL6) and ICAM around the area of injury, concurrent with an overall 
reduction in the NF-κB activity (Chen et al.).  Statins, It would seem, are able to 
ameliorate potentially harmful immune reactions, and the role of statins as 
immunomodulators is well documented (Kwak et al., 2000; Lindberg et al., 2005; Selley, 
2005; Clarke et al., 2008; Aoki et al., 2009; Li et al., 2009).  But its benefits go beyond 
reducing the deleterious effects of inflammation in TBI, statins may also be able to 
increase neurogenesis and reduce neuronal death following TBI (Lu et al., 2007). 
 Not all observed statin-induced effects in the brain are positive or consistent.  
There are several studies that indicate that statins may actually be deleterious to the CNS.  
Klopfleisch and colleagues (2008) found that inhibition of cholesterol synthesis in mature 
oligodendrocytes in vitro can actually cause the retraction of processes due to the 
disruption of Ras and Rho signaling that is dependent on the isoprenoids produced 
upstream of cholesterol in the mevalonic pathway. These metabolites are essential for the 
proper targeting of Ras and Rho to the membrane, which are integral in process 
elongation. This disruption in normal oligodendrocyte functioning also delays 
remyelination after cuprizone treatment in vivo (Klopfleisch et al., 2008).  The effect seen 
on oligodendrocyte process retraction in this study depended on the lipophilicity of the 
statin, in that lovastatin induced process retraction whereas pravastatin, a much less 
lipophilic statin was unable to do so.  Another study contradicts this when it was reported 
that the hydrophilic pravastatin retarded neurite growth of axons in neuronal culture (de 
Chaves et al., 1997).  In both instances though the retraction could be rescued with co-
treatment of mevalonic acid or with the isoprenoid analogs farnesol and geranyl-geraniol, 
but not with cholesterol, confirming that the effect in both was most likely due to a lack 
of prenylation capability as opposed to an overall change in lipid dynamics of the 
membrane (Miron et al., 2007). Isoprenoids like farnesylpyrophosphate and 
geranylgeranylpyrophosphate are needed for the prenylation for a whole host of small 
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GTPases.  These include Rho and Ras, which without proper prenylation accumulate in 
the cytoplasm (Liao and Laufs, 2005).  These GTPases play major roles in neuron growth 
and elongation(Cijiang He et al., 2006).  Therefore, it is not clear how disruption of 
cholesterol synthesis would affect myelination.  Firstly, the retraction of oligodendrocytic 
processes via inhibition of the synthesis of isoprenoids can inhibit proper myelination of 
axons.  Secondly, the inhibition of neural outgrowth via the same mechanism would 
reduce the number axons available to myelinate.  Thirdly, reduction of cholesterol itself 
would reduce materials needed to actually myelinate axons.   
The effects of potentially induced cholesterol depletion in the brain should not be 
completely dismissed. Changes in cholesterol dynamics of the plasma membrane can 
modulate the activity of signaling molecules found within the lipid bilayer, specifically 
those associated with cholesterol rich lipid rafts.  For instance, simvastatin protected 
against NMDA-induced neuronal excitotoxicity by reducing the number of NMDA 
receptors that are actually associated with lipid rafts without actually modulating the 
number of total receptors in a membrane fraction.  In this case, isoprenoids do not seem 
to involved (Ponce et al., 2008), and the change in the fluid dynamics of the lipid rafts 
may affect the efficiency of NMDA receptor activity.  Another study suggested, but 
failed to provide strong mechanistic support, that chronic simvastatin treatment could 
actually act like an NMDA receptor antagonist as well (Wang et al., 2009a). 
Cholesterol and the Aging Brain 
  Cholesterol in the CNS is not static, and is subject to regular turnover; therefore 
dysregulation of cholesterol metabolism could potentially confer detrimental effects on 
normal neuronal function and participate in cognitive decline. The lipid bilayer is 
normally asymmetrical in its distribution of various phospholipids and cholesterol, which 
contributes to the fluidity of exofacial and cytofacial leaflets of the membrane (Wood et 
al., 2002).  In mice, the exofacial leaflet gains cholesterol over its lifetime and the leaflets 
become less asymmetrical, which leads to a loss in fluidity (Igbavboa et al., 1996). The 
decrease in fluidity and the increase in cholesterol in the outer leaflet of the cell 
membrane could be due to a decreased capacity to efflux cholesterol. In ApoE knockout 
mice, the exofacial leaflet is much more concentrated in cholesterol than age-matched 
animals (Igbavboa et al., 1997) and as mice age, brain ApoE expression actually 
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increases (Masliah et al., 1996), suggesting that perhaps the brain is compensating for the 
disproportionate amount of cholesterol in the exofacial leaflet.   
 An age-dependent effect on the level of 24-OH-Chol exists in blood plasma.  The 
levels appear to decrease over the lifetime of an individual, comparing the first decade of 
life to the sixth.  This is most likely attributed to the fact that synthesis at earlier stages of 
development is much greater due to the need for cholesterol during axonal growth 
(Lutjohann et al., 1996).  When myelin production decreases as neural networks are 
established, the need for cholesterol is not as great, and therefore synthesis, and the 
process by which cholesterol is metabolized can be reduced.  In fact, 24-OH-Chol levels 
have been reported to decrease in the hippocampal regions of elderly subjects, leading the 
researchers to conclude that cholesterol synthesis is decreasing, while overall cholesterol 
levels in the brain remain stable (Thelen et al., 2006). This suggests that cholesterol 
turnover is reduced in parallel with the reduction in synthesis, very similar to the 
phenomenon seen in Cyp46a KO mice which show a reduction in cholesterol synthesis as 
a way to compensate for the absence of the Cyp46a, which is mainly responsible for the 
metabolism of cholesterol to 24-OH-Chol.  
Evidence suggests that a metabolic shift in cholesterol metabolism takes place at 
mid-life.   Studies carried out in rats have shown that a whole host of genes begin to be 
expressed differently as a part of normal aging starting at mid-age, marking a shift in 
expression patterns.  A significantly disproportionate number of these are involved in 
cholesterol metabolism (Blalock et al., 2003; Rowe et al., 2007; Kadish et al., 2009). 
Several of these genes are positively correlated with cognitive impairment including 
ApoE and the sterol regulatory element-binding transcription factor (Srebf1) (Kadish et 
al., 2009).   
Cholesterol is involved in determining the permeability characteristics of cellular 
membranes, and this point is vitally important when considering the role membrane 
potentials play in neuronal signaling.  Myelin has a greater amount of cholesterol than 
most of the plasma membrane and it plays a key role in lowering the capacitance of 
axons, allowing for rapid salutatory conduction (Bartzokis et al., 2004; Dietschy and 
Turley, 2004).  As the brain ages, the extent of myelination decreases with respect to the 
total length of myelinated fiber in the neocortex, which is reduced by 40-50 % 
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(Pakkenberg et al., 2003). Thus, dysregulation in cholesterol metabolism over the 
lifespan could impact myelin, compromising its integrity, and promoting degeneration 
and related pathologies. In fact, those axons myelinated later in life are thinner and less 
thickly sheathed in myelin, and these  regions of the brain are those first affected by AD 
pathologies (Bartzokis, 2004). The demyelination and abnormalities in white matter have 
been implicated in both brain aging (Chia et al., 1983; Guttmann et al., 1998; Bartzokis et 
al., 2001) and Alzheimer disease as well (Roher et al., 2002; Bartzokis et al., 2003; 
Bartzokis et al., 2004; Chalmers et al., 2005; Bartzokis et al., 2007). 
One must also not exclude the role vascular events may play in cognitive decline, 
even though these may be beyond the scope for this work, cholesterol levels are major 
risk factors in the development of atherosclerosis, and subsequently the possibility of 
having a heart attack or stroke.  The risk for developing atherosclerosis and suffering 
from a stroke increases with age, as vasculature accumulates lipid-laden plaques (Allen 
and Bayraktutan, 2008).  The brain itself is extremely vascularized, and thus cholesterol 
dysregulation seen in aging vasculature is potentially mirrored in the brain.  Occlusion of 
small capillary beds throughout the brain would result in small areas of hypoxia, which 
can lead to cell death in areas deprived of normal blood flow (Thomas et al., 2002).  
These “mini-strokes” over time can be visualized as hyperintensities on MRI brain scans, 
and over time the recurrence of these events may lead to an underappreciated level of 
damage with serious cognitive effects.  Many see these hyperintensities as part of normal 
aging, but the effects of these are not well studied.  
The Hippocampus and Memory 
One of the most studied individuals in science was a man known by the initials 
HM.  In order to attenuate debilitating intractable seizures in the 1950s, HM underwent 
surgery to remove a posterior portion of the temporal lobe, which in turn destroyed 
approximately two-thirds of his hippocampus (Scoville and Milner, 1957) after which he 
was unable to form any new memories for the remainder of his life.   Without the 
hippocampus, we humans along with the majority of our mammalian relatives are unable 
to acquire new memories or engage in spatial memory (deToledo-Morrell et al., 1988).  
As in the case of HM, older memories acquired before a lesion are undisturbed, negating 
the notion that the hippocampus is where memories are archived, but rather where 
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memories are reinforced and acquired, as will be discussed below, most likely through 
the strengthening of synaptic connections. As we age or develop certain 
neurodegenerative diseases, our ability to acquire new memories becomes impaired.  It is 
no surprise then that loss of synaptic plasticity is the hippocampus during aging is highly 
associated with this impairment and is very similar to deficits seen with hippocampal 
ablation (deToledo-Morrell et al., 1988).  Animal models for both aging and Alzheimer’s 
disease that attempt to replicate this phenomenon of age-related cognitive decline are 
discussed in more detail below. 
Alzheimer’s Disease Progression and Treatment 
Alzheimer’s disease is the most common form of dementia and was first 
described by Dr. Alois Alzheimer in the early part of the 20
th
 century.  It is a progressive 
neurodegenerative disease considered to be fatal.  The most prominent symptom early in 
the disease is the loss of episodic or declarative memory with latter symptoms including 
problems speaking, loss of executive functions, and changes in personality and behavior. 
Because of the rate at which the population is aging along with the duration of the 
disease, AD is becoming a major global health concern. AD exerts a considerable  burden 
on the healthcare industry as well as on the financial stability of the nations of the world 
with the cost of treating and caring for AD patients costing over 100 billion dollars a year 
(Fillit and Hill, 2005; Sanders and Morano, 2008). 
Most cases of AD are sporadic with the majority of cases occurring after the age 
of sixty-five.  Age is the greatest risk factor for acquiring AD, with further increased risk 
in older individuals that carry the ApoE4 allele. Familial forms of early-onset AD do 
exist and are typically caused by the presence of an autosomal dominant mutations in the 
amyloid precursor protein (APP), presenilin 1 (PSEN1) or presenilin 2 (PSEN2) genes 
(Shepherd et al., 2009) all of which increase the production of amyloid beta (Aβ).  
AD is associated with two specific pathological hallmarks, often referred to as 
plaques and tangles, both of which must be present for proper post-mortem diagnosis.  
The symptoms of the disease tend to follow the pathological changes that occur in the 
brain as the disease progresses, which include the formation of these senile plaques and 
neurofibrillary tangles (Davis et al., 1999), leading to cell death throughout various brain 
regions.  These senile plaques are composed of deposits of amyloid beta peptides, 
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activated glia associated with increased inflammatory responses and degenerating 
neurons (Dickson, 1997).  Neurofibrillary tangles are composed of hyperphosphorylated 
tau proteins (tau being the protein that makes up the microtubules of the cytoskeleton) 
which form paired helical filaments (Shepherd et al., 2009). Human pathology is 
correlated with the progression of observed cognitive deficits, as seen when Braak 
staging is compared with scores on the Mini-Mental State Examination (Nelson et al., 
2009).  Yet, it is important to note that there is evidence of gross pathology in the absence 
of cognitive deficits (Davis et al., 1999).   
Some of the first noticeable symptoms of AD are the effects seen in short-term 
memory or the acquisition of new memories.  This is often referred to as forgetfulness or 
general confusion about the placement of objects, the recall of words, or recollection of 
events occurring only minutes to hours before. One of the first areas of the brain affected 
by AD is the hippocampus with symptoms mirroring the functions of those regions 
sequentially affected by AD’s pathological progression (Smith, 2002). As the disease 
progresses and more regions begin to atrophy, the severity of the symptoms increase until 
one is completely demented and is only a mere shell of who they used to be.  The 
progression from mild-memory loss at early stages of the disease, often referred to as 
mild-cognitive impairment, to the final stages of the disease can span nearly a decade 
(Burns and Iliffe, 2009).  
There are very few FDA-approved treatments, the most prominent of which 
attempt to increase the availability of the neurotransmitter acetylcholine or reduce 
excitotoxicity by antagonizing NMDA receptors (Scarpini et al., 2003).  Such drugs do 
not target the cause of the disease, and therefore will always lack in their long-term 
efficacy.  The development of therapeutics for AD has proven challenging because the 
actual cause of the disease remains elusive and with every hypothesized cause there is a 
corresponding targeted therapeutic.  Given that the most quoted hypothesis for the cause 
of AD is the amyloid cascade hypothesis, it is no wonder that a great many drugs under 
development target A  either directly or indirectly by targeting those proteins involved in 
its processing.  Yet there are other therapeutics under investigation including NSAIDS, 
fish oil, antioxidants and various currently used drugs that may confer pleiotropic effects 
that may prevent the onset or at least attenuate the progression of AD (Hull et al., 2006). 
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AD and the Cholesterol Connection 
One of the major risk factors for Alzheimer’s disease, besides age, is carrying the 
ApoE epsilon 4 allele (ApoE 4).   As mentioned above, ApoE is a vital component in the 
movement of cholesterol within the brain (Wolozin, 2004).  Transgenic mice (PDAPP) 
that express the human ApoE 4 gene have increased levels of A 42 at an earlier age and 
greater deposition of A  later in life.  At the same time, these animals show reduced 
levels of ApoE in the CSF.  These findings suggest the possibility that ApoE4 carriers 
have reduced ApoE levels in the CSF and that increasing levels of ApoE may help reduce 
A  (Bales et al., 2009) which in a lipidated state aids in its degradation (Jiang et al., 
2008).  It is also hypothesized that ApoE4 contributes to poor transport of cholesterol in 
the brain and, thus, reduced capability of lowering A  levels (Refolo et al., 2000). 
It has been observed that individuals with AD pathology have higher serum levels 
of total cholesterol as well as LDL (Lesser et al., 2009). Epidemiological data has shown 
that statins as well as other lipid lowering drug may reduce the risk of developing 
dementia (Jick et al., 2000; Wolozin et al., 2000; Rockwood et al., 2002; Rodriguez et al., 
2002; Sparks et al., 2006; Wolozin et al., 2007; Sparks et al., 2008; Haag et al., 2009), 
however there are instances where statins were reported to have no effect (Rea et al., 
2005; Arvanitakis et al., 2008).  It has also been found that AD patients have a 
significantly higher level of 24-OH-Chol in their plasma than healthy volunteers 
(Lutjohann et al., 2000; Papassotiropoulos et al., 2000) suggestive of a dysregulation in 
cholesterol metabolism in the  AD brain.  The elevated 24-OH-Chol may provide a 
biomarker of early stage AD only, given that the levels of 24-OH-Chol are reduced in 
late-stage AD patients because fewer neurons are capable of catabolizing cholesterol 
(Abildayeva et al., 2006).  
Interestingly, it would not appear that it is as simple as “high cholesterol is bad, 
low cholesterol is good” in the context of predicting cognitive functioning later in life.  In 
the elderly (defined as patients over 65), low serum cholesterol levels are actually 
negatively associated with cognition, and when coupled with carrying ApoE 4, the rate 
of cognitive decline is actually increased (van den Kommer et al., 2009).  Yet, at midlife, 
high serum cholesterol actually increases the risk of AD and vascular dementia later in 
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life (Solomon et al., 2009), which creates a bit of a conundrum as far as trying to 
determine what therapy to provide as well as how long to provide it.  
Amyloid precursor protein (APP) is the major protein implicated in AD 
pathology.  Its aberrant processing, folding, and aggregation is what some believe is the 
culprit behind the development of the disease.  Cholesterol plays a part in the processing 
of this particular protein. Animals that are fed a diet containing high levels of cholesterol 
tend to develop more AD pathology (Sparks et al., 1994; Sparks et al., 2002; Pappolla et 
al., 2003).  Hypercholesterolemia may actually lead to cholesterol enrichment of 
microdomains within the cell membrane, favoring APP cleavage, and subsequent 
increased A  production via γ-secretases located within these domains (Refolo et al., 
2000). A popular hypothesis explaining the effects of cholesterol and APP processing 
considers the important role cholesterol plays in membrane fluidity.  APP can be 
potentially processed by three different secretases, α, β, and γ.  The sequence in which 
these proteases act on the APP determines whether or not the toxic form of Aβ is formed. 
Alpha secretase cleavage forms the APPsα fragment and precludes Aβ formation.  It is 
thought that high levels of cholesterol would favor the cleavage of the APP by the beta 
and gamma secretases, which would produce the Aβ40 or Aβ42 peptides, which are 
thought to be responsible for AD pathology (Golde and Eckman, 2001; Wolozin, 2001).  
One mustn’t forget that the most common risk factor for acquiring AD is age.  As 
mice age, the lipid dynamics of neuronal membranes change and the fluidity of the 
exofacial layer of the membrane decreases.  As mentioned, this is most likely attributable 
to the twofold increase in cholesterol levels within the exofacial layer of the membrane 
(Igbavboa et al., 1996; Wood et al., 2002; Rojo et al., 2006).    Furthermore, high 
cholesterol can accelerate AD pathology in a transgenic mouse model (Refolo et al., 
2000) and its depletion can inhibit Aβ production (Simons et al., 1998).  Polymorphisms 
in the Cyp46 gene, which encodes the enzyme responsible for the majority of cholesterol 
turnover in the brain are also associated with greater levels of Aβ accumulation in human 
brain tissue and an increase risk of developing AD (Papassotiropoulos et al., 2003). This 
suggests that by lowering cholesterol or impeding its synthesis one could reduce Aβ 
levels and reduce the risk of AD.   Both of these have been shown (Fassbender et al., 
2001; Kojro et al., 2001; Refolo et al., 2001; Schneider et al., 2006).   
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Liver X Receptors (LXR): Master Metabolic Regulators 
LXR may be considered as a master regulator of metabolism in the body because 
of its diverse ability to regulate the crosstalk between a number of signaling pathways 
that include lipid metabolism, insulin signaling as well as immune responses.  Given its 
diverse role, it has been the subject of various studies in hopes to exploit its regulatory 
nature in the context of various disease models to both better understand the disease as 
well as find potential therapies. Perhaps LXR’s largest role is in lipid metabolism, and 
several components of cholesterol metabolism share a common denominator in the LXR, 
which includes regulatory aspects of its transport and efflux. This transcription factor, as 
we will see, also plays an important role in lipogenesis as well as in glucose control.  
Pharmacological manipulations of LXR have implications in treating a large list of 
diseases associated with cholesterol dysregulation, specifically atherosclerosis and AD. 
LXR is a member of the nuclear receptor superfamily. LXRs exist in two 
isoforms, LXR-  and LXR- .  Both isoforms heterodimerize in an obligatory fashion 
with the retinoic acid receptor (RXR) (Apfel et al., 1994; Teboul et al., 1995; Willy et al., 
1995; Janowski et al., 1996).   The LXR-  isoform is predominately expressed in the 
liver, intestines, and adipose tissue, whereas LXR-  is considered more ubiquitous and is 
the more active of the two in the brain (Janowski et al., 1996); yet, the gene targets of 
both isoforms overlap considerably, and one can potentially compensate for the loss of 
the other (Zelcer and Tontonoz, 2006).   
The endogenous ligands of LXR are various oxysterols, including 27-
hydroxycholesterol, 24(S),25-epoxcholesterol and 24(S)-Hydroxycholesterol, which is 
the major activating species in the brain (Hu et al., 2003; Tontonoz and Mangelsdorf, 
2003).  LXR can be pharmacologically activated with at least two known agonists, 
T0901317 and GW3965, with T0901317 having a much more robust effect on the 
receptor’s targets (Albers et al., 2006). The GW3965 compound is considered by some to 
be a partial agonist because it can only achieve 37% activation of LXR-  and 62% of 
LXR-  when compared to T0901317 treatment (Albers et al., 2006).  This also suggests 
that GW3965 has a slight preference for LXR- , which has implications for its effect on 
peripheral organs like the liver.  
25 
 
The classical pathway for the receptor’s activation involves binding of the ligand, 
subsequent release of the co-repressors NCoR and SMRT and binding of co-activators 
that enhance expression (Hu et al., 2003; Zelcer and Tontonoz, 2006).  Those genes 
targeted by LXR contain an LXR binding element.  These elements are direct repeats of 
the sequence AGGTCA separated by four nucleotides (Janowski et al., 1996).   
The LXRs, as noted above, are regulators of cholesterol homeostasis and their 
target genes are directly involved in cholesterol metabolism (Schultz et al., 2000; 
Venkateswaran et al., 2000; Zhang et al., 2001; Cao et al., 2002; Joseph et al., 2002a; 
Whitney et al., 2002; Liang et al., 2004; Ulven et al., 2004; Karten et al., 2006) as well as 
genes involved in the synthesis of both fatty acids and bile acids (BA) (Ulven et al., 2005; 
Watanabe et al., 2005). The first LXR gene target discovered was cholesterol 7-alpha 
hydroxylase (CYP7a1), a rate-limiting enzyme in the production of BA (Peet et al., 
1998). A summary of LXR gene targets is shown below (Figure 1.3).  
LXR activation leads to an upregulation of major fatty acid synthesis genes as 
well as to an increase in plasma triglyceride levels.  Much of this is attributed to its 
upregulation of SREBP1 (Schultz et al., 2000), which shares some of LXR’s other gene 
targets including  ApoE (Ulven et al., 2004),  ApoA-1, a variety of ATP binding cassettes 
(e.g. ABCA1, ABCG1), fatty acid synthase (FAS), phospholipids transfer protein 
(PLTP), and lipoprotein lipase (Peet et al., 1998; Naik et al., 2006).  
In the periphery, apart from it integral role in the lipogenesis, LXR is responsible 
for reverse cholesterol transport (RCT) and acts as a sensor of excess dietary cholesterol.  
When LXR is absent in mice, cholesterol accumulates due to a decrease in one of it 
targets, CYP7a1, disrupting the main pathway by which cholesterol is removed from the 
body (Zelcer and Tontonoz, 2006).   
As mentioned above, LXR upregulates the expression of ATP-binding cassettes 
like ABCA1 and ABCG1 transmembrane transporters which facilitate the lipidation of 
lipid-poor apolipoproteins within HDL complexes allowing shuttling of cholesterol back 
to the liver to be degraded into BA (Brooks-Wilson et al., 1999).  Macrophages are 
integral in the removal of cholesterol from blood vessels, and the dysregulation of this 
process can lead to atherosclerosis. LXR is highly expressed in macrophages and foam 
cells within atherosclerotic lesions (Watanabe et al., 2005). These macrophages are 
26 
 
involved in the movement of cholesterol out of the macrophages to HDL particles.  It 
follows that LXR activation can inhibit the development of atherosclerosis in mice (Dean 
et al., 2001; Joseph et al., 2002b) given its role in upregulating the genes that facilitate 
RCT.  
LXR activation leads to the upregulation of a host of genes involved in lipid 
synthesis, specifically triglycerides. Given that the production of lipids is dependent on 
available materials, it is not surprising that LXR helps regulate the crosstalk between 
carbohydrate availability and the production of triglycerides.  The expression of insulin-
sensitive glucose transporter 4 (GLUT4) in adipocytes is dependent on LXR- , which is 
downregulated in diabetic patients who have become insulin-resistant (Dalen et al., 
2003).  The increase in GLUT4 on the surface of adipocytes allows for the production of 
triglycerides in the adipose tissue as a result of an increase in glucose uptake, providing 
further evidence of LXR’s role as a glucose sensor engaged in the upregulation of 
lipogenic processes (Mitro et al., 2007).  In hyperinsulinemic mice (db/db mice), 
hypertryglyeridemia and the accumulation of triglycerides in the liver was greatly 
increased when they were treated with an LXR agonist (Chisholm et al., 2003). There is 
also evidence that LXR can act on pancreatic beta cells to increase the insulin levels, 
which would further lead to an increase in triglyceride formation (Efanov et al., 2004).  
LXR is also known to be anti-inflammatory in macrophages where their 
activation leads to inhibition of NF- B dependent signaling (Zelcer and Tontonoz, 2006).  
This includes the inhibition of classic inflammatory-associated genes after insult with 
lipopolysaccharide (LPS) in macrophages, including the inhibition of inducible nitric 
oxide (iNOS), cycloxygenase (COX), and interleukin six (IL-6).  LXR activation also 
reduces the inflammatory response in the aorta of atherosclerotic mice (Joseph et al., 
2003).  The ability of LXR to reduce inflammation has been shown in glial cultures as 
well, where GW3965 inhibits the normal inflammatory response associated with a 
fibrillar Aβ insult as well as promote its phagocytosis in microglia (Zelcer et al., 2007).   
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LXR in Brain Aging and AD 
Given the many links between cholesterol metabolism and AD, and knowing that 
the LXRs are intimately involved in several facets of lipid metabolism it may not be 
surprising that pharmacological modulation of the LXR pathway has been implicated in 
the reduction of biomarkers associated with AD pathology.   Endogenous oxysterols 
(Janowski et al., 1996) including 24(S)-OH-Chol, the major cholesterol metabolite of the 
brain, bind to LXRs.   Activation of LXR is directly involved in the upregulation of key 
proteins associated with AD as well as being involved in cholesterol metabolism and 
transport including apolipoprotein E and several ATP binding cassettes (Teboul et al., 
Figure 1.3: Liver X Receptor gene targets: Upon heterodimerizing with RXR and 
binding to a ligand either endogenous or synthetic, LXR activation leads to the 
upregulation and downregualtion of genes involved in various metabolic and non-
metabolic pathway, specifically in the upregulation of genes involved in lipid 
metabolism and the downregulation of classically associated inflammatory genes. 
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1995; Schultz et al., 2000; Zhang et al., 2001; Cao et al., 2002; Whitney et al., 2002; 
Liang et al., 2004; Ulven et al., 2004; Zelcer and Tontonoz, 2006). As mentioned, the 
oxysterol 24-OH-Chol is elevated in the plasma of AD patients and has been suggested as 
being an AD biomarker (Lutjohann et al., 1996; Lutjohann et al., 2000; Papassotiropoulos 
et al., 2000; Lutjohann and von Bergmann, 2003). Evidence of alterations with aging 
include the recent observation by our lab that LXR-  is significantly upregulated in the 
hippocampus of aged male F344 rats (Rowe et al., 2007).  Furthermore, SREBP as well 
as ApoE are upregulated in rats at midlife as part of shift in metabolism, both of which 
are direct targets of LXR activity (Kadish et al. 2009).  The cause and effect relationship 
between aging and in increase in LXR and its targets are not full understood and these 
results indicate either a compensatory role of LXR in the aged brain or perhaps a 
deleterious outcome of increased levels of cholesterol metabolites   
 Most of the research targeting LXR with synthetic agonists has shown it to be 
more beneficial in nature. Some studies find that LXR activation reduces Aβ processing 
and/or levels in both in vitro and in vivo models along with associated cognitive deficits 
(Sun et al., 2003; Koldamova et al., 2005; Burns et al., 2006; Riddell et al., 2007; Zelcer 
et al., 2007). The mechanism behind this reduction in Aβ is not well understood, but may 
be due to an increase in ApoE and ABCA1 along with an increase in cholesterol transport 
mechanisms within the brain (Pfrieger, 2003b; Hirsch-Reinshagen et al., 2004; Wahrle et 
al., 2005; Abildayeva et al., 2006; Bjorkhem, 2006). For instance, Burns and colleagues  
found that in an in vitro system, A  levels were reduced with LXR activation and 
ABCA1 upregulation, but only if there was a cholesterol efflux acceptor (ApoA1) 
available in the media along with ABCA1(Burns et al., 2006).  Without ABCA1, A  was 
not reduced (Wahrle et al., 2005). Therefore, a direct link between the expression and 
function of both ABCA1 and the apolipoproteins seems to exist and that the co-
expression of both is essential to confer benefits. Furthermore, a potential mechanism 
explaining the ability to reduce A  through LXR activation has been somewhat 
elucidated in that lipidated ApoE, driven by a LXR agonist, is able to subsequently 
promote the proteolysis degradation of Aβ through facilitating the endocytosis of Aβ into 
microglia or making the Aβ available for extracellular enzymatic degradation (Jiang et 
al., 2008).  
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Chapter 2: Materials and Methods 
Introduction 
Described below are the general materials and methods used throughout the six 
experiments discussed within this document.  They include not only descriptions of the 
protocols used, but also the rationale for their use.  The protocols are generalized and are 
not identical across all the experiments due the use of different models and experimental 
designs. Therefore, a separate description of the materials and methods used in a 
particular study is included within its respective chapter.  
Animal Models of Alzheimer’s Disease 
 There exist today a great and varied number of mouse models of AD.  Typically, 
the models exploit the expression of a select gene or set of genes that act to induce some 
pathological characteristic of the disease state.  AD pathology is marked by the presence 
of dense senile plaques created from the deposition of Aβ, created from the proteolytic 
cleavage of amyloid precursor proteins (APP) (Jankowsky et al., 2004), as well as 
neurofibrillary tangles composed of hyperphosphorylated Tau protein (Selkoe, 2001).  
The most commonly used AD models overexpress gene mutations that are found in 
familial forms of AD. These include the gene variants of APP and presenilin 1 (PS1), 
both of which are associated with the overproduction of Aβ.  APP is cleaved by a series 
of enzymes to create a number of different A  species.  PS1 is a γ-secretase that is 
integral in the formation of Aβ.  Mutations in PS1 as well as the protein on which it acts, 
APP,  are known to lead to familial forms of AD and result in the  overproduction of A  
(Citron et al., 1992; Cai et al., 1993; Haass et al., 1994; Rogaev et al., 1995; Sherrington 
et al., 1995; Jankowsky et al., 2002; Jankowsky et al., 2004).   
 Juxtaposed to the  experimental models of AD which  genetically manipulate 
specific genes is that fact that very few cases of AD are known to be directly caused by a 
specific gene (Morrissette et al., 2009).  Most cases of AD are sporadic without any 
concrete indication of causality and not familial in origin. Nonetheless, despite the earlier 
onset of the familial form, sporadic and familial AD are usually pathologically 
indistinguishable (Selkoe, 2001).  Given this similarity, it is believed that the use of 
experimental models of familial AD may provide insight into the sporadic form of the 
disease, as well.   
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 Triple transgenic model: The triple-transgenic model (3xTg) of AD appears to be 
an ideal model in that it presents with both pathological hallmarks required for diagnosis 
in the post-mortem brain, plaques and tangles, and does so in a relatively quick manner. 
The mouse was developed by Frank LaFerla and colleagues in 2003 at the University of 
California, Irvine and has been characterized by that lab and its collaborators.  The mouse 
was created by microinjecting two independent transgenes (human APPswe and tauP301L) 
into embryos harvested from PS1M146Vknockin mice (Oddo et al., 2003).  The first 
pathological manifestations in the mice is intraneuronal A  appearing between 3-4 
months of age which appears to be oligomeric (Oddo et al., 2006).  Extracellular Aβ is 
not seen until around 12 months of age.   
 In this model, Aβ formation precedes tangle formation and  an antibody vaccine 
toward oligomeric Aβ clears both forms of pathology, suggesting a causative role of A  
in tangle formation (Oddo et al., 2006).  Synaptic plasticity is also impaired in the 
animals as they age, determined by measuring EPSPs in the CA1 region of the 
hippocampus.  Synaptic deficits correlate with sequential increases in Aβ  accumulation 
(Oddo et al., 2003), and are indicative of decreased ability to form memories.  Thus, in 
these animals, the reduction in synaptic plasticity correlates with cognitive deficits, 
specifically in hippocampal-dependent spatial memory as measured by the Morris water 
maze (MWM) and passive avoidance tasks (Billings et al., 2005). 
 Double-transgenic model: Various versions of the “double transgenic mouse” 
model (2xTg) exist, but the model used in the present studies makes use of the 
overexpression of both the APPswe and PS1Δ9 genes.  These mice were originally created 
by crossing a mouse carrying the APPswe mutation with a mouse carrying the PS1Δ9 
mutation (Borchelt et al., 1996).  Later a line was created through the co-injection of both 
transgenes which co-segregated making the production of progeny more efficient 
(Jankowsky et al., 2001). The mouse strain used in the experiment described below is of 
the original type and was created by crossing founder mice expressing either APPswe or 
the PS1Δ9 mutation.  Mice expressing both transgenes were then backcrossed to C57Bl6 
mice for 10 generations to create a congenic strain.  
Models co-expressing these mutations present with accelerated Aβ deposition 
with observable deposits at 6 months of age with the majority of deposits located in the 
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frontal and entorhinal cortices and the hippocampus with deposition continuing to worsen 
as the mouse ages (Gordon et al., 2002; Jankowsky et al., 2004; Savonenko et al., 2005).  
This accelerated processing is due to the co-expression of both the delta-9 PS1 mutation 
along with the APPswe mutation, whereas animals expressing only one of these fail to 
present with Aβ deposition at this same rate (Borchelt et al., 1997).  
Behavioral characterization of this model shows that anxiety levels are not 
significantly higher when compared to age-matched controls (Reiserer et al., 2007).  
There is an age-dependent effect on episodic memory deficits, which correlate with A  
accumulation (Savonenko et al., 2005).  Similarly, mice co-expressing both transgenes 
also show impairments in a version of the Barnes maze  and show less of an impairment 
in reference  memory but rather a deficit in learning flexibility (Reiserer et al., 2007).  
Lalonde and colleagues have shown that spatial memory deficits do exist though 
(Lalonde et al., 2005).  Furthermore, other mouse models of AD, specifically those that 
express only human mutations of APP without expressing the mutant form of PSEN1 
show performance deficits in contextual fear conditioning (Comery et al., 2005; Jiang et 
al., 2008), another behavioral paradigm that assesses contextual memory. 
 Given that this particular 2xTg model presents with Aβ pathology and behavioral 
deficits, it appears to be an appropriate model for therapeutic intervention studies to 
examine potential attenuation of both pathology and related cognitive deficits.  
 
The Fischer 344 (F344) as a Model of Normal Aging 
A commonly used rodent model of aging is the F344, a rat model used by various 
aging research groups over the past two decades (Barnes et al., 1987; Barnes et al., 1990; 
Barnes et al., 2000; Gant et al., 2006; Rowe et al., 2007; Brewer et al., 2009; Kadish et 
al., 2009).  As seen in human aging (Park et al., 2002),  deficits in memory can be 
detected in F344 rats with the Morris water maze (MWM) starting around mid-age and 
continue to worsen with increasing age (Shukitt-Hale et al., 1998; Bizon et al., 2009).  
Much of the work done by members of our research group has been carried out in F344s, 
including electrophysiological studies, behavioral studies and microarray studies 
(Landfield and Lynch, 1977; Landfield et al., 1978; Landfield and Pitler, 1984; Gant et 
al., 2006; Rowe et al., 2007; Brewer et al., 2009; Kadish et al., 2009).  Given the amount 
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of data amassed with this particular model, it is only reasonable that the aging studies 
described here would include the use of this model so that appropriate comparisons can 
be made to both previously observed deficits seen in various behavioral paradigms as 
well as changes in gene expression as measured with microarray technology. 
 
The Morris Water Maze (MWM) and Cognitive Assessment  
Rationale 
The Morris water maze has become the gold standard for assessing learning and 
memory deficits in rodents and is used extensively in models of aging and 
neurodegenerative disease.  It has been 25 years since the water maze was first described 
as a spatial memory paradigm by Dr. Richard Morris at the University of St. Andrews 
(Morris, 1981).  It was developed to study spatial localization in rats and forces the 
animal to use its surrounding visualized environment to navigate (Brandeis et al., 1989).   
The aquatic context of the environment also allows for assessment of spatial memory 
even if locomotor deficiencies exist. Essentially, an animal in the maze must use distal, 
extramaze cues to orient themselves within a pool filled with water and then locate a 
fixed platform hidden just beneath the surface of the water (Morris et al., 1982; Vorhees 
and Williams, 2006). Navigation is dependent on these distal visual cues and precludes a 
repeated pattern of movement implying a strategy that would use muscle memory 
(Sutherland et al., 1983; D'Hooge and De Deyn, 2001).  The spatial navigation within the 
maze is not entirely hippocampal dependent, but performance in the hidden-platform 
MWM is severely impaired when the hippocampus is lesioned providing support for the 
role of the hippocampus in spatial memory (Morris et al., 1982; Morris et al., 1986).  
Interestingly, blocking long-term potentiation (LTP), considered by some to underlie 
hippocampal-dependent learning,  impairs performance in the MWM similar to that seen 
with hippocampal lesions (Morris et al., 1986).  
During the training phase of the MWM, when animals are taught how to perform 
the task, the aged animals show slower acquisition during the first few days of training.  
However, by the end of this period, several days later, the aged animals perform as well 
as younger animals.  Thus, the aged animals “learn” the task, but at a slower rate.   The 
“memory” part of the task comes during the “probe trial” after the acquisition phase.  
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During the probe trial, the submerged platform is removed, and various measures are 
taken to assess recall.  Aged animals typically show impaired performance on the probe 
trial (Rapp et al., 1987).  Age-related deficits observed in spatial memory also resemble 
those seen in animals with damage in hippocampal circuitry (Bizon et al., 2009), 
suggesting that the impaired ability of aged animals to perform as well as younger 
animals could be due to deleterious changes occurring in the hippocampus with aging.  
When assessing the cognitive ability of older animals in the MWM, other various 
age-related deficits that could potentially confound the observed behavior must also be 
considered.  Visualization of the distal extramaze cues is an integral part of orienting in 
the maze, and the animal’s visual acuity must be at a level that will allow them to see the 
spatial cues.  Dr. Morris originally described performing a cue task (Morris, 1981; Morris 
et al., 1982) to assess the ability of the animal to see a conspicuous platform that was 
placed in various locations in the maze to assure that the animal would be able to be 
trained on the task.  Similarly, training the animal to find a marked platform while being 
placed in different quadrants over the course of training assures that the animal has an 
appropriate level of visual acuity but also understands the point of the task, which is to 
find a submerged platform to escape from swimming. 
When assessing aging differences in cognition it is also important to consider 
differences in locomotor ability of the animals.  A commonly used outcome measure for 
the MWM is latency to the platform during training.  Older animals tend to have reduced 
swim speed making this measurement problematic in assessing cognitive differences 
(Gallagher et al., 1993).  A better measurement is length to platform during training 
sessions, which is not dependent on swim speed.  This may not be as an important 
consideration when determining differences between groups of the same age, where 
differences in swim speed itself could be an interesting outcome measure in experiments 
involving drug intervention. 
As mentioned above, the probe sessions are important in assessing memory and 
are usually executed by placing an animal in the pool after the platform has been 
removed and allowing the animal to freely swim for 60-90 seconds. The animal displays 
recall if it uses the extramaze cues to orient to the quadrant where the platform was 
previously located and spends more time in the quadrant trying to locate the platform in 
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order to escape. Various measurements are used to analyze performance during a probe 
session, including: latency/path length to goal, number of platform crossings, percent 
time in goal quadrant and cumulative distance to platform.   It has been found that in 
aging animals cumulative distance, thus proximity to the area in which the platform was 
located during previous training sessions, is a better assessment of whether or not the 
animal is using reference memory to locate the platform as opposed to an alternative 
search pattern that would allow the animal to cross the platform area with an inflated 
success rate.  Such a search pattern may produce reduced latency and path length 
measures (Gallagher and Nicolle, 1993).   
The percent time spent in a particular quadrant also allows for determining 
whether the animal is spending more time looking for the platform in the goal quadrant, 
suggesting the use of spatial memory to locate the platform.     Even though the free swim 
probe session lasts 60-90 seconds, it is common to assess only the first 30 seconds given 
that animals will often determine that the platform is not in its normal location and then 
begin searching throughout the pool (Vorhees and Williams, 2006), therefore skewing 
data in a way that does not represent the animal’s initial behavior upon introduction into 
the maze.  
 
MWM General Apparatus and Protocol 
The pool is a galvanized metal water tub 183 cm in diameter and 60 cm high. It is 
enclosed within black curtains that produce a semi-dark environment within the testing 
room.  The bottom and inward facing sides of the pool are painted black to provide 
contrast for the video camera system and facilitate the tracking of the albino rats used in 
this study. Three large contrasting spatial cues hang from three of the four surrounding 
walls and are lit by LED rope lights that wrap around the pool itself as well as LED lights 
that project a beam of light onto the cues.  This allows for visualization of the spatial cues 
and provides contrast needed for the Videomex tracking system and accompanying water 
maze software (Columbus Instruments).    Illumination in the pool area is verified with a 
lux meter to ensure it is at a in a visible range for F344 rats.  The pool is filled with water 
(25±1C°) to a height sufficient enough to submerge a 15 cm diameter platform (by 2 cm 
of water.    
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Prior to the training phase, cue training takes place to verify the eyesight by the 
rats.  During cue training, a conspicuous cue is suspended from the ceiling and hangs 
approximately 12 inches above the submerged platform marking its location.  Aged 
animals are often unable to pull themselves on top of the platform, so the platform was 
submerged during cue training to aid the rats.  Cue training lasts for three days with each 
rat given three trials a day.  A trial consists of 60 seconds to find the platform, 30 seconds 
to acclimate to the surrounding while on the platform, and 120 seconds within a holding 
cage heated by a heat lamp before being reintroduced to the maze.  On day one, animals 
were introduced to the maze in the same quadrant for every trial.  On subsequent days, 
the animal was introduced in different quadrants every trial, rotating the drop spot in a 
clockwise fashion.  
Seventy-two hours after the last cue-training trial, the training phase commenced 
with the animals trained in a similar manner as described above, but with the suspended 
cue removed.  Throughout the training sessions (3 trials/session/day) we rotated the drop 
spot within the day, and subsequently rotated the first drop spot of the day on following 
days in the same clockwise fashion in order to ensure that the rat was using the spatial 
cues for orientation within the maze instead of an alternative search pattern. 
Twenty-four hours after the last day of training the platform was removed from 
the maze and animals given 60 seconds to swim freely while being monitored by the 
tracking system.   The probe session provides a variety of different measurements to 
assess memory.  These include: latency to goal, path length to goal, number of goal 
crossings, proximity to goal, percent time spent in goal quadrant and number of goal 
quadrant entries.  The goal is defined as the extended annulus of the platform equaling 
2.8 times its original area.   
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Active Avoidance (AA) as a Learning and Memory Paradigm 
Rationale 
The active avoidance learning paradigm has been used to assess learning for many 
decades, but has been overshadowed by the MWM which has proliferated as the task of 
choice when assessing spatial memory. It is also an assessment of hippocampal 
dependent spatial memory in rats, and given the potential pitfalls of behavioral 
experiments, it is often useful to have additional behavioral methods to assess memory 
within a cohort. Also, mice are notoriously, if not more anecdotally, difficult to assess in 
the MWM, thus the active avoidance learning task may, therefore, be useful as an 
alternative task to assess cognitive deficits associated with aging and related dementias in 
mice.   
The essential premise of the task is to train an animal to actively avoid an 
unconditioned stimulus (US), a footshock, by remembering the context in which it was 
shocked during the training sessions. The task employs a light/dark dual chamber or 
shuttle box.  During training, the animal is placed in the dark side of the shuttle box, 
which is innately preferred by nocturnal rodents, and a light footshock applied.  
Historically the footshock is preceded by a conditioned stimulus (CS) such as a tone or 
buzzer, but in the studies to be described we have not included this, forcing the animal 
instead to use the contextual space that surrounds it to remember that a shock occurred in 
the dark side of the chamber.  Following a shock, animals typically move to the other, lit 
side of the shuttle box (the side it doesn’t innately prefer).  The animal learns to move to 
the light side of the shuttle box in order to avoid a shock.  Performance can be measured 
through the analysis of latency to escape the chamber on subsequent sessions, as well as 
the number of avoidances in a given training session.  
 Given the role of the hippocampus in spatial memory, it is important to ascertain 
whether or not active avoidance learning is in fact hippocampal dependent.  Classically 
this is done by lesioning the hippocampus and determining whether performance on the 
behavioral task is impaired.  Olten and Issacson (1968) found that surgical ablation of the 
hippocampus results in poorer performance than sham control animals. Furthermore, they 
found that one-way active avoidance, used in the present experiments, appeared to be 
more hippocampal dependent than the related two-way active avoidance paradigm (Olton 
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and Isaacson, 1968b).  Similarly, kainite depletion of neurons within the hippocampus 
can also lead to impairment (Munoz and Grossman, 1981) along with intrahippocampal 
injections of the muscarinic antagonist scopolamine (Brito and Brito, 1990).  Even 
though it is thought that a simple, paired CS, such as a buzzer, that elicits a learned 
response is partially amygdalar as well as hippocampal-dependent(Anagnostaras et al., 
2001), making the task more stringent by removing any CS besides the spatial context 
should only strengthen the role the hippocampus plays in this particular paradigm. 
AA General Protocol 
Slight differences exist in the protocols used for specific experiments described 
below, but the general method for all remains very similar.  Changes made were typically 
introduced to improve data acquisition or to remove potential confounds.  The standard 
protocol includes introducing the animals to the behavior room for twenty minutes prior 
to the start of training.  Animals are placed behind a divider in the room blocking any 
view of the apparatus.  Soft music is playing in the room to block extraneous noise.   
The apparatus itself consisted of a dual-chambered shuttle box with an 
electrifiable wire grid floor hooked to a scrambler.  One chamber was masked with black 
tape and kept very dark, while the other was lit by an overhead lamp.  The two chambers 
were divided by a guillotine door. The grid floor in the dark chamber was set to deliver a 
footshock of 0.8 mA for 25 seconds.   
 Animals were trained over the course of one week with one training session per 
day, which included three separate trials divided by a one-minute inter-trial interval.  
Animals were placed in the dark side of the chamber facing away from the door.  
Following a 4-5 second delay, the footshock was applied.  This typically induced a rapid 
exit to the light side of the chamber in which no shock was applied.  Time to escape the 
chamber was recorded for each trial and avoidances were noted, with an avoidance being 
defined as exiting the chamber before the footshock begins. After approximately 4 
training sessions a probe session took place 24 hours after the final training session.  
During this probe session, the animals were placed in the dark side of the chamber for 30 
seconds; however, no footshock was applied. The latency to escape was measured.  
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Contextual Fear Conditioning (CFC) as an Assessment of Spatial Memory  
Rationale 
Pavlovian conditioning is the elicitation of a response via a CS, such as a tone, by 
pairing the tone with an US such as a footshock over several sessions, and is the basis for 
many rodent-based behavioral paradigms.  The response is typically an innate behavior 
such as freezing, in the case of rodents, when faced with a perceived danger, a natural 
defense mechanism to avoid being seen by a predator (Bolles, 1970).  In the absence of a 
CS, it is possible to induce such freezing behavior in specific contexts when paired with 
an US. Under these conditions, two brain regions are believed to play a role in triggering 
this behavior, namely the amygdala and the hippocampus.  Lesions to the amygdala seem 
to completely block freezing behavior in both a cued environment where a CS is present 
as well as a contextual environment where a CS is not present, indicating the amygdale as 
being critical in the formation of US associated memory (Phillips and LeDoux, 1992), 
whereas hippocampal lesions only interfere with contextual-elicited freezing (R. J. 
Blanchard and D. C. Blanchard, 1969; D. C. Blanchard and R. J. Blanchard, 1972; S. 
Maren and M. S. Fanselow, 1997) suggesting that both regions are involved in fear 
conditioning, but the hippocampus appears preferential to conditioning involving the 
recollection of the environment in which an aversive event took place. Furthermore, 
hippocampal lesions made one day after training also block contextual fear conditioned 
responses, while leaving tone-elicited freezing intact (Kim and Fanselow, 1992; Maren 
and Fanselow, 1997).  
Given the role the hippocampus plays in contextual fear conditioning, researchers 
have used this particular paradigm to assess hippocampal dependent cognitive deficits in 
various animal models of AD. These models typically show impairment on this task 
(Corcoran et al., 2002; Dineley et al., 2002; Comery et al., 2005; Jiang et al., 2008).   
 
CFC General Protocol 
Figure 2.1 outlines the sequence for the general CFC protocol used in experiments 
described below.  Animals were first introduced into an environment that will be referred 
to as the contextual environment in which the animal eventually receives an unpleasant 
shock. The contextual environment is defined as one half of a two-chamber shuttle box 
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with a wire-grid electrifiable floor.  The door to the other side of the chamber was closed.  
Three of the walls of the contextual environment were covered by aluminum and a large 
and prominent black and white cue was placed on the back wall of the chamber.  The 
front wall, facing the observers, was partially visible to allow for visual scoring of 
behavior.  A lamp was placed directly overhead a clear Plexiglas door and the room lights 
were off.  The chamber was wiped clean with ethanol between each animal. 
The animal is placed in the contextual environment and monitored for 2 min to 
determine the baseline behavior (Figure 2.1).  Following baseline observation, the animal 
is exposed to an audible conditioned stimulus (CS) for twenty-two seconds.  During the 
final two seconds of the CS, the animal receives a 2-second footshock, the unconditioned 
stimulus (US).  This sequence is then repeated once so that the animal receives only two 
footshocks in the contextual environment during the whole training component of the 
CFC paradigm.  
 Twenty-four hours after the CS/UCS pairing, the animal is placed back into the 
contextual environment and observed for 5 minutes by two observers. Freezing behavior 
is defined as the lack of any movement other than that associated with respiration. 
Approximately 1-2 hours after completion of behavioral observations within the 
contextual environment, the animals are placed in a novel environment that differed 
substantially from the contextual environment consisting of a cylindrical glass chamber 
with a metal bottom and lid.  The chamber was washed with 4% acetic acid between 
animals to reduce olfactory cues.  
Incidences of disagreement between the observers were removed from statistical 
consideration.  Freezing behavior within the contextual environment was calculated by 
subtracting out the baseline behavior in the same environment (pre-UCS) from the 
freezing behavior observed 24 hours later post-UCS.  
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
 
Long-Term Potentiation (LTP), Memory and the Aging Hippocampus 
Rationale 
LTP is considered an essential mechanism underlying learning and memory 
formation in the hippocampus and other brain regions. Age-related changes in LTP 
induction and maintenance are believed to contribute to a decrease in cognitive acuity.  
When synapses are repetitively stimulated, the communication between the neurons 
within those synapses is strengthened.  This enhancement can last for hours to days.  It 
was first reported by Lomo in 1966 who described a long-lasting potentiated response 
that could be evoked in the dentate gyrus if the perforant path leading to the dentate was 
Figure 2.1: Schematic of contextual fear conditioning protocol.  On day 1, the 
animals experiences two CS-UCS pairings within the contextual environment.  
Twenty-four hours later the animals is returned to the same contextual environment as 
is observed for freezing behavior for five minutes minus the CS.  Later in the day, the 
mouse is placed in a novel environment and observed for freezing behavior befor and 
after the CS.  
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stimulated initially with several conditioning stimuli (Lynch, 2004). In initial reports it 
was referred to as frequency potentiation but is now known as long-term potentiation or 
LTP.  LTP can thus be measured to determine synaptic plasticity and changes in the post-
synaptic potential.  LTP is most commonly measured in the hippocampus (Malenka and 
Nicoll, 1999), but can be elicited in other brain areas, as well.  As mentioned, specific 
agents that block hippocampal LTP, impair the ability of animals to perform on the 
MWM suggesting that LTP may play a role in spatial memory.   
LTP is also often induced in experimental settings with a stimulus rhythm called a 
theta burst, which mimics the frequency (~7 Hz) observed in animals during exploratory 
behavior (Bland et al., 1980; Larson et al., 1986).  This theta frequency brain activity is 
thought to facilitate the formation of memories of the surrounding environs.  It has also 
been found that interventions that improve LTP, improve memory and that a 
phenomenon much like LTP is observed after the acquisition of  a novel experience 
(Geinisman et al., 1995). 
Because LTP is implicated in learning and memory, researchers soon began 
examining whether LTP is affected by the aging process.  Some of the first studies 
showed little effect of aging on LTP.  Landfield and Lynch (1977) looked for 
impairments in LTP and found that potentiation in hippocampal slices from older animals 
was not different than that recorded in slices from young animals, despite impaired 
memory retention in the older animals  (Landfield and Lynch, 1977).  However, they did 
find that impairment did present itself in the inability of aged rats to develop latter 
processes of potentiation within the context of a biphasic pattern of potentiation 
(potentiation was induced, depressed and then potentiated a second time).  Aged animals 
were less able to develop the second phase of this pattern and also showed more 
prominent exhaustion of the synapses after prolonged stimulation (Landfield et al., 1978). 
While recording LTP in vivo, Barnes later found that LTP decayed more quickly in the 
dentate gyrus, with the EPSPs in aged animals declining at a faster rate in the older 
compared to younger cohort even though the same level of potentiation was achieved as 
observed by Landfield and Lynch in vitro (1977). This faster decay was correlated with 
poorer spatial memory on the circle maze as well (Barnes, 1979), further providing 
support for a connection between sustained LTP and memory, and also suggesting that 
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memory retention or the lack thereof my be affected by increased rate of LTP decay.   
Differences in LTP in aged animals may, in fact, be due to their inability to maintain LTP 
over the long-term (Geinisman et al., 1995; Bach et al., 1999). This was reiterated in a 
study looking at aged mice in which hippocampal slices from older mice were not able to 
maintain late-LTP, which is cAMP-dependent, and these deficits were correlated with 
performance on the circular maze much like Barnes’ aged rats (Barnes, 2003).  
 A few reports in the literature suggest that inducing LTP is harder in the aged 
brain.   Aged rats seem to require more intense stimulation at the presynaptic neuron to 
induce LTP, in a sense making it more difficult to induce LTP (Landfield and Pitler, 
1984; Moyer et al., 1992; Moyer and Disterhoft, 1994; Geinisman et al., 1995), which 
could be likened to speaking more loudly to a person hard of hearing.  The age-associated 
deficits observed in LTP recordings may be due to calcium signaling, which is known to 
be dysregulated in aging animals (Landfield et al., 1989; Thibault et al., 1995; Campbell 
et al., 1996). Calcium plays a role in LTP induction and can be blocked with a calcium 
chelator (Lynch et al., 1983).   
 
LTP General Protocol 
There are a large number of protocols used to induce and record LTP in the 
hippocampus and include both in vivo and in vitro methods.  The LTP measurements 
described here are all in vitro recordings done within sections of the hippocampus.  
Hippocampal slices are prepared as previously described (Thibault et al., 1995), but 
briefly, animals are deeply anesthetized with CO2 and then quickly decapitated. The 
brains are rapidly removed and placed in ice-cold artificial cerebral spinal fluid (aCSF). 
The cerebellum is removed and the hemispheres are divided by a razor blade.  Extraneous 
cortical tissue is typically kept for further analysis.  The hippocampus is removed from 
the respective hemispheres that are kept cold with a frequent bath of ice-cold ACSF of 
the following constituents (in mM): 114 NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 
NaHCO3, 8 MgCl, and 0.1 Ca2Cl.  Hippocampal tissue is mounted and transversely 
sectioned in ice-cold ACSF by a Vibratome 3000 (TPI, Saint Louis, MO) to a thickness 
of 400 microns. Slices were then transferred to a recording chamber with wells 
containing oxygenated recording CSF (RCSF) containing (in mM): 114 NaCl, 3 KCl, 10 
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Glucose, 1.25 KH2PO4, 26 NaHCO3, 2.5 Ca2Cl and 1.3 MgCl.  RCSF was kept at 32  C 
with O2 perfusion of the closed interface chamber throughout the two-hour acclimation 
and recording periods. 
A twisted, bipolar, Teflon-coated stainless steel stimulating electrode was placed 
perpendicular to the slice in the Schaeffer collaterals. A sharp glass recording electrode 
(3-15 MΩ) was pulled from borosilicate glass capillaries (World Precision Instruments, 
Sarasota, FL), using a P80 pipette puller (Sutter Instruments, Novato, CA), is filled with 
ACSF and positioned in the stratum radiatum as shown in Figure 2.2.    
Data was acquired using Clampex Software and analyzed using Clampfit 10.2 
(Molecular Devices). Current outputs (I/O) were recorded during stepwise increases in 
voltage at the stimulating electrode separated by 10-second intervals.  The stimulation 
intensity needed to elicit a fEPSP (field EPSP) that was 50% of the maximum 
uncontaminated fEPSP was noted and utilized throughout.   
Baseline fEPSPs were subsequently recorded for 60 sweeps every 20 seconds for 
20 minutes using the same stimulation intensity determined by the I/O and used in PPF.  
LTP was induced with a single 1-second 100 Hz tetanus in murine slices and with a theta 
burst stimulation consisting of 10 pulses of 4 bursts each at 100 Hz every 200 ms for 2 
seconds in rat hippocampal preps.  fEPSPs were recorded for 30 minutes post-LTP 
induction with the same parameters used during baseline for a total of 90 sweeps every 
20 seconds. The I/O and PPF protocols were then repeated. 
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Afterhyperpolarization (AHP) and the Aging Hippocampus 
Rationale 
The AHP is a post-synaptic property of neuronal membranes that occurs 
following a burst of action potential.  The effect of the AHP is to decrease the ability of 
incoming stimuli to depolarize the membrane to threshold potential. The amplitude and 
duration of afterhyperpolarizations induced in the CA1 region of the hippocampus are 
increased in aged animals and is attributed to a dysregulation in Ca
2+
 (Landfield and 
Pitler, 1984; Landfield et al., 1989; Campbell et al., 1996). An increase in its size would 
make the membrane less excitable, or at least less efficient in its capacity to fire as 
readily as a young neuron. Some forms of hippocampal-dependent learning are impaired 
in aged animals, and the AHP is associated with cognitive processes, specifically 
hippocampal-dependent eye-blink conditioning (Disterhoft et al., 1986; Moyer et al., 
1990; Power et al., 1997).  Larger AHPs are found F344 rats that are impaired in the 
MWM (Tombaugh et al., 2005).    Given this, measuring the AHP within the CA1 region 
of the hippocampus has become a standard electrophysiological measure and biomarker 
of brain aging as well as age-related neurodegenerative diseases such as AD (Disterhoft 
and Oh, 2006).  
Figure 2.2: Electrode placement within the hippocampal slice preparation.  The 
twisted, bipolar stimulating electrode is placed within the Schaffer collateral axons 
running from the CA3 region to the CA1 region of the hippocampus.  The recording 
electrode is placed in the stratum radiatum among the apical dendrites of the CA1 
pyramidal neurons where it records the field excitatory post-synaptic potentials.  
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AHP General Protocol 
AHP measurements were graciously done my Mr. Tristano Pancani, a graduate 
student under the mentorship of Dr. Olivier Thibault.  Hippocampal slices were prepared 
in the same manner described above for LTP recordings.  Briefly, animals were 
anesthetized in CO2 chamber prior to decapitation, hippocampi removed and 
transversally sliced using a Vibratome to obtain 350 μm thick slices in ice cold low-
calcium artificial cerebrospinal fluid (ACSF) containing (in mM): 128 NaCl, 1.25 
KH2PO4, 10 Glucose, 26 NaHCO3, 3 KCl, 0.1 CaCl2, 2 MgCl2. Slices were then 
transferred in an interface-type chamber and maintained in oxygenated (95% O2, 5% 
CO2) high-calcium ACSF containing 2mM CaCl2, at 32
o
C for at least 2hrs to allow 
recovery of the tissue. At the time of the experiment each hippocampal slice was placed 
in a recording chamber (RC22C, Warner Instruments, Co., Hamden, CT) maintaining a 
continuous flow of oxygenated ACSF pre-heated at 32°C using a TC2Bip/HPRE2 in line 
heating system (Cell Micro Controls, Northfolk, VA). This setup was mounted in a Nikon 
E660E inverted microscope.  Cells were impaled with a sharp microelectrode (tip 
resistance~110 ± 24 M ), filled with 2M KMeSO4 and 10mM HEPES pH 7.4.  All 
experiments were performed in current clamp mode with bridge balance compensation 
and capacitance neutralization. Signals were digitized at 2 kHz and low-pass filtered at 1 
kHz. Recordings of membrane input resistance (IR) were obtained approximately 5 min 
after impalement measuring the steady hyperpolarization obtained injecting 200 pA 
hyperpolarizing current with an Axoclamp 2B amplifier (Axon instruments) for 800 ms 
while holding the cell at -70mV. To generate an afterhyperpolarization (AHP) cells were 
held at -65 mV (baseline) and depolarized with a 100 ms current pulse in order to 
generate three Na
+
 action potentials (APs) delivered through the intracellular electrode. 
AHPs were elicited every 30s and at least 6 AHPs were averaged per each cell. Medium 
AHP (mAHP) represents the peak hyperpolarization reached after the end of the 
depolarizing stimulus, slow AHP (sAHP) represents the hyperpolarization 800 ms after 
the end of the stimulus and the AHP duration was measured from the end of the 
depolarizing step until return to baseline. Neurons with input resistance < 50MΩ, holding 
current > 500pA and AP height < 0mV, were excluded from in this study. Data were 
acquired using pClamp 8.0 (Axon Instruments) software through a Digidata 1320A, A/D 
46 
 
converter (Axon Instrument) while mAHP, sAHP as well as duration of AHPs were 
calculated using Calmpfit software (Axon Instruments). 
Microarray Analysis of Hippocampal Tissue 
Rationale, Strengths and Pitfalls 
 Microarray technology is a very powerful tool for studying complex processes at 
the gene level.  A single chip allows the researcher to explore the intricacies of gene 
expression in very specific ways.  The experiments described below utilize this 
technology in the context of chronic drug treatment, and gene expression analysis is 
performed on tissue taken from the hippocampal region of the brain.  This type of 
analysis has been used successfully before in experiments assessing gene expression 
patterns combined with behavioral correlates (Blalock et al., 2003; Rowe et al., 2007; 
Kadish et al., 2009).  These types of studies allow one to assess gene expression patterns 
that are unique to different stages of the aging hippocampus (Blalock et al., 2005), and 
thus allow one to determine whether or not certain drug interventions are able to affect 
such patterns, and potentially ameliorate those deficits associated with said patterns. Yet 
there are some disadvantages of this technology cannot be ignored.  The GeneChips used 
here have the capability to detect over 35,000 genes and, thus, an exceptionally large 
number of genes must be detected as being significantly changed in order for the data set 
to be meaningful.  This in return means that the dataset produced is potentially unwieldy 
in its magnitude.  Analysis of the data can be cumbersome and time-consuming.  This 
forces the researcher to narrow their focus on certain expression patterns that help explain 
other collected data or mine the data to better answer the question at hand.  The strength 
is that the data can also be used to create more hypotheses driven research that will better 
elucidate the results observed as well as give a much broader and realistic view of how 
complex and interconnected signaling pathways truly are. 
General Protocol 
Using the same techniques used to prepare hippocampal slices for 
electrophysiological recording described above, the hippocampus is removed and 
processed as described previously (Blalock et al., 2003; Rowe et al., 2007; Kadish et al., 
2009). Briefly, RNA is extracted from hippocampal tissue with Trizol and is precipitated 
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with ethanol, reconstituted in RNAse-free water, and quantified and checked for RNA 
integrity with an Agilent 2100 bioanalyzer. RNA was processed to generate biotin-
labeled cRNA following the standard protocol in the Affymetrix expression analysis 
technical manual, of which 20 µg of labeled-cRNA was then applied to a full genome rat 
(230v2.0) or mouse (430v2.0) GeneChip (Affymetrix) for hybridization (one chip per 
animal). Scanned microarray images were analyzed using the Microarray Suite 5.0 
(MAS5; Affymetrix) algorithm. I have tried to ensure that the number of animals used for 
each experiment exceeds a minimum of eight per group with the exception of the pilot 
study described in chapter five.  This allows for more relevant representation of the 
expression pattern seen in the animals when exposed to a given treatment.    
Statistical methods used are similar to those previously described (Blalock et al., 
2003).  Data are prepared for analysis with extensive outlier removal techniques to 
remove repeats as well as unannotated genes along with filtering by presence and absence 
calls as well as probe set grade. Genes determined to be present and annotated and 
meeting pre-determined criteria were analyzed for significant differences with a one-way 
or two-way ANOVA depending on the specific experimental design. The statistics used 
for a given experiment will be discussed in more detail in their respective chapters. 
DAVID (Database
 
for Annotation, Visualization, and Integrated Discovery) 
functional analysis was completed on genes that were found to be significantly 
modulated.  Gene accession numbers were uploaded into DAVID 
(http://david.abcc.ncifcrf.gov/), web-based software to determine functional pathways 
that are overrepresented by the gene list provided (Dennis et al. 2003). The functional 
pathways are listed in table format with pathway description, number of genes found 
representing the pathway, and the EASE score (p-value).  The EASE score is a modified 
Fisher exact p-value and describes the enrichment of the pathway and the likelihood of 
finding said number of genes given the number of genes associated with a pathway as 
well as the  number of genes detected with the GeneChip.  
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ELISA for the Assessment of Amyloid Beta (A ) Levels 
Rationale 
 In order to determine the levels of detergent-soluble and insoluble levels of A  in 
the cortices of the transgenic models used in these studies, a well characterized serial 
extraction method was used to extract A  from the tissue.  Subsequently, the total amount 
of A  in the respective fractions was measured using a two-site sandwich ELISA 
(Murphy et al., 2007).  
Soluble A  Extraction  
The materials used for these assays were graciously provided by Dr. M. Paul 
Murphy and Ms. Tina Beckett kindly assisted.  Frozen cortical tissue was first placed in 
either RIPA buffer (50 mM Tris-HCL, 150 mM NaCl, 1% Triton X-100, 0.5% 
Deoxycholate, 0.1% SDS) or SDS (2% SDS in water alone) with a 1X complete protease 
inhibitor to create a concentration of 0.1mg/uL and then homogenized with a polytron.  
Five hundred microliters of the homogenate was then aliquoted to a microcentrifuge 
tubes and centrifugated at 100,000xg for one hour.  The supernatant was collected and the 
remaining pellet was reserved at -80  C for formic acid extraction.  
Insoluble A  Extraction 
 Reserved pellets from the previous extraction were sonicated in 70% formic acid 
(FA) and centrifugated at 100,000xg for 1 hour.  The supernatant was stored at -80  C 
until later use.  Upon thawing the FA samples were neutralized by 1:20 dilution in TP 
buffer (1M Tris base, 0.5 M Na2HPO4). 
Assay 
All samples were diluted for sandwich ELISA in AC buffer [0.02 M sodium 
phosphate buffer (pH 7.0), 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace (Serotec), 0.2% 
BSA, 0.05% CHAPS, and 0.05% NaN3].  Sandwich ELISAs for total Aβ levels for both 
the detergent soluble fraction along with the FA soluble fraction utilized capture antibody 
Ab9 (human Aβ1-16) and detection antibody 4G8 (human Aβ17-24). In short, 384-well 
plates were coated with capture antibody in PBS overnight at 4°C.  Plates were then 
washed with 1X PBS and blocked with SYNBLOCK (Serotec) for two hours at room 
temperature (RT) after which the plate was allowed to dry.  Standards and samples were 
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then loaded into the well in duplicates or triplicates and incubated overnight at 4°C. 
Plates were then washed with 1X PBST (PBS + Tween 20) followed by 1X PBS. 
Biotinylated 4G8 (4G8-BIO) was added and allowed to incubate for 4 hours at RT.     
The 4G8-BIO was detected with neutravidin-HRP incubated at RT for two hours.  The 
plate was developed with TMB developing solution and stopped with 6% o-phosphoric 
acid and read with a Vector plate reader. Data were then corrected for dilution factors and 
is presented as either fmol or pmol per milligram of tissue.  
Tissue Histology 
 Various histological methods were used throughout. These include staining for 
neutral lipids (oil red O), collagen (Gomori trichrome), and amyloid beta (WO2 ab).  
These methods are described briefly here. 
Oil Red O   
This particular stain of lipids was developed decades ago (McVean et al., 1965), 
but is still used to detect lipids within frozen tissue, and specifically as way to detect lipid 
accumulation in the liver (Fiorini et al., 2004).  This stain is considered an efficient 
method by which to assess the extent of steatosis induced by chronic treatment with an 
LXR agonist. 
Flash frozen livers were sectioned (10 m) on glass slides and stored at -80 C. At 
a later time, the tissue was thawed and allowed to air dry for 30 minutes, fixed in ice-cold 
10% formalin for 5 minutes and washed three times in distilled water.   
Sections were stained with oil red O stain via two different vehicles. Certain 
sections were placed in 100% propylene glycol, stained in 5% oil red O stain in 100% 
propylene glycol (Sigma Aldrich) for 8 minutes at 60 C, and subsequently placed in 85% 
propylene glycol.  Slides were rinsed in distilled water and counterstained with 
hematoxylin and subsequently mounted with an aqueous mounting media.   
Other sections were stained with oil red O stain that had been prepared in 100% 
isopropyl alcohol and the sections were processed with the MicroProbe System (Fisher 
Scientific). This allowed for more intense staining as well as improved the efficiency of 
the staining process. In short, the liver sections were first thawed and washed twice with 
PBS.  The tissue was fixed in 10% formalin for 15 minutes at room temperature (RT) and 
subsequently rinsed with 60% isopropyl alcohol.  The sections were then stained with oil 
50 
 
red O for 30 minutes at RT.  Sections were again rinsed with 60% isopropyl alcohol 
twice, washed twice with distilled water and counterstained with hematoxylin for 30 
seconds, after which the slides were rinsed again with distilled water and mounted with a 
warmed glycerol gelatin.  
Aß Pathology 
 A  pathology was visualized in the CA1 region of the hippocampus with 
immunohistochemistry (IHC) utilizing the monoclonal WO2 antibody that binds the N-
terminal (human Aβ2-8) region of human A  and is used to detect all forms of human A  
(Miles et al., 2008).  Such studies provide information on the total A  load within 
specific regions of the brain. Given that the deposition of is a key pathological hallmark 
of AD, changes in total A  load allow for the assessment of potential benefits of 
therapeutic interventions.  
 The actual histology was done by a collaborator, Dr. Inga Kadish, at the 
University of Alabama, Birmingham, and her methods are referenced here (Wang et al., 
2003; van Groen and Kadish, 2005). Depending on the study, rats or mice were deeply 
anesthetized with intraperitoneal pentobarbital
 
and intracardial perfusion performed with 
ice cold saline.  The brains were removed and placed in cold 4% paraformaldehyde for at 
least two hours or overnight and then transferred to a 30% sucrose solution for 24 hours 
or until they sank to the bottom of the container in which they were stored.  The brains 
were then placed in an antifreeze solution (15% sucrose, 30% ethylene glycol) and kept 
at -20°C. Frozen brains were shipped to the University of Alabama and sectioned on a 
freezing microtome to a thickness of 35 microns and stained with WO2 and detected with 
biotinylated goat anti-mouse and later visualized with ExtrAvidin and Ni-enhanced DAB.  
 The A  densities were measured as described (J. Wang et al., 2003; T. van Groen 
and I. Kadish, 2005).  A photomicrograph of the CA1 region of the hippocampus was 
digitized with a digital camera and converted to grayscale using Paintshop Pro 7.  The 
area of the CA1 region that was stained by WO2 was measured in several sections of the 
region using the ScionImage (NIH) program. The data are presented as mean densities 
from the measured sections within a single section. 
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Chapter 3: Effects of TO901317, an LXR Agonist, in a 
Triple Transgenic Mouse Model of AD 
Introduction 
There is good reason to consider the roles that lipids, especially cholesterol, play 
in the brain.  The brain contains nearly 25% of the entire cholesterol pool within the 
body, while only making up 2% of the total body weight. Most, if not all of this 
cholesterol is made de novo (Dietschy and Turley, 2001) and its turnover is thought to be 
very slow, most of which is attributed to its catabolism by Cyp46 to 24-OH-Chol, which 
readily diffuses out of the brain (Bjorkhem et al., 1997).  Cholesterol efflux to 
Apolipoprotein E (ApoE)  may also plays a role in the transport of cholesterol  out of the 
brain (Wahrle et al., 2004).  Dysregulation in cholesterol metabolism, specifically during 
aging, could potentially have a negative effect on neuronal function.  
Much more attention has been turned to the role of lipid metabolism in the brain 
given that epidemiological data suggests that lipid-lowering drugs may confer some 
benefit in lowering one’s risk of acquiring AD (Jick et al., 2000; Wolozin, 2004; Wolozin 
et al., 2004; Rea et al., 2005; Sparks et al., 2006; Wolozin et al., 2006; Arvanitakis et al., 
2008; Haag et al., 2009). Hypercholesterolemia is correlated with an increased risk of 
presenting with AD-related pathology (Kuo et al., 1998; Pappolla et al., 2003) and 
increased dietary cholesterol leads to an increase in amyloid-β (Aβ) levels in specific 
breeds of rabbits  and transgenic mouse models (Refolo et al., 2000; Sparks et al., 2000). 
Cholesterol levels within the plasma membranes are thought to influence Aβ processing, 
with higher cholesterol levels leading to increased production (Xiong et al., 2008) and 
lower cholesterol levels leading to a reduced rates of amyloidogenic processing 
(Bodovitz and Klein, 1996; Simons et al., 1998; Kojro et al., 2001) perhaps due to 
modulations in γ-secretase activity within cholesterol enriched microdomains (Wahrle et 
al., 2002).   A major risk factor for AD is carrying the ApoE ε4 allele which leads to the 
production of an ApoE isoform that is not as efficient in binding and transporting Aβ 
(Corder et al., 1993; Strittmatter et al., 1993; LaDu et al., 1994; LaDu et al., 1995). 
Cholesterol is also thought to accumulate around senile plaques found in the brains of 
human AD patients as well as transgenic mouse models (Mori et al., 2001) and therefore 
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may play a role in AD pathology itself. These plaques are often associated with ApoE as 
well (Huang, 2006), which may be playing a role to remove both cholesterol and Aβ.   
Microarray data obtained from studies in aged rats show that expression levels of 
certain genes intimately involved in cholesterol metabolism change around mid-age 
(approximately 12 months of age).  These include LXR itself and as well as some of its 
target genes, including SREBP and ApoE (Rowe et al., 2007; Kadish et al., 2009).   
Currently there is not a clear understanding as to why such an upregulation in this 
pathway is occurring.  One could argue that such an upregulation is a compensatory 
measure to deal with changes in lipid dynamics.  Alternatively, such an upregulation 
could be contributing to correlated cognitive decline.   Understanding the role LXRs are 
playing in this capacity could be key in elucidating the more complex role overall 
cholesterol metabolism may be playing in AD.  
LXRs themselves are nuclear receptors that bind to endogenous oxysterols 
(cholesterol metabolites), (Janowski et al., 1996) including 24(S)-OH-Chol, the major 
brain cholesterol metabolite, which, perhaps coincidentally, are elevated in the plasma of 
AD patients (Lutjohann et al., 1996; Lutjohann et al., 2000; Papassotiropoulos et al., 
2000; Lutjohann and von Bergmann, 2003).  Upon LXR activation, key proteins involved 
in cholesterol metabolism and transport including ApoE and several ATP binding 
cassettes such as ABCA1 (Teboul et al., 1995; Schultz et al., 2000; Zhang et al., 2001; 
Cao et al., 2002; Whitney et al., 2002; Liang et al., 2004; Ulven et al., 2004; Zelcer and 
Tontonoz, 2006) are upregulated. The LXR gene target ABCA1, specifically,  is involved 
in cholesterol efflux trough the lipidation of apolipoproteins (Lawn et al., 1999) and is 
thought to be essential in the lipidation of ApoE, considered by some to be integral in the 
efflux of amyloid-β (Aβ) (Hirsch-Reinshagen et al., 2004; Hirsch-Reinshagen et al., 
2005; Wahrle et al., 2005). 
LXR activation has been shown to reduce Aβ processing and/or levels in both in 
vitro and in vivo models, along with associated cognitive deficits (Sun et al., 2003; 
Koldamova et al., 2005; Burns et al., 2006; Riddell et al., 2007; Zelcer et al., 2007). The 
mechanism behind this reduction in Aβ as well as the improvement in cognition is not 
well understood, but has been attributed to its ability to increase ApoE and ABCA1, 
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which in turn increases efflux of both cholesterol and Aβ (Pfrieger, 2003b; Hirsch-
Reinshagen et al., 2004; Wahrle et al., 2005; Abildayeva et al., 2006; Bjorkhem, 2006).   
Taking into consideration the role that LXR appears to play in AD etiology and 
pathology, we tested the hypothesis that chronically activating LXR with a potent 
agonist, TO901317, can attenuate some of the deleterious pathologies and associated 
cognitive decline in a unique mouse model of AD that presents with both pathological 
hallmarks of the disease, plaques and tangles, the triple transgenic model (3xTg) of AD 
(APPSWE, PS1M146V, and TauP301L).  Pathology in this model progresses with the 
development of intracellular accumulation of Aβ, subsequent aggregation in extracellular 
plaques, and eventual appearance of tangles. It has been shown that the temporal 
progression of said pathologies correlates with a mirrored decline in the cognitive 
abilities of these animals (Billings et al., 2005; Oddo et al., 2006).   
Materials and Methods 
Animals  
Experiments were conducted in compliance with the institutional guidelines of the 
Animal Care and Use Committee at the University of Kentucky. Ten month-old female 
triple transgenic mice expressing APPSWE, PS1M146V, and TauP301L (3xTg-AD) were 
maintained in a 10 hour dark and 14 hour light cycle in groups of three or four.  Animal 
weights and food consumption were recorded every Monday, Wednesday and Friday 
throughout the study.  Food consumption was determined from the difference in the 
amount of food remaining in a respective cage following its earlier allotment divided by 
the number of days between feedings and the number of animals in the cage.  This was 
considered an approximated average daily food intake per animal per day.  
Medicated Diets 
Two different diets were created and formulated using the AIN-93G purified diet 
from Harlan Teklad as the base diet.  The mice were divided into treatment groups and 
fed the following diets: control diet (CON) consisting of the AIN-93G only (n=15) or 
TO901317 diet (TO9) formulated at 400 mg of active compound per kilogram of chow 
(n=13).  The intended dose of T09 for the study was 50 mg/kg body weight, but the 
calculated dose, based on average food consumption for the treatment groups was  
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approximately 33 mg/kg body weight and was determined using the daily average food 
intake, the concentration of drug in the diet, and the average weight of the mice in the 
group.    
One-way Active Avoidance 
The one-way active avoidance paradigm, a hippocampal-dependent memory task 
(Olton and Isaacson, 1968a; Munoz and Grossman, 1981), was used to assess cognitive 
ability of the mice.  Mice were trained in a dual chambered, light/dark, one-way active-
avoidance box with an electrifiable wire-grid bottom (Med Associates, VT). Mice were 
acclimated to the dimly lit training room for twenty minutes with soft music playing to 
mask sounds in the room before each session. On day one, the mice were acclimated to 
the box for a total of 120 seconds during which time they roamed freely. Baseline activity 
was recorded, including time spent in each chamber to determine chamber preference.  
Mice were then trained on the task with three trials per session for a total of four 
sessions over three days.  During a single trial the mice were introduced to the dark side 
of the box and given 4 seconds to exit to the benign, lighted side before a 0.8 mA, 25-
second foot shock was introduced.  A guillotine door between the chambers was dropped 
upon proper exit.  Time to exit was recorded.  The mouse was removed from the light 
chamber and immediately placed in a holding cage for one minute until subsequent trials.  
Day one of training consisted of one morning session. Day two of training consisted of a 
morning and an afternoon session and day 4 consisted of one morning session.  Chamber 
preference is presented as time (seconds) spent in one of two chamber choices over a 
two-minute interval and compared across the groups with a 2-way ANOVA. Training 
data is presented as mean number of avoidance/animal/session.  Count data was first 
transformed by taking its square root and then averaged across treatment groups.  Mean 
transformed counts were compared with a repeated measure two-way ANOVA.    
Blood Collection and Tissue Isolation 
Eight of the mice from each treatment group were anesthetized with an 
intraperitoneal (i.p.) injection of phenobarbital at a dose of 100 mg/kg and transcardially 
perfused with 0.9% PBS. Blood was collected via cardiac puncture from the right 
ventricle immediately prior to perfusion. Mice were then decapitated via guillotine.  
Brains were removed, and bisected with one hemisphere flash frozen in liquid nitrogen 
55 
 
and reserved for immunoassays. The hearts and livers were also harvested.  Hearts were 
weighed and normalized to body weight (mg/g).  Hearts and livers were flash frozen in 
liquid nitrogen.   
Serum Analysis 
Collected blood was centrifugated at 3,000 rpm for 10 minutes in BD Microtainer 
Tubes to separate out plasma. Plasma was aliquoted into centrifuge tubes and stored at     
-20°C until analysis.  Serum samples were analyzed by the Comparative Pathology 
Laboratory at the University of California, Davis by a Roche COBAS Mira Plus 
Chemistry Analyzer.  Values were averaged across the groups and compared with a one-
way ANOVA. 
Liver Histology 
To determine the extent of lipid accumulation in the liver of drug treated mice, oil 
red O staining was used. Flash frozen livers were sectioned (10 m) on glass slides and 
stored at -80 C. At a later time, the tissue was thawed and allowed to air dry for 30 
minutes, fixed in ice-cold 10% formalin for 5 minutes and then washed three times in 
distilled water.  Sections were placed in 100% propylene glycol and then stained in 
filtered 5% oil red o stain in propylene glycol (Sigma Aldrich) for 8 minutes at 60 C, and 
subsequently placed in 85% propylene glycol.  Slides were rinsed in distilled water and 
counterstained with hematoxylin.   
Microarrays 
Hippocampi were microdissected from one hemisphere (n=8/group) and placed in 
tubes on dry ice with RNA subsequently extracted using TRIzol reagent and precipitated 
with ethanol, reconstituted in RNAase-free water, and quantified and checked for RNA 
integrity with Agilent 2100 bioanalyzer RNA was then hybridized to an Affymetrix 
GeneChip Mouse Genome 430v2 array.  Scanned microarray images were analyzed using 
the MicroarraySuite 5.0 (MAS5; Affymetrix) algorithm.  Probe set annotations were 
downloaded from Affymetrix. Data were analyzed with a one-way ANOVA.  Genes  
with p<0.05 were compared with a t-test. Data were further analyzed through the use of 
the Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com). 
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DAVID (Database
 
for Annotation, Visualization, and Integrated Discovery) 
functional analysis was completed on genes that were found to be significantly 
modulated. Gene accession numbers were uploaded into DAVID 
(http://david.abcc.ncifcrf.gov/), web-based software to determine functional pathways 
that are overrepresented by the gene list provided (Dennis et al. 2003). The functional 
pathways are listed in table format with pathway description, number of genes found 
representing the pathway, and the EASE score (p-value).  The EASE score is a modified 
Fisher exact p-value and describes the enrichment of the pathway and the likelihood of 
finding said number of genes given the number of genes associated with a pathway as 
well as the number of genes detected with the genechip.  
CA1 Aβ Load 
Eight brain hemispheres of mice from each of the treatment groups were removed 
after saline perfusion, flash frozen and later thawed and placed in 4% paraformaldehyde 
for two hours at which point the hemispheres were placed in a 30% sucrose solution for 
24 hours and then placed in an antifreeze solution (15% sucrose, 30% ethylene glycol) 
until sectioning.  Brains were sectioned 35 microns thick on a freezing microtome and 
immunohistochemically stained with WO2 that recognizes the Aβ peptide (Miles et al., 
2008).  Amyloid beta densities were measured as previously described (van Groen and 
Kadish, 2005). 
Soluble and Insoluble Aβ Levels 
Fifty to one hundred milligrams of tissue from 7-8 cortices of mice from each 
treatment group were placed in enough (radio-immunoprecipitation assay) (RIPA) buffer 
to create equal concentrations of 0.1 mg/uL of tissue.  Tissue was then homogenized by a 
polytron set at medium speed.  Five hundred microliters of the homogenate was aliquoted 
to microcentrifuge tubes and centrifuged at 100,000 x g for one hour.  The supernatant 
was collected and the remaining pellet was reserved for formic acid (FA) extraction.   
The pellet was sonicated in 70% FA for 30 second at 0.5 second pulses.  The 
homogenate was then centrifugated at 100,000 g for one hour.  The aqueous layer was 
collected and stored at -80°C until further use.   
RIPA and FA samples were thawed on ice and vortexed well to mix.  FA samples 
were neutralized with 1:20 dilution in TPB.  Sandwich ELISA was conducted using Ab9 
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and 4G8 antibodies and detected with neutravidin-HRP and read with a Victor plate 
reader.  Data are presented as the log transformation of fmol/mg tissue. 
Correlation Between Hippocampal Aβ load and Cortical Aβ Levels in TO9-treated 
Animals 
Mean densities of Aβ staining within the CA1 region of the hippocampus were 
plotted along with either the soluble or insoluble cortical Aβ levels from the same mice.  
Regression analysis was completed. A line was fitted to the plotted data and the R-
squared value and p-value were generated.  Further correlation analysis was completed to 
obtain the Pearson r value. Data are presented with the best-fit line along with its 95% 
confidence band. 
Slice Preparation and Extracellular Recording 
Five to seven mice (n=7 Control, n=5 T0901317) from each treatment group were 
anesthetized in a CO2 filled chamber before rapid decapitation.  Brains were quickly 
removed and placed in a bath of oxygenated artificial cerebral spinal fluid (ACSF) of the 
following constituents (in mM): 114 NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 
NaHCO3, 8 MgCl, and 0.1 Ca2Cl. Hippocampi were transversely sectioned with a 
Vibratome 3000 yielding 350 m slices.  Slices were transferred to a recording chamber 
wells containing oxygenated recording CSF (RCSF) of the following constituents (in 
mM): 114 NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 NaHCO3, 2.5 Ca2Cl and 1.3 MgCl.  
RCSF was kept at 32  C with O2 perfusion of the closed interface chamber throughout the 
two-hour acclimation and recording periods.   
A twisted, bipolar Teflon coated stainless steel stimulating electrode was placed 
perpendicular to the slice in the Schaeffer collaterals, while the sharp glass recording 
electrode (3-15 MΩ) was positioned in the stratum radiatum.  The slice was stimulated 
manually, approximately once every 20 seconds for ten minutes with 0.1 volts to 
acclimate the slice.   Current outputs (I/O) were recorded during stepwise increases in 
voltage at the stimulating electrode to determine maximum output.  Baseline fEPSPs 
were recorded for 20 minutes with voltage needed empirically determined to elicit 50% 
of the maximum output as determined by I/O.  LTP was induced with a 1.0 second train 
of 100 Hz. fEPSPs were recorded for 30 minutes post-LTP induction with the same 
parameters used during baseline.   
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Statistical Note 
All results are represented as the mean + SEM.  The one-way ANOVA was used 
throughout this study, except where noted due to the nature of the original experimental 
design which included a third treatment group (which received the anti-diabetes drug, 
pioglitazone).  The data collected from this subset of animals are not included in this 
description as it did not test specifically the hypothesis of interest for this dissertation.  
The data from all three groups are to be presented together in a manuscript designed for 
publication.  (In its entirety, the study was designed with the three treatment groups 
(control, TO9, pioglitazone), and was an attempt to take advantage of a one-time 
opportunity to test key hypotheses and questions related to AD in a limited number of 
3xTg animals made available to us.)   
Results 
Body Weights and Food Consumption  
At the end of three months of treatment, the average percent change in body 
weights between the control and TO9-treated groups were significantly different as 
determined  by a 2-way repeated measure ANOVA (mean percent change: CON +20.46 
% ± 6.06 % ; TO9: -1.34% ± 4.29%).  Thus, over the course of the study, only the control 
vehicle-treated animals gained weight while the TO9-treated mice essentially maintained 
their initial weights.  Despite the lack of change in body weight in the TO9-treated 
animals, there was no significant difference in food consumption over the course of the 
study between groups (mean grams of food/mouse/day: CON 2.79 ± 0.54; TO9 2.48 ± 
0.3).  
Active Avoidance 
Each mouse was given 120 seconds to freely explore the dark and light chambers 
of the active-avoidance shuttle box (Figure 3.1A).  Both groups showed a significant 
preference for the dark side of the chamber [mean time (seconds): Dark 72.4 ± 2.3, Light 
47.8 ± 2.3; 2-way ANOVA; p<0.0001; F(2,76)= 54.83]. However, there was no significant 
difference between groups with respect to the mean time spent in the dark chamber [mean 
time (seconds): CON: 74.4 ± 4.5; TO9: 74.1 ± 5.5] (Figure 3.1A), nor in the mean 
number of crossings from light to dark (CON: 7.6 ± 0.9; TO9: 4.4 ± 1.3) or in the mean 
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time (seconds) to first crossing (CON: 20.9 ± 5.6;  TO9: 9.3 ± 2.8) indicating no 
differences in chamber preference.  
The animals were trained over a course of four sessions over three days, with 
three trials per session, to avoid an impending footshock in the dark side of the chamber.  
The number of avoidances during a session was recorded for each animal. The number of 
times the mouse avoided (the count) was transformed by taking the square root of the 
count and averaging the transformed data across the group to allow for statistical analysis 
with a 2-way ANOVA.   There was an overall effect of time on learning in the AA 
paradigm (Figure 3.1B) as well as a trend toward an effect of TO9 on learning as 
measured by the mean number of times the TO9-treated mice actively avoided the dark 
chamber over the four training sessions (2-way repeated measures ANOVA; p = 0.0832; 
F(3,75)=3.256).  
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Figure 3.1:  Learning and memory assessment in 3xTg-AD mice treated for three 
months with TO901317 using one-way active avoidance: A. There was a significant 
difference in the preference for the dark side of the chamber for both groups [CON 
(n=15) & TO9 (n=11);*** p<0.0001; F(2,76)= 54.83; 2-way ANOVA], but there was no 
significant difference between the level of preference between groups.   B. Treatment 
with TO9 (n=11) showed a trend toward increased learning ability across the training 
sessions as compared to controls (n=15) [repeated measures 2-way ANOVA; 
F(3,75)=3.256; p=0.0832]. 
 
 
A.  
B.  
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Long-term potentiation 
Baseline fEPSPs were recorded within the CA1 region of the hippocampus for 
twenty minutes prior to LTP induction from 1-3 slices taken from 3 TO9- treated animals 
and 5 control animals. There was no significant difference in the mean amplitudes of the 
fEPSPs across all treatment groups [mean amplitudes (mV): CON 1.46 ± 0.16; TO9 1.18 
± 0.19; one-way ANOVA]. LTP was induced with a single 1-second train at 100 Hz 
within the CA1 region of the hippocampus. CON and TO9 animals showed no significant 
change in the slope of the fEPSP during the first three minutes following the induction 
[post-tetanic potentiation (PTP)] of LTP.  Neither group maintained LTP over the course 
of the 30 minute after induction and TO9-treated animals actually dropped below 
baseline levels and had significantly lower fEPSP slopes than the control group (% 
baseline fEPSP slope.: CON  98.78 ± 3.44 & TO9 88.02 ± 1.13; by one-way ANOVA 
and Newman-Keuls post-hoc (p<0.05).   
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Figure 3.2:Long-term potentiation recorded from the CA1 region of the 
hippocampus of 3xTg-AD mice treated for three months with TO91317.  A. Neither 
CON-treated (n=5) or TO9-treated animals (n=3) were able to sustain LTP for thirty 
minutes after a 1 second, 100 Hz tetanus stimulation. B. There was not a significant 
difference in the induction of LTP (post-tetanic potentiation (PTP) between the groups).  
C. During the last five minutes of recording post-tetanus, TO9-treated mice showed a 
significant reduction in the slopes of the fEPSP as compared to CON, with TO9 animals 
actually dropping below the mean baseline (one-way ANOVA; Newman-Keuls post 
hoc; *p < 0.05).   
A. 
B. C. 
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Heart Weights 
The hearts of the animals were weighed upon removal from the chest cavity. 
Hearts were visibly larger in the TO9-treated mice.  Because of the difference in body 
weight between groups, heart weight was normalized to body weight.  TO9 caused a 
significant increase in heart weight (mg heart weight/g body weight: CON 3.24 ± 0.17; 
TO9 5.67 ± 0.19; one-way ANOVA, and Tukey post-hoc; p<0.05).  
 
Liver Histology 
Qualitative analysis of oil-red O staining in the livers of the 3xTg-AD mice 
demonstrated heavy lipid staining in the livers of TO9-treated mice, indicative of 
steatosis of the liver. Figure 3.3B and C show representative histological liver sections 
stained with oil-red O.  TO9 treatment resulted in large red-stained vacuoles which were 
largely absent in the livers of the control vehicle-treated mice.  
 
 
 
 
 
 
 
 
 
 
Control
T0901317
Figure 3.3: Assessment of potential cardiotoxicity and hepatotoxicity.  A. TO9 
significantly increased the heart weights of mice  after three months of treatment (one-
way ANOVA, Tukey post hoc *p<0.05). B & C. Representative liver images of oil-
red-O staining of liver tissue. TO9-treated mice (C) appeared to have larger, more 
lipid-laden livers as compared to CON livers (B) as determined with oil red O stain. 
 
A. B.  
C.  
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Serum Analysis 
A full chemistry panel was completed on the serum from animals of both 
treatment groups (Tables 3.1 and 3.2). Three of ten serum markers measured showed 
significant deviations between treatments.   TO9-treated animals had significant increases 
in calcium, glucose and uric acid as compared to CON vehicle-treated groups.  The 
combination of elevated calcium along with uric acid in humans has been found to be 
associated with the formation of kidney stones and may be a sign of hypertension (Tisler 
et al., 2002).  The elevated glucose suggests that the TO9 treatment likely exacerbated a 
pre-existing hyperglycemia in these mice.   
 
 
 
 
 
 
 
 
 Ca2+ 
ion homeostasis 
BUN 
kidney function 
ALT 
liver function 
CK 
muscle function 
Uric Acid 
kidney function 
 mg/dL mg/dL U/L U/L mg/dL 
CON 
(n=15) 
9.26 ± 0.39 26.43 ± 4.29 93.07 ± 27.95 799.4 ± 192.73 1.74 ± 0.24 
TO9 
(n=11) 
**10.88 ± 
0.41 
23 ± 1.95 98.18 ± 12.2 1289 ± 295.71 *3.625 ± 0.80 
 
 
 
 
Table 3.1: Blood serum analysis of organ function in 3xTg-AD mice treated with 
control vehicle or TO9 for three months: Values are reported as mean values ± S.E.  
Values indicated with an asterisk were found to be significantly different by a one-way 
ANOVA and Student Newman-Keuls post-hoc;**p<0.01, *p<0.05.  Serum marker 
abbreviations: BUN: blood/urea nitrogen: ALT: alanine transaminase: CK: creatinine 
kinase.  
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  CHOL HDL LDL TAG GLUC 
 mg/dL mg/dL mg/dL mg/dL mg/dL 
CON 
(n=15) 
113.9 ±  13.4 63.61 ± 7.9 11.31 ± 1.46 101.8 ± 19.4 167.4 ± 19.23 
TO9 
(n=11) 
142.98 ± 4.95 70.92 ± 6.04 11.93 ± 1.28 99.47 ± 10.66 **316.56± 
7.27 
Immunohistochemical Assessment of Aβ Load in the CA1 of the Hippocampus 
WO-2 Staining of CA1: WO-2 staining (antibodies directed toward human Aβ2-8) 
revealed both intracellular and extracellular Aβ deposition in this model (Figure 3.4B and 
C). TO9-treated animals showed a significant reduction in the levels of Aβ in the CA1 
region of the hippocampus. Average Aβ densities in control vehicle- and TO9- treated 
animals were 100.3 ± 3.19 and 80.25 ± 6.80, respectively; (one-way ANOVA and Tukey 
post hoc;p<0.05).   Surprisingly, a reduction in Aβ within the CA1 region did not confer a 
positive effect on LTP, as determined also from measures within the CA1 from the 
contralateral hippocampus of the same animals. 
Soluble and Insoluble Aβ in Cortical Tissue 
Cortical tissue was saved and used to measure soluble and insoluble Aβ levels. 
Similar to the effects seen on Aβ load in the CA1, TO9 significantly reduced the levels of 
soluble Aβ in the RIPA-isolated fraction from homogenates of cortical tissue in 3xTg 
mice by ~28% (CON 0.943 ± 0.047; TO9 0.6745 ± 0.102; one-way ANOVA and Tukey 
post-hoc; p<0.05). Interestingly, there was no significant difference in insoluble levels  
between the groups, suggesting that the reduction in Aβ load observed by WO-2 staining 
(Figures 3.4A, B and C) likely reflects reduction in soluble, intracellular Aβ. 
Table 3.2: Blood serum  metabolic panel in 3xTg-AD mice treated with control or 
TO9 for three months.  There was no significant difference in lipid levels between 
groups.  TO9 did have significantly increased glucose levels. Values indicated with an 
asterisk were found to be significantly different. (one-way ANOVA; Sudent  Newman-
Keuls post hoc; **p<0.01).  
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Figure 3.4:  Comparison of Aβ levels in the hippocampus and cortex of TO9-treated 
3xTg-AD mice.  A. TO9 significantly reduced the WO2 staining in the CA1 region of the 
hippocampus as compared to controls: n=8/group, one-way ANOVA and Tukey post-
hoc; * p<0.05. B and C. Representative photomicrographs showing WO-2 staining of the 
CA1 cell body layer.   D and E. ELISA results indicate that TO9 significantly reduced 
soluble Aβ in the cortex (one-way ANOVA, Tukey post-hoc *p<0.05), but not insoluble 
levels.    
 
A. 
B. C. 
D. E. 
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Relationship between hippocampal Aβ load and cortical Aβ Levels 
 We further evaluated the relationship between WO-2 staining in the hippocampus 
and levels of soluble and insoluble Aβ in the cortex. As shown in Figure 3.4A, cortical 
levels of soluble Aβ levels were significantly correlated (Figure 3.5A) with A  density 
measures in the CA1 region of the respective TO9-treated mice where the slope of the 
regression line significantly deviated from zero and positively correlated (R
2
=0.6496, 
F=11.12, Pearson r = 0.8060, p<0.05). There was a trend toward a positive correlation 
with the insoluble Aβ levels as well; however, this was not significant. (Figure 3.5B 
R
2
=0.4824, F = 4.661, Pearson r = 0.6946, p=0.08). 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Relationship between WO2 detected A  load within the CA1 region of 
the hippocampi and ELISA detected soluble and insoluble A  levels in the cortices 
of 3xTg-AD mice treated with TO901317 (n=7-8). A. There was a significant positive 
correlation between A  load and soluble A  levels (R
2
=0.6496, F=11.12, Pearson r = 
0.8060, p<0.05). B. A nonsignificant trend toward a positive correlation between A  
load and insoluble A   levels was observed (R
2
=0.4824, F=4.661, Pearson r = 0.6946, 
p=0.08).  
 
A. 
B. 
R2 = 0.6496 
Pearson r = 0.806 
p=0.016 
R2 = 0.4824 
Pearson r =0.6946 
p=0.0833 
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Microarray Analysis 
TO9 treatment upregulated 1272 genes and downregulated 1403 genes as 
compared to controls (one-way ANOVA; t-test post-hoc). Lists of significantly 
modulated genes along with there p-values as determined by ANOVA were uploaded to 
Ingenuity Pathway web-based software for further analysis (data not shown).  Tables 3.3 
and 3.4 list the top 20 genes most significantly upregulated or downregulated by TO9 
treatment.  The genes are organized in order of ascending p-value. Supplemental tables of 
all those genes can be found linked here: Supplemental Tables\3xtg-AD-
TO_microarray_supplemental_table.pdf 
DAVID functional analysis revealed a number of functional pathways 
overrepresented by genes that were found to be significantly modulated by three months 
of TO901317 treatment. These pathways are organized into two tables of upregulated and 
downregulated pathways.  The functional pathways are listed in order of ascending p-
value.  Not all functional pathways are listed to avoid redundancy.  Pathways were 
filtered by the number of represented molecules (5-35) and p-value (<0.05).  Lists were 
further truncated by removing pathways subsumed by more extensively represented 
pathways within a given cluster.  
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Symbol Title 
Rpl35a ribosomal protein L35a 
Mid1ip1 Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish) 
Fasn fatty acid synthase 
Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 
Btf3l4 basic transcription factor 3-like 4 
Scd2 stearoyl-Coenzyme A desaturase 2 
Scd1 stearoyl-Coenzyme A desaturase 1 
Apoe apolipoprotein E 
Srebf1 sterol regulatory element binding factor 1 
Mfsd4 major facilitator superfamily domain containing 4 
Abcg1 ATP-binding cassette, sub-family G (WHITE), member 1 
Nipsnap1 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like 
Slc35b3 solute carrier family 35, member B3 
Gpc5 glypican 5 
Pnpt1 polyribonucleotide nucleotidyltransferase 1 
Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 
Synpo2 synaptopodin 2 
Reps1 RalBP1 associated Eps domain containing protein 
Mfsd2 major facilitator superfamily domain containing 2 
Mboat5 membrane bound O-acyltransferase domain containing 5 
 
 
Table 3.3: Top twenty genes with the lowest p-values significantly upregulated in 
the hippocampi of  3xTG-AD mice treated for 3 months with TO901317.  Twenty 
genes found to be significantly upregulated in 3xTg-AD mice after three months of 
treatment with the LXR agonist TO901317 and organized in order of ascending p-
value. 
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Symbol Title 
Acn9 ACN9 homolog (S. cerevisiae) 
Spred1 sprouty protein with EVH-1 domain 1, related sequence 
Ddef1 development and differentiation enhancing 
Setd7 SET domain containing (lysine methyltransferase) 7 
Zmym1 zinc finger, MYM domain containing 1 
Ascc3 activating signal cointegrator 1 complex subunit 3 
Stard3 START domain containing 3 
Dcamkl1 doublecortin and calcium/calmodulin-dependent protein kinase-like 1 
Frmd5 FERM domain containing 5 
Bxdc2 brix domain containing 2 
EG622320 predicted gene, EG622320 
Foxk2 forkhead box K2 
Mrps15 mitochondrial ribosomal protein S15 
Trfp Trf (TATA binding protein-related factor)-proximal protein homolog (Drosophila) 
Nfya nuclear transcription factor-Y alpha 
Mrp63 mitochondrial ribosomal protein 63 
Stat1 signal transducer and activator of transcription 1 
Tns1 tensin 1 
Tnfrsf25 tumor necrosis factor receptor superfamily, member 25 
Tloc1 translocation protein 1 
 
 
Table 3.4: Top twenty genes with the lowest p-values significantly downregulated 
in the hippocampi of 3xTG-AD mice treated for 3 months with TO901317.  
Twenty genes found to be significantly downregulated in 3xTg-AD mice after three 
months of treatment with the LXR agonist TO901317 and organized in order of 
ascending p-value. 
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Functional Pathways Upregulated # p-value 
Protein Biosynthesis (Genes encoding ribosomal proteins and eukaryotic 
translation initiation factors) 
33 2.83E-07 
Oxidative Phosphorylation (Various isoforms of ATP synthase, Cytochrome c 
oxidase, ATPase, NADH dehydrogenase, Succinate dehydrogenase) 
28 4.68E-04 
mTOR Signaling Pathway (Pyruvate dehydrogenase kinase, Protein phosphatase 
2, Regulatory subunit) 
8 0.0025 
Signaling Pathway-G-Protein Families (Mitogen activated protein kinase 
kinase 1, Calmodulin 1, Guanine nucleotide binding protein, Alpha q polypeptide, 
Protein kinase, Mitogen activated kinase 3) 
8 0.0052 
Ubiquitin (Ubiquitin-like protein 5, ubiquitin-like 5, Ubiquitin C, Ubiquitin B) 10 0.0153 
Proteasome (Proteasome (prosome, macropain) subunit, alpha type 3, Proteasome 
(prosome, macropain) 26S subunit, ATPase 2, Proteasome (prosome, macropain) 
subunit, beta type 3) 
12 0.0167 
Regulation of Growth (Angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8), Insulin-like growth factor-binding protein 5 precursor, Mitochondrial 
glycerol-3-phosphate acyltransferase) 
19 0.0183 
Protein Targeting (Solute carrier family 1 (glial high affinity glutamate 
transporter), Member 3, Malonyl-CoA decarboxylase, Erbb2 interacting protein) 
30 0.0192 
Secretory Pathway (SNAP-associated protein, RAB3A, member RAS oncogene 
family, ERGIC and golgi 3, Myosin heavy chain 10, non-muscle,synaptotagmin-like 3, 
Synapsin II) 
29 0.0203 
Fatty Acid Biosynthesis (Fatty acid synthase, Stearoyl-Coenzyme A desaturase 1, 
Stearoyl-Coenzyme A desaturase 2, Protein kinase, AMP-activated, gamma 1 non-
catalytic subunit, Fatty acid desaturase 1) 
10 0.0351 
Copper Binding Protein (Amyloid beta (A4) precursor protein, Cytochrome c 
oxidase, Subunit XVII assembly protein homolog (yeast), Amyloid beta (A4) precursor-
like protein 1, Superoxide dismutase 1, Soluble) 
9 0.0351 
Acyltransferase Activity (Fatty acid synthase, Nuclear receptor coactivator 1, 
CREB binding protein, Acetyl-Coenzyme A acetyltransferase 1, Diacylglycerol O-
acyltransferase 2, Mitochondrial glycerol-3-phosphate acyltransferase) 
21 0.0404 
Transmission of Nerve Impulse/Cell-Cell Signaling (Apolipoprotein E, 
Synaptic vesicle glycoprotein 2 a, Monoamine oxidase A, Neurotrophin 3, 
Acetylcholinesterase, Glutamate receptor, ionotropic, AMPA2 (alpha 2), Myelin basic 
protein, Synaptophysin) 
29 0.0489 
Table 3.5: DAVID functional analysis of genes significantly upregulated  in 
hippocampi of 3xTG-AD mice treated for 3 months with TO901317. Functional 
pathways are listed in order of ascending p-value.   
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Downregulated # P-value 
Steroid metabolism (Lecithin-cholesterol acyltransferase, Sterol O-acyltransferase 
1, 7-dehydrocholesterol reductase, 24-dehydrocholesterol reductase, cytochrome P450, 
family 51, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1) 
21 0.002488 
Protein transporter activity (Synaptosomal-associated protein 23, Sortilin 1, 
Syntaxin 4A (placental), Syntaxin-11, Synaptosomal-associated protein) 
27 0.002689 
Membrane lipid metabolism (Phospholipase A2, group IVA (cytosolic, calcium-
dependent), UDP galactosyltransferase 8A, Phospholipase C, delta 4, Phospholipase A2, 
activating protein) 
22 0.003244 
Regulation of Wnt receptor signaling pathway (Axin1, Axin2, Dickkopf 
homolog 3 (Xenopus laevis)) 
6 0.006246 
Toll-like receptor signaling pathway (Phosphatidylinositol 3-kinase catalytic 
delta polypeptide, Toll-like receptor 2, mitogen-activated protein kinase 11, 
Phosphatidylinositol 3- kinase, regulatory subunit, polypeptide 1 (p85 alpha), Toll-like 
receptor 3 , Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) 
13 0.012962 
Cadherin-like (Mulitple protocadherins: beta 3 and alpha 2, 3, 4, 5, 8 ) 15 0.016753 
Intramolecular oxidoreductase activity (Prostaglandin E synthase 3 (cytosolic), 
Isopentenyl-diphosphate delta isomerase) 
9 0.018979 
Unfolded protein binding (Heat shock protein 1B, Calnexin, Calreticulin, 
dnaj(hsp40) homolog, suppression of tumorigenicity 13, chaperonin subunit 4 ) 
23 0.04002 
I-kappaB kinase/NF-kappaB cascade (traf family member associated nf-kappa 
b activator, interleukin-1 receptor associated kinase 2, smad nuclear interacting protein 
1) 
7 0.043463 
 
 
 
Table 3.6: DAVID functional analysis of genes significantly downregulated  in 
hippocampi of 3xTG-AD mice treated for 3 months with TO901317. Functional 
pathways are listed in order of ascending p-value.   
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Discussion 
The present study explored the effects of a three month chronic treatment with a 
potent LXR agonist in the 3xTg model of Alzheimer’s disease.  We hypothesized that 
TO901317 would improve cognition and reduce hallmark AD pathologies in the 3xTg-
AD mouse model based on its ability to alter cholesterol metabolism and studies showing 
that LXR agonists may have positive effects in other murine models of AD (Sun et al., 
2003; Koldamova et al., 2005; Jiang et al., 2008).   
Effects on Behavior and LTP.  In our behavioral analyses, we found that there was 
a nonsignificant trend toward improved performance during the learning phase of the 
active avoidance paradigm, during which TO-treated 3xTg mice appeared to perform 
better than controls over four training sessions (Figure 3.1).  This trend, however, was not 
observed during the probe session when memory was assessed, and there were no 
detectable differences between the treatment groups (data not shown).   
Consistent with a previous report, we also found that LTP was severely impaired 
in 3xTg-AD mice, as demonstrated by the amount of LTP recorded from control slices 
(Oddo et al., 2003). TO901317 treatment had no effect during the first 20-25 minutes of 
post-tetanus recording of LTP.  However, during the final phase of recording, slices from 
TO901317 treated mice were unable to sustain LTP, and actually dropped below baseline 
(Figure 3.2).  Thus, treatment with the LXR agonist appeared to exacerbate the deficits 
already present in LTP.  The microarray results provide some support for the notion that 
LTP may be modulated by the LXR agonist in such a way that would have been 
detrimental to maintaining LTP.  For example, one of the strongest downregulated gene 
pathways as identified by the DAVID functional analysis (Huang da et al., 2009) was the 
category of protein transporter activity, which includes numerous proteins involved in 
promoting the exocytosis of synaptic vesicles mediating neurotransmitter release.  
Membrane lipid metabolism, and specifically the expression of phospholipase C (PLC), 
was downregulated; this reduction could, in turn, reduce IP3 signaling and the release of 
Ca2+ from the endoplasmic reticulum store and inhibit synaptic activity.  The gene 
coding for the mGluR4 subtype of glutamate receptors was reduced with LXR and 
mGluR4 knockout mice are characterized by synaptic deficits (Pekhletski et al., 1996).  
Additional genes involved in LTP and shown to be modulated by LXR activation in the 
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present study include calcineurin, PKA and CREB.  Calcineurin gene expression was 
increased and the constitutive activation of calcineurin has been linked to LTP deficits 
(Mansuy et al., 1998).  Finally, the expression of PKA and CREB, two of the most 
important positive regulators of LTP, was reduced by LXR treatment (Lee and Silva, 
2009). 
Effects on Amyloid.  Findings consistent with published effects of LXR activation 
include the reduction in Aβ (Koldamova et al., 2005; Jiang et al., 2008).  TO was able to 
significantly reduce Aβ load within the CA1 region of the hippocampus as measured by 
IHC, as well as significantly reduce the levels of soluble Aβ in cortical tissue from these 
animals (Figure 3.4).  While there may have been a trend (p=0.08) toward a reduction in 
the insoluble form of Aβ, this was nonsignificant.  Most of the Aβ visualized with IHC 
staining with WO2 revealed intracellular deposition, which was reduced with TO 
treatment.  Circumstantially one could conclude then that the intracellular Aβ was soluble 
Aβ given that the hippocampal Aβ load was significantly correlated with the soluble Aβ 
levels.  A potential mechanism by which LXR agonist treatment reduced Aβ is by 
increasing the expression of the family of ABC transporters, which are ATP-dependent 
and responsible for causing efflux of a number of cellular constituents, including lipids 
and sterols.  Such an effect on ABCA1 has been described following LXR agonist 
treatment both in vitro and in vivo (Koldamova et al., 2003; 2005).  Alternatively, LXR 
may reduce Aβ by increasing the ApoE, which facilitates the clearance of soluble Aβ 
from the brain (Jiang et al., 2008).  The microarray results in the present studies provide 
support for both of these mechanisms and show that the expression of both ABCA1 and 
ApoE were significantly increased in the hippocampus following chronic treatment with 
the LXR agonist.  In fact, both of these were among the top 20 most significant genes 
found to be upregulated by treatment with the TO compound (Table 3.3).  Furthermore, 
the microarray results confirmed and validated our method of incorporating the drug into 
the animals’ food; these gene expression results indicate that sufficient concentrations of 
the drug were capable of reaching the brain and driving the expression of known LXR 
targets in the brain. 
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   Peripheral Side Effects.  Despite the potential benefits associated with a reduction 
in brain Aβ levels, serious peripheral side effects with chronic TO treatment were 
identified in the present study (Figure 3.3).  The livers and hearts of TO-treated animals 
were significantly larger than control mice and an Ingenuity Pathway Analysis (IPA) of 
the microarray results, which can identify toxic pathways activated by treatments or 
conditions, corroborated our findings.  In fact, the IPA analysis showed that some gene 
pathways targeted by the LXR agonist in the brain are associated with cardiac and liver 
toxicity in the periphery (e.g., cardiac and liver hypertrophy).  Histology of the livers 
showed that the likely cause of the hypertrophied liver is a buildup of lipids in the liver.  
This could be due to the excessive upregulation of genes involved in lipogenesis driven 
by chronic LXR activation.  For example, these genes are represented by the fatty acid 
synthesis and acyltransferase activity categories identified by the DAVID functional 
analysis (Table 3.5).   
In addition, blood serum analyses revealed that uric acid and calcium levels were 
significantly different than controls, suggesting potential kidney dysfunction and ion 
dysregulation. Glucose levels were also significantly increased as compared to control 
indicative of hyperglycemia and potentially diabetes in these animals. This could be 
attributed to the steatite liver.  While this is only speculation, a recent human study 
demonstrated that  intrahepatic fat rather than visceral fat is more predictive of the 
symptoms of metabolic syndrome, including hyperglycemia (Fabbrini et al., 2009).  
Unlike previous studies done for shorter periods of time, lipid levels were not 
significantly changed, perhaps indicating a certain homeostasis after longer periods on 
the drug.   
The results of this study opened up several more questions and issues, answers to 
which appeared to be critical in order to fully understand the role of the LXR pathway in 
the brain.  The mouse model had a great deal of variation, especially in weights, 
suggesting that the strain is not well established and may have a significant level of 
divergence within it.  The peripheral side effects also led to questions of appropriate 
dosage.  The dose selected was based on a study in the literature which had used a dose 
of 50 mg/kg/day administered by gavage for 11 days (Koldamova et al., 2005).  The 
present study was originally designed to deliver that dose, but over the course of the 
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study it was observed that the mice were not eating as much as anticipated; the calculated 
dose based on food consumption revealed an actual dose of 33mg/kg/day.  The studies in 
the following chapters addressed the question of whether a lower dose could be found 
that could confer the positive effects of the drug without associated peripheral side 
effects. 
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Chapter 4: Assessing TO901317 dose effects on the periphery and LXR gene targets 
Introduction 
After treating 3xTg-AD mice with TO901317 (TO) for three months, additional 
studies were undertaken to determine whether lower doses could mitigate some of the 
side effects seen with treatment at the initial dose of 50 mg/kg/day (actual dosage 
calculated based on food ingestion was estimated to be ~33mg/kg/day).  These side 
effects (discussed in Chapter 3) included increased heart weight, steatosis of the liver, 
hyperglycemia and reduced body weight as compared to control animals.  Given our 
continued interest in the role LXR activity plays in AD, it was necessary to determine a 
dosage that would activate key target pathways without inducing side effects. There 
seemed to be benefits of the drug that included a reduction in AD pathology and a trend 
toward improved learning in the 3xTg AD model; these effects, if attainable, could 
potentially outweigh some of the side effects, especially if substantially minimized.  
Therefore, a study was initiated in which mice were treated with different doses of the 
LXR agonist TO901317 (TO9) for the same duration (3 months) and some of the same 
outcome measures were assessed as in the previous study.  
 Certain groups were also concomitantly treated with fish oil (FO), given evidence 
suggesting that FO, at higher doses, can protect against steatosis of the liver (Davidson, 
2006).  This has been shown to be the case in experiments involving the treatment of 
mice with induced hepatitis with purified eicospentaenoic acid, an omega-3 fatty acid 
constituent of fish oil.  Such treatment suppresses the accumulation of fat within hepatic 
tissues, supposedly through the inhibition of SREBP, a transcription factor associated 
with the upregulation of genes directly involved in fatty acid synthesis (Kajikawa et al., 
2009b, a).   
Thus, the present study was undertaken to determine whether lower doses of the 
LXR agonist, TO901317, could potentially confer beneficial effects while reducing risk 
for peripheral side effects.  As discussed above, some groups received concomitant 
treatment with FO as an alternative strategy to reduce residual risk associated with the 
TO compound.  The results of this study proved to be quite helpful in determining doses 
that were later used in long-term treatment study in a double transgenic model (2xTg) of 
AD, which will be discussed in Chapter 5.  The experiment also allowed us to 
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demonstrate that we could detect dose-dependent effects on gene expression with 
microarray technology in a very sensitive and quantitative way.   
 
Materials and Methods  
Animals and Diets 
Twenty-eight 7 month old female B6129sv mice, a hybrid strain of the C57BL/6J 
strain and the 129/SvJ, considered to be the closest non-littermate controls to the 3xTg-
AD mice, were used. Mice were maintained in a 10 hour dark and 14 hour light cycle in 
groups of three or four.  Animal weights and food consumption were recorded every 
Monday, Wednesday and Friday throughout the study.  Food consumption was 
determined from the difference in the amount of food remaining in a respective cage 
following its earlier allotment divided by the number of days between feedings and the 
number of animals in the cage.  This was considered the approximated average daily food 
intake per animal per day.  
Six different diets were created all within the context of the AIN-93G diet from 
Harlan Teklad.  The animals were divided as evenly as possible by body weight and were 
given the following diets:  
 
 
 
Treatment Group n Diet Formulation 
Control 4 AIN-93G Diet (Harlan Teklad) 
FO 4 10 mg/day Fish Oil (2:1 EPA:DHA) 
5mg/kg TO9 5 5 mg/kg TO901317 per day 
5mg/kg TO9 + FO 5 5 mg/kg TO901317 per day + 10 mg/day Fish Oil 
20mg/kg TO9 5 20 mg/kg TO901317 per day + 10 mg/day Fish Oil 
20mg/kg TO9 + FO 5 20 mg/kg TO901317 per day + 10 mg/day Fish Oil 
 
 
 
Table 4.1: Diet formulations for the respective treatment groups.   
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TO9 was purchased from Cayman Chemicals (Ann Arbor, MI).  Fish Oil was 
provided by Zone Labs (Boston, MA).  Diets were manufactured by Harlan Teklad 
(Madison, WI) per the researcher’s formulation.  Mice were treated with the respective 
diets for 3 months.  
Tissue Collection 
All mice were anesthetized with CO2 and were subsequently decapitated via 
guillotine.  Brains were bisected out, with one hemisphere flash frozen in liquid nitrogen 
and reserved for later assays; the other hemisphere was used for microarray analysis. The 
hearts and livers were harvested.  Both were weighed and normalized to body weight 
(mg/g).  Hearts and livers were then flash frozen in liquid nitrogen.   
 
Liver Histology 
To determine the extent of lipid accumulation in the liver of drug treated mice, oil 
red O staining was performed. Flash frozen livers were sectioned (10 m) on glass slides 
and stored at -80 C. At a later time, the tissue was thawed and allowed to air dry for 30 
minutes, fixed in ice-cold 10% formalin for 5 minutes and then washed three times in 
distilled water.  Sections were placed in 100% propylene glycol, stained in 5% oil red O 
stain (Sigma Aldrich) for 8 minutes at 60 C, and subsequently placed in 85% propylene 
glycol.  Slides were rinsed in distilled water and counterstained with hematoxylin.   
Cardiac Histology: Flash frozen hearts were sectioned with a cryostat onto glass 
slides.  Tissue was later fixed with acetone for 10 minutes and subsequently incubated 
with Bouin solution for 1 hour at 56°C.  Sections were then rinsed with dH2O until clear.  
Sections were stained with Weigert hematoxylin for 10 minutes and again rinsed with 
dH2O followed by staining with Gomori Trichrome stain for 15 minutes.  Sections were 
differentiated with Acetic acid for 2 minutes at RT and washed with serially with ethanol 
and dH2O and then coverslipped with Permount (Fisher Scientific).  
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Microarrays 
Microarray analysis was completed on three of the six treatment groups, control, 5 
mg/kg TO9 and 20 mg/kg TO9.  Hippocampi were microdissected from the remaining 
unfrozen hemispheres and placed on ice with RNA subsequently extracted using TRIzol 
reagent and precipitated with ethanol, reconstituted in RNAase-free water, and quantified 
and checked for RNA integrity with Agilent 2100 bioanalyzer RNA was then hybridized 
to an Affymetrix GeneChip Mouse Genome 430v2 array.  Scanned microarray images 
were analyzed using the MicroarraySuite 5.0 (MAS5; Affymetrix) algorithm.  Probe set 
annotations were downloaded from Affymetrix. Data were analyzed with a one-way 
ANOVA.   
Results 
Animal Weights and Food Consumption 
  The mean monthly weights of the respective treatment groups did not 
significantly differ over the course of the study (data not shown).  All groups 
significantly increased in weight over time, but there was no difference between groups 
in a given month (2-way ANOVA).  There was also no difference in average food 
consumption over the course of the study. Food consumption data confirmed that the 
intended doses of TO9 were delivered. 
Liver Pathology 
  TO9 treatment significantly increased liver weight in a dose-dependent manner.  
However, only the higher dose of 20 mg/kg/day resulted in a significant elevation with 
liver weight increasing by almost 3-fold (one way ANOVA; Tukey post hoc; p<0.01).  
Co-treatment with FO was not able to mitigate the increase in liver weight.   
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Cardiac Pathology 
 Animals receiving the 20mg/kg daily dose of TO9 had significantly higher 
heart weights (Figure 4.2) but only compared to mice that received only FO.  Tri-chrome 
staining of the hearts from mice in the 20 mg/kg TO9 and 20 mg/kg TO9 + FO groups 
showed the presence of collagen staining, indicative of cardiac fibrosis. The blue stained 
collagen is indicated with arrows in Figure 4.3B.  
 
 
 
 
 
Figure 4.1:  Liver weights of mice treated for three months with 5 or 20 mg/kg/day  
of either TO9 or the combination treatment of TO9 + FO (10mg/day).    There was a 
significant difference in the weights of livers from the 20mg/kg TO9 & 20m/kg 
TO9+FO treated mice as compared to all other groups (one-way ANOVA; Tukey post 
hoc **p<0.01); (n=4-5 group). 
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Figure 4.2: Heart weights of mice treated for three months with 5 or 20 
mg/kg/day of either TO9 or the combination treatment of TO9 + FO 
(10mg/day). Heart weights were normalized to body weight.  There was a 
significant difference in the heart weights of the 20mg/kg TO and the FO treated 
mice as compared to all other groups (one-way ANOVA, Tukey post hoc *p<0.05). 
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Figure 4.3: Gomori trichrome staining of cardiac tissue from mice treated with 
control or the 20 mg/kg TO diet. A. Representative image (20X) of cardiac tissue 
from a control mouse shows confluency of cardiomyocytes and lack of blue collagen 
staining. B. Representative image (20X) of cardiac tissue from a mouse fed the 
20mg/kg TO diet shows the presence of blue collagen staining (indicated by arrows) 
along with changes in cell morphology which are largely absent in control animals. 
A. 
B. 
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Microarrays 
 Microarray analysis was completed on three of the six treatment groups: control 
(n=4), 5 mg/kg TO9 (n=5) and 20 mg/kg TO9 (n=5).  Analysis revealed a dose-
dependent effect on the mean signal-intensities of known LXR targets identified from 
literature searches. These included ABCA1, ABCG1, ApoC1, ApoD, SREBP and SCD1 
(Figure 4.4).  Other known targets, specifically those associated with the peripheral side 
effects of liver steatosis and fatty acid synthesis, were significantly affected only by 20 
mg/kg TO9 (FASn and FADS2).  These targets are shown in Figure 4.4.  Significance 
was determined using a one-way ANOVA and Tukey’s post hoc (p<0.05). Links to 
supplemental tables of all genes found to be significantly modulated can be found linked 
here: Supplemental Tables\TO9_and_FO_microarray_supplemental_table.pdf. 
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Figure 4.4: Mean signal intensities of known LXR targets.  These known LXR target 
genes show a dose-dependent upregulation of the gene expression as measured by 
microarray and analyzed with a one-way ANOVA (n=4-5); Tukey post hoc (*=p<0.05, 
**=p<0.01. ***=p<0.001). 
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Discussion 
  
The lower dose daily dose of 5 mg/kg of the TO9 compound did not have as   
severe of an effect on the liver and heart weight as did the higher dose of 20 mg/kg 
(Figures 4.1 and 4.2).  The lower dose was also able to significantly increase the gene 
expression of several key LXR targets including those associated with the beneficial 
effects of the compound (e.g., ABCA1 and various apolipoproteins).  Although the lower 
dose increased expression of several known LXR targets, not all known LXR targets 
were altered (e.g., ApoE).  Thus, whether this lower dose confers the same level of 
benefit as seen in the previous study (50mg/kg/day to 3xTg AD mice), specifically in 
reducing AD related pathologies, remains to be determined.  It should be noted that the 
addition of fish oil (FO) to the treatments was unable to attenuate the liver hypertrophy 
observed at the higher TO9 dose of 20 mg/kg, although it may have slightly reduced 
cardiac hypertrophy (Figures 4.1 and 4.2).  
 An interesting aspect of the present study was that several known targets of LXR 
were modulated in a dose-dependent manner within the hippocampus.  Again, this 
experiment is a proof of principle demonstration that the drug, included in the food, can 
exert dose-dependent effects in the brain.  Secondly, it shows that microarray technology 
is very sensitive and can reliably detect changes in gene expression in response to 
different levels (e.g., doses) of treatment, which goes beyond simple directional analysis 
(e.g., up or down expression).  Thus, microarray analyses can be used to determine the 
magnitude of the effect of pharmacological intervention on specific pathways.  
   
 
 
 
 
 
 
88 
 
Chapter 5: The Effects of Chronic LXR Activation in a 2xtg-AD Mouse Model 
Introduction 
We previously described the effects of chronic treatment with the potent liver X 
receptor (LXR) agonist TO901317 (TO9) in the 3xTg mouse model of Alzheimer’s 
disease (AD).  In addition, we examined the effects of additional doses of the TO9 
compound in a separate group of mice (hybrid strain of the C57BL/6J strain and the 
129/SvJ) considered to be the closest non-littermate controls to the 3xTg-AD mice  
(Chapters 3 and 4).  In the 3xTg model, TO9 reduced Aβ pathology with minimal effects 
on learning and memory or LTP. The triple-transgenic animals used in the study first 
described in chapter 3 present with early intracellular Aβ accumulation and have marked 
cognitive deficits. TO9 was able to lower the Aβ load within the CA1 region of the 
hippocampus as well as significantly reduce the soluble Aβ levels within the cortical 
tissue.  This appeared to translate into improved learning in the one-way active avoidance 
learning paradigm, a hippocampal dependent task. Yet there were substantial peripheral 
side effects which included steatosis of the liver as well as cardiac hypertrophy. To 
address these issues, a second study was carried out in which two different doses of the 
TO9 compound were used a low dose (5mg/kg/mouse/day) and a high dose 
(20mg/kg/mouse/day).   
The experiment described in chapter four found that the lower dose of TO9 did 
not significantly increase the liver weights of the mice as compared to animals fed either 
a control diet or a diet supplemented with fish oil.  This was also true of heart weight.  
Furthermore, the low dose was able to upregulate known LXR targets thought to be 
responsible for benefits observed.  Yet this low dose did not upregulate these genes at the 
same level as did the high dose of TO9 nor was it able to significantly upregulate all 
those genes that the high dose was able to upregulate, therefore introducing some 
uncertainty about whether or not the low dose could upregulate genes that were actually 
required to confer the compound’s benefits but were yet unknown. But the side effects 
observed with the high dose TO9 cannot be ignored, so the utilization of this dose in 
future long-term treatment studies carries certain risk.  
It was decided then to carry out a third experiment involving six months of 
treatment with both doses in a double transgenic model of AD (2xTg-AD).  There were 
89 
 
concerns about the 3xTg-AD mouse line, in that there was unresolved variability within 
the strain that could potentially confound long-term treatment results.  There were also 
issues about its availability; therefore it was more reasonable to carry out the experiment 
described below in a more stable and established mouse model of AD.    
Material and Methods 
Animals  
Experiments were conducted in compliance with the institutional guidelines of the 
Animal Care and Use Committee at the University of Kentucky. Five to six-month old 
male wild-type (n=31) and hemizygous (n=30) congenic AD mice (B6.Cg-Tg(APPswe, 
PSEN1dE9)85Dbo/J)  were purchased from Jackson Laboratories (stock number 315864) 
and maintained in a 10 hour dark and 14 hour light cycle.  Animal weights and food 
consumption were recorded throughout the study.  Food consumption is considered to be 
an approximated average in that the food consumed is averaged for 2-3 days across the 
entire population of a given cage.  
 
Medicated Diets 
All diets were purchased from Harlan Teklad (Madison, WI).  The AIN-93G diet 
was used as the base formulation into which the T0901317 (TO9) compound (Cayman 
Chemical, Ann Arbor, MI) was added.  Based on our previous studies we knew the 
approximate amount of food a mouse eats, which in our hands is approximately 3 grams 
of food per day.  Based on this figure,   three diets were formulated, two of which were to 
deliver the following doses of TO9: control diet (AIN-93G only), 5 mg/kg/body weight 
diet (AIN-93G + 45 mg TO9 per kg of diet), and 20 mg/kg/body weight diet (AIN-93G + 
200 mg TO9 per kg of diet). Intense heat associated with autoclaving along with 
irradiation was avoided to insure that the chemical structures of the incorporated 
compounds were not compromised. The 31 wild-type and 29 hemizygous mice were 
divided as equally as possible based on weight and fed one of the three diets creating six 
groups of nine to eleven mice. The mice were allowed water and the respective diets ad 
libitum for 7 months.   The groups were as follows: WT-CON (n=11), TG-CON (n=9), 
WT-5mg/kg (n=10), TG-5mg/kg (n=10), WT-20mg/kg (n=10) and TG-20mg/kg (n=10). 
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Contextual Fear Conditioning 
Conditioning took place in one half of a shuttle box with an electrifiable grid floor 
in a darkened training room lit only by a single lamp approximately one foot above the 
chamber.  Two of the walls as well as the ceiling of the chamber consisted of clear 
Plexiglas with the front wall covered halfway with red tape to allow for observation and 
the back wall covered by a black and white contrasting plus sign.  The guillotine door to 
the neighboring chamber was closed to prevent escape from an unavoidable shock.  The 
surrounding environment was kept as silent as possible.  The novel environment 
consisted of a clear glass cylinder 7 inches high and 8 inches in diameter with a 
galvanized steel lid and bottom.  The novel environment apparatus was placed in the 
opposite corner of the room in which previous training took place under normal room 
lights.   
Animals were trained and observed over two consecutive days.  On day one 
animals were brought into a dark training room individually.  Each animal was placed in 
the chamber for two minutes to freely explore.  The animals’ freezing behavior was 
observed during the initial introduction to the chamber with freezing behavior defined as 
the lack of all voluntary movement. At the end of two minutes a 22-second audible 
conditioned stimulus (CS) started (a clicking sound at 4 Hz).  During the last two seconds 
of the CS, a 1.5 mA footshock was initiated.  The entire session was then repeated once, 
followed by a 30 second interval after which the animal was removed from the training 
room. The chamber was wiped with ethanol between each animal.    
Twenty-four hours later the animals were reintroduced into the context in which 
they were shocked the previous day and freezing behavior was again observed by two 
observers using 10 second time samplings for five minutes.   The animal was then 
removed from the training room.  Approximately one hour after the last animal was 
observed in the contextual environment, the animals were introduced into the novel 
environment in a lit training room.  Animals were given 2 minutes of free exploration 
during which time freezing behavior was observed.  After 2 minutes the CS was played 
for 22 seconds and freezing behavior was again observed for 2 minutes.  The novel 
environment was swabbed with 1% acetic acid between animals to avoid olfactory 
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associations with the contextual environment.   A schematic of the CFC paradigm is 
found below in Figure 5.1.  
Contextual freezing behavior was determined by subtracting out percent freezing 
behavior in the contextual environment prior to footshock from percent freezing behavior 
in the same contextual environment 24 hours post-footshock.  Proportions of time spent 
freezing in the contextual environment for the respective treatment groups were 
transformed by taking its arcsin and then analyzed with 2-way ANOVA.   
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematic of contextual fear conditioning protocol.  On day 1, the 
animal experiences two CS-UCS pairings within the contextual environment.  
Twenty-four hours later the animal is returned to the same contextual environment 
and freezing behavior is measured for five minutes minus the CS.  Later in the day, 
the mouse is placed in a novel environment and observed for freezing behavior before 
and after the CS.  
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Tissue Collection 
Animals were anesthetized with pentobarbital (150 mg/kg) and transcardially 
perfused with 0.9% cold saline.  Blood was collected via heart puncture prior to 
perfusion.  Animals were then decapitated and brains were quickly removed and placed 
in ice-cold artificial cerebral spinal fluid and were subsequently bisected.  The right 
hemisphere was placed in cold 4% paraformaldehyde.  The hippocampus was dissected 
out of the remaining left hemisphere and was snap frozen in RNAse free tubes embedded 
in dry ice.  The livers and hearts of the animals were dissected out post-perfusion and 
weighed.  Tissue weights were normalized to body weight.  Digital photographs were 
taken of the livers for qualitative comparisons of gross changes in liver morphology. 
 
Liver Histology 
Frozen liver sections were first thawed and washed twice with PBS.  Tissue was 
fixed in 10% formalin for 15 minutes at room temperature (RT) and subsequently rinsed 
with 60% isopropyl alcohol.  The section were then stained with oil red O in 100% 
isopropyl alcohol for 30 minutes at RT.  Sections were again rinsed with 60% isopropyl 
alcohol twice, then washed twice with distilled water twice and then counterstained with 
hematoxylin for 30 seconds, after which the slides were rinsed again with distilled water 
and mounted with a warmed glycerol gelatin.  
 
Blood Collection and Serum Analysis 
Blood was collected via cardiac puncture from the right atrium immediately prior 
to perfusion. Collected blood was centrifugated at 3,000 rpm for 10 minutes in BD 
Microtainer Tubes to separate out plasma. Plasma was aliquoted into centrifuge tubes and 
stored at -20°C until analysis.  Serum samples were analyzed by the Comparative 
Pathology Laboratory at the University of California, Davis by a Roche COBAS Mira 
Plus Chemistry Analyzer. Values for each animal were averaged across the treatment 
group respective of genotype and statistically analyzed with a 2-way ANOVA and 
Bonferroni post-hoc multiple comparison test. 
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Soluble and Insoluble Amyloid Beta Levels 
RIPA Extraction: Fifty to one hundred milligrams of cortical tissue from each of 
the mice were placed in enough SDS buffer to create equal concentrations of 0.1 mg/uL 
of tissue.  Tissue was then homogenized with a polytron set at medium speed.  Five 
hundred microliters of the homogenate was aliquoted to microcentrifuge tubes and 
centrifuged at 100,000 g for thirty minutes.  The supernatant was collected and the 
remaining pellet was reserved for formic acid (FA) extraction.   
Formic Acid Extraction: Pellet was sonicated in 70% FA for 10 second at 0.5 
second pulses.  The homogenate was then centrifugated at 100,000 g for one hour.  The 
aqueous layer was collected and stored at -80°C until further use.   
ELISA: SDS and FA fractions were thawed on ice and vortexed well to mix.  FA 
samples were neutralized with 1:20 dilution in TP-buffer.  Sandwich ELISA was 
conducted using Ab9 and 4G8 antibodies and detected with neutravidin-HRP and read 
with a Victor plate reader.  Data was normalized for dilution and is presented at pmol/g 
wet tissue. 
Microarray Analysis 
Using techniques used to prepare hippocampal slices for electrophysiological 
recording described above and as previously described (Thibault et al., 1995), after the 
animals are anesthetized and blood was collected the animal was decapitated with a 
guillotine. The brains were rapidly removed and placed in ice-cold artificial cerebral 
spinal fluid. The cerebellum was removed and the brain was divided by a razor blade into 
left and right hemispheres.  The hippocampus was removed from the left hemisphere and 
processed as described previously (Blalock et al., 2003; Rowe et al., 2007; Kadish et al., 
2009). Briefly, RNA was extracted from hippocampal tissue with Trizol to and is 
precipitated with ethanol, reconstituted in RNAse-free water, and quantified and checked 
for RNA integrity with an Agilent 2100 bioanalyzer. RNA was processed to generate 
biotin-labeled cRNA following the standard protocol in the Affymetrix expression 
analysis technical manual, of which 20 µg of labeled-cRNA was then applied to a full 
mouse genome GeneChip  430v2.0 (Affymetrix) for hybridization (one chip per animal). 
Scanned microarray images were analyzed using the Microarray Suite 5.0 (MAS5; 
Affymetrix) algorithm.  
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Statistical methods used are similar to those described previously (Blalock et al., 
2003).  Data is prepared for analysis with extensive outlier removal techniques to remove 
repeats as well as unannotated genes. Genes determined to be present were analyzed for 
significant differences with a 2-way ANOVA.  
DAVID functional analysis was completed on genes that were found to be 
significantly modulated.  Gene accession numbers were uploaded into DAVID 
(http://david.abcc.ncifcrf.gov/), a web-based software to determine functional pathways 
that are overrepresented by the gene list provided. The functional pathways are listed in 
table format with pathway descriptions, number of genes found within the pathway, and 
the p-value describing the likelihood of finding that many genes with respect to the 
number of  known genes in the pathway along with the number of genes detected with the 
genechip.  
Results 
Animal Weights 
There was a significant effect of drug (F (5,35) = 27.7) and  time (F (7,35) =10.5) on 
the extent of weight change over the course of the eight months of treatment (p<0.001; 2-
way ANOVA).  All the mice gained weight over the course of the study, but mice fed the 
20mg/kg TO diet had a significantly reduced change in body weight as compared to both 
controls (Bonferroni post hoc; p<0.001) from the time the diet was first introduced 
(Figure 5.2).  
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Figure 5.2: Mean percent monthly change in body weight.  The mean animal weights 
for each treatment group (n=9-11/group) were obtained for each week and then averaged 
over a given month.  Mean monthly weights were then compared to the mean weight of 
the respective treatment group during month one and are presented here as percent change 
for each groups mean starting weight.  There was a positive change in weight for all six 
groups.  TO treatment had a dose-dependent effect on the magnitude of this change over 
the course of treatment with the 20mg/kg fed animals showing a significant lack of weight 
gain at the end of the study (2-way ANOVA, Bonferroni post hoc; ***p<0.001).    
*** 
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Food Consumption 
 As was seen in previous studies with this particular compound, there was not a 
significant difference in the daily food intake averaged for each week across the course of 
the study (Table 5.1) with mean daily consumption ranging between 2.7 and 3.1 
g/mouse/day. 
 
 
 
 
 
 
Group WT-
Control 
(n=11) 
TG-Control 
(n=9) 
WT-
5mg/kg 
(n=10) 
TG-5mg/kg 
(n=10) 
WT-
20mg/kg 
(n=10) 
Tg-
20mg/kg 
(n=10) 
g/day 
Mean±SE 
2.9 ± 0.05 2.8 ±0.03 2.97 ± 0.04 2.7 ± 0.04 2.9± 0.04 3.1 ± 0.03 
 
Contextual Fear Conditioning 
 Figure 5.3 shows the percent freezing within the individual sessions of the CFC 
paradigm. There was a marked difference in the freezing behavior between the WT and 
TG animals, indicating memory deficits in the transgenic animals.  
Freezing behavior was observed and measured 24 hours after the last conditioning 
session within the same environment that a footshock was delivered before to measure 
memory recall of the spatial context (Figure 5.4).  Data are represented as the arc sin 
transformation of the proportion of time spent freezing during a five minute interval.  
There was a significant effect of drug (F(2,54)=9.0; p<0.001) and genotype (F(1,54)=11.14; 
p<0.01) on freezing behavior (2-way ANOVA).  WT animals spent a significantly greater 
amount of time freezing in the contextual environment when compared to TG animals 
Table 5.1: Mean food consumption. All mice were allotted 5 grams of food per 
day per mouse.  The food was placed in a cage of 1-4 mice.  Remaining food was 
measured and divided by the number of mice in a cage and by the number of days 
since the time they were last fed.  This number is considered an approximate 
average.  Average daily food intake for each mouse was averaged for a given week 
and then averaged over the course of the study.  There was not a significant 
difference in the average daily food intake for any of the groups. 
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and TO treatment increased freezing behavior in all groups. The 20mg/kg TO-treated WT 
mice spent a significantly greater amount of time freezing than the CON-treated WT 
mice (p<0.05; Bonferroni post hoc).   Within the TG mouse cohort, only the 20 mg/kg 
TO-treated animals showed significantly increased freezing behavior that both the CON- 
and 5mg/kg TO9-treated TG animals (p<0.05; Bonferroni post hoc).  
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Figure 5.3: Mean percent freezing of mice from the different treatment groups 
over the course of the CFC sessions.  Freezing behavior was absent during baseline 
observations (n=9-11/group).  Freezing behavior increases dramatically after the first 
CS/UCS pairing for the WT animals and remained high 24 hours later in the contextual 
environment, with the highest freezing behavior seen in WT-20mg/kg TO9.  Only Tg-
20mg/kg TO9 mice appear to exhibit a similar level of response within the contextual 
environment as did the WT.  Freezing behavior within the novel environment was low 
for both WT and TG animals. 
 
. 
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Figure 5.4: Proportion of time spent freezing for all groups within the contextual 
environment 24 hours after final CS-UCS pairing. (n=9-11/group) There were both 
significant effects of drug (F(2,54) = 9.0; p<0.001) and genotype (F(1,54)=11.14;p<0.01) 
on the amount of time spent freezing in the contextual environment (2-way ANOVA). 
WT animals showed a dose-dependent increase in freezing behavior with 20mg/kg 
significantly increasing freezing behavior as compared to WT-Controls (Bonferroni 
post hoc; *p<0.05). High doses of TO9 were able to increase freezing behavior in the 
TG-20mg/kg mice, which froze more than both TG-Con and TG-5mg/kg TO9 groups 
(Bonferroni post hoc; p<0.05) within the same context. 
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Serum Analysis 
An extensive blood serum analysis was completed on the serum from all of the 
animals in the study.  Data revealed not only dramatic treatment effects on specific serum 
markers, but also genotype differences. Mean values for all the respective treatment 
groups can be found in Table 5.2A and Table 5.2B.  These values are represented in a 
graphical form as well in order to facilitate a clearer understanding of the effects of both 
genotype and drug on individual biomarkers.   Table 5.2A shows blood markers used to 
determine normal organ function while Table 5.2B lists metabolic markers.  
There was a significant effect of genotype and drug on the levels of alanine 
transaminase (ALT) with higher levels seen in the TG animals and with TO9 treatment.  
Cholesterol levels were found to be significantly higher in TG as compared to WT 
animals treated with either CON or 5mg/kg TO9 diets.  The 20 mg/kg TO9 diet 
significantly increased cholesterol levels as compared to both CON and 5 mg/kg TO9 
treated groups irrespective of genotype. HDL levels were significantly reduced by both 5 
and 20 mg/kg TO9 doses. LDL levels were significantly higher in CON-treated TG 
animals as compared to WT and were significantly increased in both genotypes with 
either TO9 dose.  Triglyceride levels were significantly reduced with 5mg/kg TO9 in 
both genotypes, but with higher doses there was a significant divergence, with TG 
animals showing increased triglyceride levels with 20 mg/kg TO9.  Glucose levels were 
significantly increased by TO9 in a dose-dependent fashion.  
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Tables 5.2A & 5.2B: Serum analysis of pre-determined metabolic markers: Pre-
determined serum biomarkers were measured for all animals within the study.  Values 
are presented as means across 9-11 animals per treatment group ± SE and were 
compared with 2-way ANOVA and Bonferroni multiple comparison test.  Levels of 
significance are indicated on the following graphs. A. Normal organ function. 
Biomarkers indicating normal organ function indicate potentially problematic peripheral 
drug effects of high TO9 doses.  B. Metabolic markers. Key metabolic biomarkers show 
significant effects of TO9 on lipid and glucose metabolism.  
B. 
A. 
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Figure 5.5: Serum panel assessing normal organ functions.  Panel of serum 
biomarkers indicating potential changes in normal functioning in key organs associated 
with drug metabolism and system homeostasis (n=9-11/group).  High doses of TO9 lead 
to a significant increase in ALT levels, indicative of liver damage.  BUN levels 
remained similar for all groups indicative of proper kidney function.  CK levels did 
appear to climb with higher dosage suggesting that muscle damage, including cardiac 
damage may be present. Significance was determined with a 2-way ANOVA and 
Bonferroni post hoc test (***p<0.001, *p<0.05). 
 
 
103 
 
 
 
 
 
 
 
Cholesterol
CON 5 mg/kg 20 mg/kg
100
150
200
250
300
WT
TG
m
g
\d
L
**
***
***
***
HDL
CON 5 mg/kg 20 mg/kg
0
50
100
150
200
WT
TG
m
g
\d
L
**
***
**
LDL
CON 5 mg/kg 20 mg/kg
0
50
100
150
WT
TG
m
g
\d
L
*
***
***
Triglycerides
CON 5 mg/kg 20 mg/kg
0
10
20
30
40
50
WT
TG
m
g
\d
L
** *
Glucose
CON 5 mg/kg 20 mg/kg
0
200
400
600
WT
TG
m
g
\d
L
**
***
Figure 5.6: Serum panel assessing lipid and glucose metabolism.  Standard lipid 
and glucose measurements from serum of WT and 2xTg–AD mice treated with 
control, 5 mg/kg TO9 or 20 mg/kg TO9 for 6 months (n=9-11/group). Higher doses 
of TO9 conferred the greater effect on various lipid levels, with cholesterol levels  
significantly increased by 20mg/kg TO9.  This was accompanied by an increase in 
LDL levels and a reduction in HDL levels.  Significance was determine with a 2-way 
ANOVA and Bonferroni post hoc test (*p<0.05, **p<0.01, ***p<0.001). 
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Liver Pathology 
Liver weights were normalized to body weight and were found to be significantly 
increased in a dose-dependent fashion without any effect of genotype (Figure 5.4).  Low 
and high doses of TO9 increased liver weight by 2 and 3 times the respective controls (2-
way ANOVA; Bonferroni post hoc; p<0.001).   
Figure 5.5 shows representative digital images of livers from TG and WT mice 
treated with control, 5mg/kg TO9 or 20mg/kg TO9.  There was a gross morphological 
change in the size and coloration of the livers that seemed to mirror the dose-dependent 
effects on liver weights.  Mice treated with both low and high doses of TO9 displayed 
extensive liver hypertrophy. 
 Figure 5.6 shows oil red O staining of liver sections taken from the livers 
pictured in Figure 5.5.  Hypertrophy of the livers appears to be directly associated with 
the concurrent accumulation of neutral lipids in large vacuoles within the hepatic tissue. 
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Figure 5.7: Dose-dependent changes in liver weights of both WT and TG 
treated with 5 mg/kg or 20 mg/kg TO9.  There was a significant effect of 
drug on the weights of the livers treated with either control diet, 5 mg/kg TO 
diet or 20 mg/kg TO diet for six months (n=9-11/group).  The 5 mg/kg TO diet 
and the 20 mg/kg TO diet increased the weights of the livers by 2 and 3 fold, 
respectively (2-way ANOVA; Bonferroni post hoc; *** p<0.001).   
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Figure 5.8: Representative digital images of livers taken from WT and TG 
mice treated with 5 mg/kg or 20 mg/kg TO9.  Gross morphological changes in 
liver size appeared to be dose dependent.  The gross changes in size correspond to 
changes in weights. 
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Figure 5.9: Liver histology from WT and TG mice treated with 5mg/kg or 20 
mg/kg TO9.  Oil red O staining of liver sections from WT and TG mice treated with 
5mg/kg or 20mg/kg TO9 showed increased staining as compared to WT-Control.  Lipid 
staining appeared to be higher in Tg-control animals indicating steatosis of liver as a 
result of the transgene.  Greater lipid staining in the TG-Control animals did not 
translate to significant difference in liver weight. 
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Heart Pathology 
 Heart weights were significantly increased as a result of TO9 treatment 
(p<0.0001). There was also a significant effect of genotype on heart weight (p=0.0386) 
but there was no significant interaction effect as determined by 2-way ANOVA.  In WT 
animals, both 5mg/kg TO9 and 20mg/kg TO9 significantly increased the heart weights 
(Bonferroni post hoc; p<0.01), but only the 20mg/kg TO9 significantly increased the 
heart weight in TG animals (Bonferroni post hoc; p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Genotype and drug effects on heart weight of 2xTg-AD mice. There 
was a significant effect of drug (F(2,54) = 12.3; p<0.0001) on heart weight as well as an 
effect of genotype (F(2,54) = 4.9; p<0.05), though there was not a significant interaction 
(n=9-11/group; 2-way ANOVA).  Both doses of TO9 significantly increased heart 
weights of WT mice while only the 20mg/kg TO9 dose increased the heart weights of 
TG mice ( Bonferroni post hoc;**p<0.01 ***p<0.001).  
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Soluble Aβ Levels 
As expected there was a significant difference in the soluble Aβ levels between 
the WT animals that do not express the transgenes and the TG animals that do (2-way 
ANOVA).  Within the context of the transgenic animals, the 20mg/kg TO9 dose was able 
to significantly lower levels of soluble Aβ in the cortices of the mice as compared to both 
CON-treated (Bonferroni post hoc; p<0.01) and 5mg/kg TO9-treated animals (Bonferroni 
post hoc; p<0.05) in what appears to be a stepwise, dose-dependent decrease in soluble 
Aβ levels.  There was no effect of drug on insoluble levels (data not shown).   
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Figure 5.11: Soluble A  levels in the cortices of WT and Tg mice treated with 
control, 5mg/kg TO and 20mg/kg TO for six months.  As expected,  a difference in 
Aβ levels was seen between WT and TG animals with very low levels found in the WT  
(n=9-11/group; F(2,53) = 206.3; p<0.0001; 2-way ANOVA).  In 2xTg AD mice, The 
LXR agonist, TO9, reduced soluble Aβ in a dose dependent manner [2-way ANOVA 
;Bonferroni post hoc; *p<0.05 (20mg/kg vs. 5mg/kg) and **p<0.01 (20mg/kg vs. 
Control)]. 
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Microarray Analysis 
 Data were first filtered as being present or absent.  Only probe sets with a grade of 
A were kept for further analysis and repeated probe sets were filtered.  There were a total 
of 15011 genes found to meet these criteria.     Two-way ANOVA analysis revealed only 
significant effects of genotype and drug whereas there was no overall interaction effect 
with FDRs as follows: Genotype = 0.36, Drug = 0.33, Interaction = 2.028 .  Genes were 
further filtered by median FDR (0.02) producing a list of 12,372 genes.   The 1825 genes 
that were found to be significantly modulated at a p-value of 0.05 fit specific expression 
patterns.   These patterns and the number of respective genes represented by those 
patterns can be found in Table 5.3. Graphical representations of those patterns are shown 
in Figures 5.12-5.14.  Tables 5.4-5.7 list the top twenty genes that are found to be either 
divergent in WT versus 2xTg mice or share the same linear pattern in respect to the 
upregulation and downregulation of specific genes.  Supplemental tables listing all genes 
within the respective categories listed in Table 5.3 have been linked here: Supplemental 
Tables\2xtg-AD-TO_microarray_supplemental_table.pdf. 
 DAVID functional analysis of genes categorized by patterns described in 
Table 5.3 was completed as well.  A selection of functional pathways can be found listed 
in Table 5.8.  These functional pathways were generated by all genes that fit the same 
pattern of the top twenty genes shown in Tables 5.4-5.7.  Patterns shown were selected 
based on their low p-value, their molecule representation, or their relevance to 
neurodegenerative disease.   Not all functional pathways are listed due to redundancies of 
molecules within similar pathways.  Pathways are listed in order of ascending p-value, 
where the p-value was determined by the likelihood of finding the number of known 
genes within the given pathway from the provided list. Lists were further truncated by 
removing pathways subsumed by more extensively represented pathways within a given 
cluster. 
 To further explore the effect of the drug on functional pathways, genes 
represented graphically in Figure 5.13 and 5.14 were collapsed into two groups: 
upregulated by drug and downregulated by drug and is presented graphically in Figure 
5.15.  A second DAVID analysis was completed on this set of genes.  Pathways most 
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overly represented by the genes within this list are listed in Tables 5.9 and 5.10 along 
with select genes within a given pathway.      
 
 
 
 
 
 
 
 
Directional Description Number of Sig. Genes 
Divergent Genes Upregulated in TG 571 
Divergent Genes Downregulated in TG 364 
Linearly Increased by TO9 in WT and TG 234 
Linearly Decreased by TO9 in WT and TG 173 
Upregulated by 5 mg/kg & 20 mg/kg TO9 127 
Downregulated by 5mg/kg & 20 mg/kg TO9 131 
Upregulated by 20 mg/kg  TO9 only 97 
Downregulated by 20 mg/kg TO9 only 57 
Upregulated by 5mg/kg TO9 only 45 
Downregulated by 5 mg/kg TO9 only 26 
Total Modulated Genes 1825 
 
 
Table 5.3: Expression patterns and number of significantly modulated genes as a 
function of genotype and drug dose. There was a significant effect of drug and 
genotype on gene expression levels as determined by 2-way ANOVA (p<0.05; 
Median FDR= 0.02).Standardized signal intensities of significantly modulated genes 
followed particular expression patterns.  These patterns are listed above along with the 
number of genes within each respective pattern.  
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Figure 5.12: Divergent gene expression patterns in TG versus WT 
mice. A. A total of 571 genes were found to be upregulated in TG (TG) 
animals versus WT mice and (B) 364 genes were downregulated as an 
effect of the transgene being present. Select functional pathways and 
represented gene numbers are shown with their respective pattern of 
expression. 
 
A. 
B. 
Cell Death (46) 
Inflammatory Response (25) 
Phagocytosis Engulfment (5) 
Oxidative Phosphorylation (34) 
Glycolysis (7) 
Transmission of Nerve Impulse (15) 
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Figure 5.13: Linear gene expression patterns shared by both TG and 
WT mice treated with either 5 mg/kg and 20 mg/kg TO9. A.  A total 
of 234 genes were found to be upregulated in a linear fashion as a 
function of drug dose in both WT and TG mice and  (B) 173 genes were 
linearly downregulated as a function of dose. Select functional pathways 
and represented gene numbers are shown with their respective pattern of 
expression. 
 
 
A. 
B. 
Ribosome (11) 
Lipid Transport (6) 
Lipoprotein (15) 
Cholesterol Biosynthetic Process (3) 
Response to Heat (3) 
Histone Fold (4) 
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Figure 5.14: Gene expression patterns shared in both TG and WT 
mice treated with either 5 mg/kg TO9 or 20 mg/kg TO9. A. A total of 
127 genes were found to be upregulated in similar magnitude with either 
drug dose in both WT and TG mice (B) while 131 genes were 
downregulated by either dose. Select functional pathways and represented 
gene numbers are shown with their respective pattern of expression. 
Select functional pathways and represented gene numbers are shown with 
their respective pattern of expression. 
A. 
B. 
Cofactor Binding (7) 
Fatty Acid Metabolism (4) 
Oxidoreductase (12) 
Endocytosis (8) 
Transport (32) 
Regulation of Synaptic Platicity (3) 
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Symbol Title 
Ccl6 chemokine (C-C motif) ligand 6 
Clec7a C-type lectin domain family 7, member a 
Gp49a glycoprotein 49 A 
Cd68 CD68 antigen 
Mpeg1 macrophage expressed gene 1 
Lyz2 lysozyme 2 
Cd14 CD14 antigen 
Ccl3 chemokine (C-C motif) ligand 3 
Itgb2 integrin beta 2 
Ctsd cathepsin D 
AU020206 expressed sequence AU020206 
Trem2 triggering receptor expressed on myeloid cells 2 
C1qc complement component 1, q subcomponent, C chain 
Cd53 CD53 antigen 
C1qa complement component 1, q subcomponent, alpha polypeptide 
Plek pleckstrin 
Rnase4 ribonuclease, RNase A family 4 
Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 
C3ar1 complement component 3a receptor 1 
Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 
 
 
 
Table 5.4: Top twenty genes with the lowest p-values significantly upregulated in 
2xTg-AD mice.  Twenty genes found to be significantly upregulated in 2xTg-AD mice 
as compared to WT mice.   
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Symbol  Title 
Arpp21 cyclic AMP-regulated phosphoprotein, 21 
Sst somatostatin 
Crhbp corticotropin releasing hormone binding protein 
B3gat3 beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) 
Cox5a cytochrome c oxidase, subunit Va 
Stx6 syntaxin 6 
Dennd5a DENN/MADD domain containing 5A 
Gabra1 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 1 
Pvalb parvalbumin 
Fam81a family with sequence similarity 81, member A 
Vgf VGF nerve growth factor inducible 
Ccl27a chemokine (C-C motif) ligand 27A 
Trak2 trafficking protein, kinesin binding 2 
Car2 carbonic anhydrase 2 
Stmn4 stathmin-like 4 
Ahcyl1 S-adenosylhomocysteine hydrolase-like 1 
Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 
Zcrb1 zinc finger CCHC-type and RNA binding motif 1 
Tmem59l transmembrane protein 59-like 
Npy neuropeptide Y 
 
 
 
Table 5.5: Top twenty genes with the lowest p-values significantly downregulated in 
2xTg-AD mice.  Twenty genes found to be significantly upregulated in 2xTg-AD mice 
as compared to WT mice.   
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Symbol  Title 
Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 
Mid1ip1 Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) 
Scd1 stearoyl-Coenzyme A desaturase 1 
Srebf1 sterol regulatory element binding transcription factor 1 
Scd2 stearoyl-Coenzyme A desaturase 2 
Apod apolipoprotein D 
Apoc1 apolipoprotein C-I 
Lpcat3 lysophosphatidylcholine acyltransferase 3 
Abcg1 ATP-binding cassette, sub-family G (WHITE), member 1 
Acsl1 acyl-CoA synthetase long-chain family member 1 
Mfsd2 major facilitator superfamily domain containing 2 
Fads2 fatty acid desaturase 2 
Prom1 prominin 1 
Ggt1 gamma-glutamyltransferase 1 
Apoe apolipoprotein E 
Col9a1 collagen, type IX, alpha 1 
Tgm2 transglutaminase 2, C polypeptide 
Trim35 tripartite motif-containing 35 
Col4a3bp collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
 
 
 
Table 5.6: Top twenty genes with the lowest p-values significantly upregulated in 
a linear fashion in both WT and TG mice treated with TO9 for six months.  
Twenty genes found to be significantly upregulated in a linear fashion.   
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Symbol  Title 
Idi1 isopentenyl-diphosphate delta isomerase 
S100b S100 protein, beta polypeptide, neural 
Cyp51 cytochrome P450, family 51 
Egfl6 EGF-like-domain, multiple 6 
Dmp1 dentin matrix protein 1 
Mkks McKusick-Kaufman syndrome protein 
Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 
Apc adenomatosis polyposis coli 
Sacm1l SAC1 (suppressor of actin mutations 1, homolog)-like (S. cerevisiae) 
Hist2h3c2 histone cluster 2, H3c2 
Lap3 leucine aminopeptidase 3 
Mmgt1 membrane magnesium transporter 1 
Sbk1 SH3-binding kinase 1 
Epha6 Eph receptor A6 
Jhdm1d jumonji C domain-containing histone demethylase 1 homolog D (S. cerevisiae) 
Kctd21 potassium channel tetramerisation domain containing 21 
Nudt5 nudix (nucleoside diphosphate linked moiety X)-type motif 5 
Sc5d sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog (S. cerevisae) 
Nipa1 non imprinted in Prader-Willi/Angelman syndrome 1 homolog (human) 
Ppp2r5c protein phosphatase 2, regulatory subunit B (B56), gamma isoform 
 
 
 
Table 5.7: Top twenty genes with the lowest p-values significantly downregulated in 
a linear fashion in both WT and TG mice treated with TO for six months.  Twenty 
genes found to be significantly downregulated in a linear fashion. 
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Functional Pathway: Increased in TG Gene Count p-value 
Inflammatory Response 25 1.72x10-8 
Locomotory Behavior 24 1.01x10-6 
Lytic Vacuole 23 2.52x10-6 
Phagocytosis Engulfment 5 0.002638 
Zymogen 16 3.67x10-5 
Cell Death 46 0.0018 
Natural killer mediated cytotoxicity 17 4.53x10-5 
Proteolysis 37 0.007718 
Cytokine-cytokine receptor interaction 20 0.000685 
Leukocyte differentiation 15 0.001012 
Transmembrane receptor activity 42 6.84x10-5 
Regulation of apoptosis 30 0.012 
Cytokine production 11 0.002398 
 
 
 
 
 
 
 
Table 5.8. DAVID functional analysis of signficanlty modulated genes categorized 
by expression patterns. Tables 5.4A-D list select biological pathways modulated by the 
presence of a the transgene or the TO compound at both the 5 mg/kg  dose and the 20 
mg/ kg dose.  Pathway listings include the number of genes within the pathway and the 
significance level  (p-value) based on the likelikhood of finding such a number of genes 
within a pathway by chance based on the original gene list provided in relation to the 
number of genes associated with a particular functional pathway (continued on page 
119). 
  A. 
(Continued on the following page) 
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Functional Pathway: Decreased in TG Gene Count p-value 
Oxidative Phosphorylation 34 5.04x10-22 
NADH dehydrogenase activity 11 1.13x10-7 
Mitochondrial envelope 31 5.94x10-10 
Glycolysis 7 0.001348 
Neuron projection 12 0.001603 
Transmission of nerve impulse 15 0.008375 
 
Functional Pathway: Linear Increase Gene Count p-value 
Ribosome 11 2.96x10-6 
Lipid transport 6 0.0076 
Cellular lipid metabolic process 17 0.0114 
Lipoprotein 15 0.0289 
Cellular carbohydrate metabolic process 11 0.00949 
 
Functional Pathway: Linear Decrease Gene Count p-value 
Cholesterol biosynthetic process 3 0.04 
Response to stress 16 0.012 
Response to heat 3 0.031 
EGF, extracellular 4 0.0233 
Histone fold 4 0.006471 
 
 
 
 
 
 
 
C. 
B. 
D. 
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Figure 5.15: Gene expression patterns of all genes upregulated or 
downregulated by 5mg/kg or 20mg/kg TO9. A.  Genes linearly increased and 
genes upregulated equally by both doeses were collapsed into a single list 361 gene 
upregulated by drug. B. Genes linearly decreased and genes downregulated equally 
by both doeses were collapsed into a single list 304 gene downregulated by drug. 
Select functional pathways and represented gene numbers are shown with their 
respective pattern of expression. 
 
A. 
B. 
Lipid Metabolic Process (23) 
Acyltransferase (11) 
Lipid Transport (6) 
Blood Vessel Development (12) 
Vesicle-mediated transport (16) 
Response to Heat (4) 
Steroid Biosynthetic process (3) 
Regulation of Apoptosis (18) 
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Upregulated with LXR Agonist in 2xTg Mice # p-value 
Lipid metabolic process (apolipoprotein E, fatty acid synthase,  ATP binding 
cassette A1,sterol regulatory element binding trasnscription factor, Stearoyl-Coenzyme 
A desaturase 1 & 2,  Fatty Acid desaturase 1 & 2, Angiotensinogen, acetyl-Coenzyme A 
carboxylase alpha, hydroxyacyl-Coenzyme A dehydrogenase) 
23 0.046776 
Acyltransferase activity (diacylglycerol O-acyltransferase 2, gamma-
glutamyltransferase, glycerol-3-phosphate acyltransferase, acetyl-Coenzyme A 
acetyltransferase) 
11 0.007341 
Ribonucleoprotein complex biogenesis and assembly (eukaryotic 
translation initiation factor 5, ribosomal RNA processing 1 homolog, ribosomal protein 
L7, splicing factor arginine/serine rich-5, nucleolar protein 5A)  
17 0.000164 
Oxidoreductase activity, acting on the CH-OH group of donors, NAD or 
NADP as acceptor (malic enzyme 2 & 3, glyoxylate reductase, carbonyl 
reductase 1)   
8 0.008294 
Lipid transport (apolipoprotein E, ATP binding cassette G1, Apolipoprotein C1, 
Apolipoprotein D)  
6 0.040288 
G-protein-coupled receptor binding (endothelin 1, neuron specific gene family 
member 2, chemokine ligand 12) 
6 0.006645 
Blood vessel development (endothelin 1, leukocyte cell derived chemotaxin, 
endoglin, ras homolog gene family member B, endomucin) 
12 0.024426 
Cellular carbohydrate catabolic process (pyruvate kinase, 
phosphofructokinase, glucosamine, glucose phosphate isomerase) 
7 0.004799 
 
 
 
Table 5.9: DAVID functional analysis of genes significantly upregulated  in 
hippocampi of 2xTG-AD mice treated for 6 months with TO901317.  Functional 
pathways are listed with the number of genes representing the pathway . 
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Downregulated with LXR agonist in 2xTg mice # p-value 
Vesicle-mediated transport (low density lipoprotein receptor-related  
protein 4, huntingtin interacting protein 1, exocyst complex component 3, 
caveolin 1, clathrin interactor 1, synaptojanin 1, synaptojanin 1 binding 
protein) 
16 0.048263 
Response to heat (heat shock protein 1B, heat shock protein 1, 
crystallin alpha b) 
4 0.013912 
Regulation of hydrolase activity (cytochrome c somatic, 24-
dehydroxycholesterol reductase, regulator of calcineurin 1) 
9 0.011042 
Inactivation of MAPK activity 3 0.019186 
Steroid biosynthetic process (7-dehydroxycholesterol reductase, 24-
dehydroxycholesterol reductase, sterol-C5-desaturase, cytochrome p450 
family 51, isopentenyl-diphosphate delta isomerase) 
6 0.011667 
Regulation of apoptosis (superoxide dismutase, 2, cytochrome c 
somatic, S100 protein beta polypeptide, neuroblastoma ras oncogene, 
scinderin, fibroblast growth factor receptor 3, cell division cycle and 
apoptosis regulator 1) 
18 0.0066 
Nucleosome (multiple histone clusters) 5 0.004384 
Regulation of synaptic plasticity (glutamate receptor-ionotropic, 
myosin VI) 
4 0.0224 
Regulation of MAPKKK cascade 3 0.044766 
Regulation of protein metabolic process 12 0.011776 
 
 
 
Table 5.10: DAVID functional analysis of genes significantly downregulated in 
hippocampi of 2xTG-AD mice treated for 6 months with TO901317.  Functional 
pathways are listed with the number of genes representing the pathway. 
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Discussion 
The liver X receptor (LXR) is a key regulator of lipid metabolism in the brain and 
has been shown to be altered with brain aging (Rowe et al., 2007; Kadish et al., 2009).  
Further, many of its gene targets, including ApoE and the ABCA1, have been implicated 
in Alzheimer’s disease (AD)-related pathology.  The present study was undertaken to test 
the hypothesis that chronically activating LXR, which drives the expression of genes 
involved in cholesterol metabolism and transport, will reduce pathology and cognitive 
deficits associated with AD.  We used the APPswe and PS1Δ9 double transgenic mouse 
model (2xTg) of AD originally created by crossing a mouse carrying the APPswe mutation 
with a mouse carrying the PS1Δ9 mutation (Borchelt et al., 1996).  The 2xTg model 
presents with accelerated Aβ deposition with observable deposits at 6 months of age 
(Gordon et al., 2002; Jankowsky et al., 2004; Savonenko et al., 2005).  Thus, chronic 
treatment with the LXR agonist was initiated at this critical point.   
Effect on Aβ Levels.  Similar to what was observed in the 3xTg model of AD 
(Chapter 3), we found that soluble levels of Aβ were reduced.  Further, this reduction was 
dose-dependent as TO9 reduced levels by ~12% and 40% at the 5 mg/kg and 20mg/kg 
doses, respectively (Figure 5.10).  Additional analyses will be required to determine Aβ 
deposition within specific brain regions including the hippocampus.  Nevertheless, 
because soluble Aβ levels correlated with Aβ load (measured by staining with the WO-2 
antibody and IHC) in the 3xTg model (Figure 3.5), we can infer a similar reduction in 
total Aβ load in the 2xTg model, as well.        
Effect on Behavior.  Another goal of the present study was to determine whether 
treatment with an LXR agonist could reduce associated cognitive deficits in an animal 
model of AD. In the 3xTg animals treated for three months with TO9, there was a trend 
toward improved learning on the active avoidance learning and memory paradigm in the 
absence of any significant effect on memory.  In the present study we chose the 
contextual fear conditioning paradigm, another common behavioral task used to assess 
hippocampal dependent memory in various AD mouse models (Comery et al., 2005; 
Jiang et al., 2008).  Animals receive a brief footshock paired with a conditioned stimulus 
(i.e., tone or clicking sound) within a specific context or environment.  Memory for the 
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context in which the footshock is delivered is measured as freezing behavior when the 
animal is exposed to the same contextual environment 24 hours later.  Freezing behavior 
is also observed within a novel environment, serving as a measure of context 
discrimination.  Twenty-four hours after being shocked, freezing behavior was 
significantly increased in both wild-type and transgenic mice within the contextual 
environment, although overall freezing behavior appeared to be somewhat less in the 2x-
Tg as compared to their wild-type counterparts.  Chronic TO9 treatment at the higher 
dose of 20mg/kg significantly increased freezing behavior above that observed in both 
control and 5mg/kg TO treated animals irrespective of genotype (Figure 5.3).  
Discrimination between the contextual and novel environments was demonstrated by low 
freezing behavior within the novel environment in both genotypic groups.  Furthermore, 
when the conditioned stimulus was played in the novel environment, freezing behavior 
increased slightly, but not to the extent observed previously in the original context.  
Together, these results indicate that activation of the LXR pathway can improve 
contextual memory.  Our results are similar to those recently reported in another AD 
model, the Tg2576 mouse (hAPPswe), where mice were treated with a LXR agonist for a 
much shorter duration (5 days) and at 5 months of age, prior to significant Aβ deposition 
(Jiang et a., 2008).  Interestingly, memory was improved only in Tg2576 mice and not 
the wild-type counterparts.  In contrast, we observed an effect in both wild-type and 
transgenic animals suggesting that LXR activation may have a more generalized effect on 
memory that is also independent of reductions in soluble Aβ (Figure 5.10).    
Effect of Alzheimer’s Disease Transgenes on Hippocampal Gene Expression.  The 
microarray results indicated that a total of 935 genes were divergently expressed between 
wild-type and 2xTg mice, indicating a strong effect of the transgenes on hippocampal 
gene expression (Figure 5.11).  The presence of both the APPswe mutation and the PS1Δ9 
mutations led to a substantial upregulation of genes involved in immune response. 
Inflammatory responses are prominent in the brains of AD patients and are thought to be 
in response to the accumulation of Aβ in the brain (Golde, 2002; Wyss-Coray, 2006), 
thus the 2xTg model appears to recapitulate this aspect of the disease.  DAVID functional 
analyses suggested a generalized inflammatory state in the 2xTg model as the following 
functional pathways were all significantly upregulated including inflammatory response, 
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cytokine-cytokine receptor interaction, cytokine production, and natural killer mediated 
cytotoxicity. Accompanying the upregulation in inflammatory pathways was the 
upregulation of gene pathways involved in cell death including regulation of apoptosis.  
Perhaps exacerbating inflammation/cell death, were key cellular pathways that were 
downregulated and included glycolysis and oxidative phosphorylation, suggesting 
impaired mitochondrial bioenergetics.  These results are consistent with studies showing 
reduced brain metabolism in AD and impaired mitochondrial dysfunction, with AD 
neurons characterized by fewer normally functioning mitochondria (Wang et al., 2009b).  
Other gene pathways downregulated include neuron projection and transmission of nerve 
impulse suggestive of impaired synaptic function in the 2xTg mice.  
General Effect of LXR Activation on Hippocampal Gene Expression in Wild-type 
and 2xTg Mice. A total of 361 genes were upregulated at both doses of the LXR agonist 
in both wild-type and 2xTg mice (234 of these were increased in a linear or dose 
dependent fashion – Table 5.3).  The most significant upregulated pathways were lipid 
metabolic process and acyltransferase activity, representing pathways also identified in 
the prior 3xTg study. Another upregulated pathway included ribonucleoprotein complex 
biogenesis and assembly, a pathway very similar to protein biosynthesis (also identified 
in the 3xTg study).  Genes within these categories are involved in ribosomal assembly 
and protein translation.  A novel pathway not identified in the prior 3xTg study was blood 
vessel development. Apart from upregulating similar functional pathways, multiple well-
established LXR gene targets consistently upregulated throughout these studies include 
ApoE, ABCA1, SREBF, FASN, ApoD, ApoC1, ACAT, ABCG1, FADS2, SCD1, and 
MBP.   
A total of 304 genes were downregulated at both doses of the LXR agonist in both 
wild-type and 2xTg mice (173 of these were decreased in a linear or dose dependent 
fashion – Table 5.3).  Some of the gene pathways significantly downregulated by chronic 
TO9 included vesicle-mediated transport, steroid biosynthetic process, and regulation of 
apoptosis.  Unlike the 3xTg study, where one of the major functional pathways 
downregulated was TOLL-like receptor signaling pathway, there appeared to be a lack of 
effect on inflammatory processes.  Perhaps the LXR-mediated anti-inflammatory effect is 
dose-dependent and was not observed here because of the lower doses used.  
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Peripheral Effects.  The results above need to be viewed within the context of the 
significant liver and cardiac pathology which include cardiac and liver hypertrophy 
(Figures 5.4 through 5.7), most likely due to lipid accumulation within these tissues.  
Notable serum markers also altered by treatment with the LXR agonist included ALT 
(indicative of liver damage), glucose (likely due to hepatic steatosis), and unfavorable 
alterations in total cholesterol, LDL and HDL levels at the higher 20mg/kg dose of the 
TO compound.  Thus, while there may be several CNS-related benefits associated with 
LXR activation, particularly for neurodegenerative conditions such as AD, the significant 
peripheral side effects will likely limit its use in the clinical setting.  
Summary of LXR Activation in Transgenic AD Models.  Below is a speculative 
model that attempts to synthesize results from the three previously described studies in 
which LXR agonists were given chronically in two AD different AD mouse models.   
The key component within the pathway is the upregulation of various aspects of lipid 
metabolism, including cholesterol synthesis and transport, which in turn has downstream 
effects that include the modulation of key genes involved in synaptic plasticity, apoptosis 
and the reduction of Aβ pathology.  Questions about the role of LXR on integral aspects 
of memory remain.  There is a disconnect between the reduced ability to maintain LTP 
and perceived improvement in memory.  At the same time, we see improvements in 
contextual memory absent of any correlated reductions in AD-associated pathology. 
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Figure 5.16: Speculative model of the role of chronic LXR activation role in the 
AD brain.   This model attempts to integrate key findings in studies involving the 
long-term treatment of AD mouse models with a potent LXR agonist.  The central 
component to this pathway is the upregulation of cholesterol metabolic pathways, 
which in turn leads to changes in gene expression patterns that may explain measured 
changes in synaptic plasticity, cognition and pathology.   
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Chapter Six: Short-term and Long-term Statin Treatment in mid-aged F344 Rats 
 
Introduction 
As reiterated throughout this document, the brain is one of the largest pools of 
cholesterol in the entire body, with 25% of the total cholesterol contained within its 
tissues.  Most, if not all, of this cholesterol is made de novo by neurons and glia, whose 
cholesterol content is affected little by extracerebral levels (Andersson et al., 1990; 
Edmond et al., 1991; Jurevics and Morell, 1995; Dietschy and Turley, 2001).  Most of 
this cholesterol is contained within myelin sheaths that encase axons.  Therefore, 
dysregulation in cholesterol metabolism over the lifespan may have greater impact on 
myelin than other brain components, making it more susceptible to degeneration and 
related pathologies. In fact, those axons myelinated later in life are thinner and less 
thickly sheathed in myelin.  These regions of the brain are first affected by AD 
pathologies (Bartzokis, 2004). The demyelination and abnormalities in white matter have 
been implicated in both brain aging (Chia et al., 1983; Guttmann et al., 1998; Bartzokis et 
al., 2001) and AD as well (Roher et al., 2002; Bartzokis et al., 2003; Bartzokis et al., 
2004; Chalmers et al., 2005; Bartzokis et al., 2007). 
Further corroborating this notion of potential metabolic dysregulation leading to 
age-associated impairments are links between dyslipidemia and the risk of acquiring 
dementia (Notkola et al., 1998; Yaffe et al., 2002; Pappolla et al., 2003).  Recently, it was 
shown that high cholesterol levels at midlife increase the risk of AD and vascular 
dementia later in life (Solomon et al., 2009), yet in the elderly (>65 years of age), lower 
cholesterol levels may actually predict cognitive decline (van den Kommer et al., 2009). 
Lipid metabolism also seems to make a shift in midlife, at the time when 
cognitive deficits begin to first emerge.   Studies carried out in rats have shown that a 
whole host of genes begin to be expressed differently as a part of normal aging starting at 
this critical time point.  A significantly disproportionate number of these are involved 
specifically in cholesterol metabolism (Rowe et al., 2007; Kadish et al., 2009). Several of 
these genes are also positively correlated with cognitive impairment, including ApoE and 
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the sterol regulatory element-binding transcription factor (Srebf1) (Kadish et al., 2009).  
Given this shift in lipid metabolism, and the potential emergence of metabolic 
dysregulation, it is of great interest to pharmacologically intervene in very targeted ways 
to prevent or ameliorate those deficits correlated with these events.  
 One of the most common classes of drug used to treat dyslipidemia within the 
periphery is the family of inhibitors of 3-hydroxy-3-methylglutaryl (HMG)-CoA 
reductase, or statins.  These drugs act to lower total cholesterol levels by competitively 
inhibiting the rate limiting enzyme in its synthetic pathway (Endo et al., 1976). There 
have been anecdotal reports though that HMG-CoA reductase inhibitors (statins) impair 
short-term memory (Galatti et al., 2006).  This seems juxtaposed to epidemiological data 
suggesting that statins may actually reduce the risk of acquiring AD (Jick et al., 2000; 
Wolozin et al., 2007), which is marked clinically by short-term memory deficits.   
Unfortunately, there have been few studies that have directly tested the hypothesis 
that chronic treatment with statins improves cognition as well as electrophysiological 
correlates of memory formation.  Those studies that have been completed are often 
conflicting in their results, some showing statins to be protective in various conditions 
including traumatic brain injury (Wu et al., 2008), drug induced amnesia (Parle and 
Singh, 2007) and induced inflammatory states (Clarke et al., 2008) while other studies 
have shown that statins can actually inhibit LTP by reducing levels of geranlygeraniol 
(Kotti et al., 2006), a product of the cholesterol synthesis pathway.    
Because statins are so widely prescribed throughout the world, and given the 
inconsistencies in reported data obtained from experiments utilizing these drugs, it was of 
interest to explore the effects of statins within a context similar to that in which the drugs 
are normally prescribed: to mid-age adults.  The following experiments were designed to 
address the role cholesterol regulation and metabolism plays in the brain as it passes 
through midlife into later life.  Cholesterol synthesis was targeted with two of the most 
commonly prescribed statins, simvastatin and atorvastatin.  It was hypothesized that by 
reducing cholesterol synthesis over the lifetime of an aging rodent model, we could 
attenuate deficits specific to the aging brain.  More specifically, by inhibiting the 
synthesis of cholesterol in mid-age F344 rats, it would be possible to ameliorate age-
associated deficits in long-term potentiation (LTP) and reduce the increased 
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afterhyperpolarization (AHP) that is observed in aged rats as well as attenuate correlated 
cognitive decline. Until these experiments, very few published studies have looked at the 
effects of long-term, chronic treatment of statins in rodents, especially focusing on 
statins’ effects on the CNS.   
Materials and Methods 
Animals and Diets: Short-term Treatment 
The original intended use of the rats described under the subheading, short-term 
treatment, was to study the effects of LXR activation in normal aging.  Unfortunately the 
animals would not eat the medicated diet, and therefore this particular study had to be 
abandoned.  These rats were then utilized in a pilot study to ensure that the F344 rats 
would in fact consume the statin-medicated diets.  After 1-2 months of treatment, it was 
decided to electrophysiologically study key biomarkers of aging in the hippocampi of 
these mid-aged animals. 
  In this short-term study, 15 month-old male Fischer 344 rats were obtained from 
an aged rat colony and fed either a simvastatin (n=11) or atorvastatin (n=9) medicated 
diet formulated to deliver a daily dose of 20 mg/kg body weight of the respective statin or 
a control diet (n=9).  Both diets were produced by Harlan Teklad (Madison, WI) using 
the AIN-93 G diet formulation and were available to the animals in pellet form along 
with water ad libitum for a span of 1-2 months.  Animals were housed in pairs and were 
kept on a 12 hour light/dark cycle.  Animals’ weights and food consumption were 
monitored throughout.  Animals were treated in compliance with the institutional 
guidelines of the Animal Care and Use Committee at the University of Kentucky.  . 
Electrophysiological Recording: Short-term Treatment 
Long term potentiation. Nine to eleven rats from each treatment group were 
anesthetized in a CO2 filled chamber before rapid decapitation.  Brains were quickly 
removed and placed in a bath of chilled oxygenated artificial cerebral spinal fluid (ACSF) 
of the following constituents (in mM): 114 NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 
NaHCO3, 8 MgCl, and 0.1 Ca2Cl. Hippocampi were transversely sectioned with a 
Vibratome 3000 yielding 400 m slices.  Slices were transferred to a recording chamber 
containing oxygenated recording CSF (RCSF) of the following constituents (in mM): 114 
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NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 NaHCO3, 2.5 Ca2Cl and 1.3 MgCl.  RCSF 
was kept at 32  C with O2 perfusion of the closed interface chamber throughout the two-
hour acclimation and recording periods. 
A twisted, bipolar, Teflon-coated stainless steel stimulating electrode was placed 
perpendicular to the slice in the Schaeffer collaterals, while the sharp glass recording 
electrode (3-15 MΩ) filled with ACSF was positioned in the stratum radiatum.   
Data were recorded and analyzed with Clampex and Clampfit software 
respectively. Current outputs (I/O) were recorded during stepwise increases in voltage at 
the stimulating electrode. The stimulation intensity required to elicit a fEPSP that was 
50% of the maximum uncontaminated fEPSP was used for baseline recording, LTP 
inducing tetanus, and post titanic recordings.  Prior to delivering an LTP inducing stimuli, 
baseline fEPSPs were subsequently recorded every 20 seconds for 20 minutes using the 
same stimulation intensity noted above.  LTP was induced with a theta burst stimulation 
consisting of 10 bursts of 4 pulses each at 100 Hz every 200 ms for 2 seconds. Post-
titanic FEPSPs were recorded every 20 seconds for 30 minutes after LTP was induced 
with the same parameters used during baseline.   
Mean slopes and amplitudes of the last fifteen minutes of post-LTP recording 
were compared using one-way ANOVA.  Slices whose baseline fEPSPs changed more 
than 20% during recording were omitted from the analysis.    
Afterhyperpolarization: Nine to eleven rats per treatment group were sacrificed 
and hippocampi removed to obtain 350 m thick slices. Slices were maintained in ice 
cold low-calcium artificial cerebrospinal fluid (ACSF) of the following constituents (in 
mM): 128 NaCl, 1.25 KH2PO4, 10 Glucose, 26 NaHCO3, 3 KCl, 0.1 CaCl2, 2 MgCl2. 
Slices were then transferred in an interface-type chamber and maintained in oxygenated 
(95% O2, 5% CO2) high-calcium ACSF containing 2mM CaCl2, at 32
o
C for at least 2hrs 
to allow recovery of the tissue. Hippocampal slices were placed in a recording chamber 
(RC22C, Warner Instruments, Co., Hamden, CT) maintaining a continuous flow of 
oxygenated ACSF pre-heated at 32°C using a TC2Bip/HPRE2 in line heating system 
(Cell Micro Controls, Norfolk, VA). This setup was mounted in a Nikon E660E inverted 
microscope.  Cells were impaled with sharp microelectrode, filled with 2M KMeSO4 and 
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10mM HEPES pH 7.4 (tip resistance~110 ± 24 M ), pulled from borosilicate glass 
capillaries (World Precision Instruments, Sarasota, FL) using a P80 pipette puller (Sutter 
Instruments, Novato, CA).  All experiments were performed in current clamp mode with 
bridge balance compensation and capacitance neutralization. Signals were digitized at 2 
kHz and low-pass filtered at 1 kHz. Recordings of membrane input resistance (IR) were 
obtained approximately 5min after impalement by measuring the steady 
hyperpolarization obtained from injecting 200pA hyperpolarizing current with an 
Axoclamp 2B amplifier (Axon instruments) for 800ms while holding the cell at -70mV. 
To generate an afterhyperpolarization (AHP) cells were held at -65mV (baseline) and 
depolarized with a 100ms current pulse in order to generate three Na
+
 action potentials 
delivered through the intracellular electrode. AHPs were elicited every 30s and at least 6 
AHPs were averaged per each cell. Medium AHP (mAHP) represents the peak 
hyperpolarization reached after the end of the depolarizing stimulus, slow AHP (sAHP) 
represents the hyperpolarization 800ms after the end of the stimulus and the AHP 
duration was measured from the end of the depolarizing step until return to baseline. 
Neurons with input resistance < 50MΩ, Holding current > 500pA and APs height < 0mV, 
were excluded from in this study. Data were acquired using pClamp 8.0 (Axon 
Instruments) software through a Digidata 1320A, A/D converter (Axon Instrument) while 
mAHP, sAHP as well as duration of AHPs were calculated using Calmpfit software 
(Axon Instruments).  
Animals and Diets: Long-term Treatment  
Experiments were conducted in compliance with the institutional guidelines of the 
Animal Care and Use Committee at the University of Kentucky.  Male F344 rats were 
purchased at 9 months of age from the NIA aged rat colony.   Upon receipt the animals 
were acclimated to a control diet (AIN-93G from Harlan Teklad).  After two weeks of 
acclimation, when the animals were approximately 10 months old, they were started on 
their respective diets eaten ad libitum for 9 months.  Animals were given a control 
(n=11), simvastatin (n=11) or an atorvastatin (n=11) diet. Animals were housed two per 
cage in clear plastic cages with wire grid tops and maintained in a 12 hour dark and light 
cycle.  Food consumption and animal weights were recorded throughout the study, 
approximately 2-3 times/week. (It should be noted that food consumption was averaged 
133 
 
across two animals within a single cage and should be considered an approximate 
average). 
Medicated diets were formulated within the context of AIN-93G diet by Harlan 
Teklad, Madison, WI. Tablets containing 80 mg of Atorvastatin and Simvastatin were 
crushed with a mortar and pestle to create a fine powder.  This powder was incorporated 
in the diet by the manufacturer at a concentration of 200mg/Kg and subsequently 
pelleted.  Intense heat along with irradiation was avoided to insure that the chemical 
structures of the incorporated compounds were not compromised. 
 
Behavioral Characterization: 
The rotorod was used to assess motor coordination of the rats after 8-9 months of 
treatment. Rats were trained on the rotorod apparatus for three days prior to a final 
accelerated test.  The training consisted of a one-minute training trial per animal per day 
at a constant RPM.  Animals were started at 8 RPM and graduated to 10 and 12 RPM on 
the two subsequent training days.   Animals were repositioned on the rotorod upon falling 
during the training sessions.  The final accelerated test involved a trial in which the 
rotorod revolution speed accelerated from 4-40 RPM over the course of the trial. Latency 
to fall during the accelerated task was recorded.  
The Morris water maze consisted of a pool (183x60cm) enclosed within black 
curtains that produce a semi-dark environment within the testing room.  The bottom and 
sides of the pool had been painted black. Three large contrasting spatial cues hanging 
from three of the four surrounding walls are lit by LED rope lights that wrap around the 
pool itself as well as LED can lights surrounding the pool and projecting light upward.  
This allowed for visualization of the spatial cues as well as created contrast needed for 
the Videomex tracking system and accompanying water maze software (Columbus 
Instruments).  The pool was filled with water (25±1°) to a height sufficient enough to 
submerge a hidden platform 15 centimeters in diameter by 2 cm of water.    
The animals were brought into the dark testing room lit by only one red heating 
lamp and two monitors.  During cue training, a conspicuous cue was suspended from the 
ceiling and hung 12 inches above the submerged platform marking its location.  The 
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platform was submerged during cue training to aid the rats getting on to the platform.  
Cue training lasted for three days with each rat given three trials a day.  A trial consisted 
of 60 seconds to find the platform, 30 seconds to acclimate to its surrounding while on 
the platform, and 120 seconds within a holding cage heated by a heat lamp before being 
reintroduced to the maze.  On day one, animals were introduced to the maze via the same 
quadrant for every trial.  On subsequent days, the animal was introduced in different 
quadrants every trial, rotating the drop spot in a clockwise fashion.  
Seventy-two hours after the last cue-training trial, the animals were trained in a 
similar manner as described above, but with the suspended cue removed.  Throughout the 
training sessions (3 trials/session/day) the drop spot was rotated within the day. The first 
drop spot of each day was rotated in the same clockwise fashion in order to insure that 
the rat was using the spatial cues for orientation within the maze. Both latencies to goal 
as well as path length to goal were used to determine cognitive differences between 
treatment groups during training.  
During the MWM probe trial, platform was removed from the maze and animals 
were given 60 seconds to swim freely while being monitored.  Memory was assessed 
using the percent of the time the animal spent in the goal quadrant during the first 30 
seconds of the free swim as well as the number of times the animal entered the goal 
quadrant.  
Tissue Collection 
Animals were anesthetized with pentobarbital (60mg/kg) and transcardially 
perfused with 0.9% cold saline.  Blood was collected via heart puncture prior to 
perfusion.  Animals were then decapitated and brains were quickly removed and placed 
in ice-cold artificial cerebral spinal fluid and were subsequently bisected.  The right 
hemisphere was placed in cold 4% paraformaldehyde.  The hippocampus was dissected 
out of the remaining left hemisphere and was snap frozen in RNAse free tubes embedded 
in dry ice.   
Serum Analysis 
 Blood was drawn via cardiac puncture and collected in Vacutainer tubes with 
lithium/heparin. Blood was centrifugated at 3,000 RPM at room temperature for ten 
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minutes to separate out plasma.  Five hundred microliters of serum from each animals 
(n=33) were collected and stored at -20° C until shipped for analysis.  Analysis was 
carried out by the Comparative Pathology Laboratory at the University of California, 
Davis by a Roche COBAS Mira Plus Chemistry Analyzer. 
Microarray Analysis 
Hippocampi were microdissected from the remaining unfrozen hemispheres 
(n=8/group) and placed on ice with RNA subsequently extracted using TRIzol reagent 
and precipitated with ethanol, reconstituted in RNAse-free water, and quantified and 
checked for RNA integrity with Agilent 2100 bioanalyzer RNA was then hybridized to 
an Affymetrix GeneChip Rat Genome 230-2.0 array.  Scanned microarray images were 
analyzed using the MicroarraySuite 5.0 (MAS5; Affymetrix) algorithm.  Probe set 
annotations were downloaded from Affymetrix. Data were analyzed with one-way 
ANOVA after removal of outliers and repeats.  
 DAVID (Database
 
for Annotation, Visualization, and Integrated Discovery) 
functional analysis was completed on genes that were found to be significantly 
modulated. Gene accession numbers were uploaded into DAVID 
(http://david.abcc.ncifcrf.gov/), web-based software to determine functional pathways 
that are overrepresented by the gene list provided (Dennis et al. 2003). The functional 
pathways are listed in table format with pathway description, number of genes found 
representing the pathway, and the EASE score (p-value).  The EASE score is a modified 
Fisher exact p-value and describes the enrichment of the pathway and the likelihood of 
finding said number of genes given the number of genes associated with a pathway as 
well as the number of genes detected with the genechip.  
Brain Cholesterol Measurements 
Cortical samples were homogenized in methanol and HCL and subsequently 
extracted with a methanol:chloroform extraction. The lipid layer was removed and dried 
under a stream of nitrogen and reconstituted in methanol.  Free cholesterol measurements 
were done from aliquots of these samples.  Other aliquots were saponified in KOH in 
methanol.  Lipids were re-extracted, dried and reconstituted in the manner described 
above and these prepared samples were used to measure cholesterol esters.   Samples 
were analyzed using Liquid Chromatography and tandem mass spectrometry with ABI-
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4000 Q-TRAP hybrid triple quadrupole/iontrap mass spectrometer coupled with an 
Agilent 1100 liquid chromatography system. Measurements that were at were greater 
than two standard deviations away from the mean within a group were excluded. 
Results 
Animal Weights and Food Consumption: Short-term Treatment 
  Change in overall body weight was indistinguishable between groups over the 
course of treatment with a decrease in weight of less than 2% for all experimental groups. 
There was not a significant difference in daily food consumption across treatment cohorts 
within respective groups.   
LTP Recording: Short-term Treatment 
 Long-term potentiation (LTP) was recorded in transverse slices of the 
hippocampus in field CA1.  LTP was induced with theta burst stimulation (TBS) via a 
stimulating electrode placed in the stratum radiatum after 20 minutes of baseline 
recording (Figure 6.1A). Simvastatin (SIMVA) treated animals showed a significant 
increase in LTP as compared to control and atorvastatin (ATORVA)-treated animals. The 
slope values of the field excitatory post-synaptic potentials (fEPSP) during the last fifteen 
minutes of recording were significantly greater in slices prepared from SIMVA-treated 
animals. 
 There were no significant differences in the mean baseline amplitudes across the 
treatment groups (mean baseline amplitudes of the EPSP ± SE: CON -1.032mV ± 0.073, 
SIMVA -1.167 mV ± 0.09, ATORVA -0.887 mV ± 0.082; one-way ANOVA).  
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Figure 6.1: Long-term potentiation recorded in the CA1 region of the 
hippocampus in mid-aged F344 rats treated for 1-2 months with statins. A. 
Simvastatin significantly enhanced LTP as measured by the slopes of the EPSPs  
compared to both control and ATORV- treated animals(n=9-11/group). B. The slopes 
of the EPSPs during the last fifteen minutes of recording were significantly greater 
than the slopes of both CON and ATORVA-treated animals (one-way ANOVA, 
Dunnett’s post hoc *p<0.05).  
 
A.  
B.  
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AHP Recording: Short-term Treatment 
 Figure 6.2A is a representative image of an AHP following a burst of action 
potentials and the points at which the respective peaks were measured. AHPs were 
recorded from 22-25 pyramidal hippocampal neurons per treatment group with each 
group consisting of 9-11 animals. The mAHP was defined as the most hyperpolarized 
portion of the AHP and occurred within 50 ms following the end of the depolarizing 
stimulus.  The sAHP was measured 800 ms after the end of the stimulus. There were no 
significant differences in the mAHP (Figure 6.6B) and the sAHP (Figure 6.2C) between 
the three treatment groups. However, statin treatment did significantly reduce the 
duration of the AHP (Figure 6.3), by approximately 33%. 
          
 
 
 
 
Figure 6.2: AHP measurements in the CA1 region of the hippocampus of mid-aged 
F344 rats treated for 1-2 months with statins. A. Representative image of an 
afterhyperpolarization showing stimulus, mAHP, sAHP and the duration of the AHP. 
B&C. No significant differences between groups were observed in regards to the peak 
values of the mAHP or the sAHP after depolarization (n=9-11/group: 22-25 cells/group).  
A. 
B. C. 
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Peripheral Measurements: Long-term Treatment 
There was a significant interaction effect of drug and time on body weight over 
the course of the study as seen in Figure 7.1A (F=(18, 270) = 2.0; p<0.01; repeated 
measures 2-way ANOVA).  SIMVA animals had significantly lower body weight 
compared to CON during the last two months of treatment (Bonferroni post hoc; p<0.01).  
Surprisingly, the average daily food intake did not differ significantly across the 
treatment groups (Figure 6.4B) 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: AHP measurement in the CA1 region of the hippocampus of mid-aged 
F344 rats treated for 1-2 months with statins. The duration of the AHP was 
significantly reduced by both simvastatin and atorvastatin treatment (one-way ANOVA, 
Tukey post hoc *p<0.05). 
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An extensive blood chemistry profiles panel was determined from the serum of all 
the animals in the study to evaluate overall health and drug efficacy (Table 6.1).  Results 
indicated that there was not a significant difference in the indicators of normal kidney, 
liver and muscle function.  Unlike previous studies using statins in rats (Krause and 
Newton, 1995), we did see a significant reduction in total cholesterol levels with both 
SIMVA and ATORVA by 27% and 19% respectively compared to CON animals.  
SIMVA was able to significantly reduce LDL levels by 37%, whereas ATORVA lowered 
triglycerides by 59%.   Select lipid markers affected by statin treatment are listed below 
in Table 6.1 and presented graphically in Figure 6.5.   
 
 
 
Monthly Mean Weights
0 1 3 4 5 6 7 8 9 10
400
450
500
550
600
CON
SIMVA
ATORVA
*
Month
W
e
ig
h
t 
(g
ra
m
s
)
Figure 6.4: Monthly mean body weights and average daily food consumption of rats 
treated for 9 months with statins (n=11/group). A. Mean body weights were the same 
at the start of the statin treatment, but there was a significant drug effect on the groups 
over the course of the study. SIMVA-treated animals had significantly lower body 
weights than controls during the last two months of treatment (repeated measure 2-way 
ANOVA, Bonferroni post hoc *p<0.05).  B. The approximated average daily food 
consumption was not found to be significantly different (one-way ANOVA).   
 
A. B. 
141 
 
 
 
Table 6.1:  Blood serum analysis after 9 months of statin treatment (n=11/group). 
Serum levels of measured markers showed no effect of drug on key markers of normal 
liver, kidney and muscle function.  Both SIMVA and ATORVA significantly lowered 
cholesterol levels by 27% and 19%, respectively.  SIMVA had a greater lowering effect 
on LDL whereas Atorvastatin conferred a greater reduction of triglycerides.  Neither 
SIMVA nor ATORVA affected HDL levels (one-way ANOVA; Tukey’s post hoc; * = 
p<0.05, ** = p<0.01). 
 
 
Figure 6.5: Key serum lipid markers in rats treated for 9 months with statins 
(n=11/group).  A.  Both SIMVA and ATORVA significantly lowered cholesterol 
levels by 27% and 19% respectively as compared to CON. B. ATORVA conferred a 
greater reduction of triglycerides than did SIMVA. C.  Neither SIMVA nor ATORVA 
affected HDL levels D. SIMVA had a greater lowering effect on LDL (one-way 
ANOVA; Tukey’s post hoc * = p<0.05, ** = p<0.01). 
A. B. 
C. D. 
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Locomotor Assessment 
 The rotorod task was used to assess potential motor impairments. It has been 
reported that statins may induce certain myopathies (Gotto, 2003), therefore it seemed 
reasonable to assess possible muscle impairments across treatment groups to determine 
the presence of side effects as well as to determine whether or not cofounds existed 
before running the animals in the MWM to assess learning and memory, given that 
performance in the maze could have been hindered by a lessened ability to swim. 
Animals performed the rotorod task similarly with no significant difference in either the 
capability to learn the task or in their ability to perform during the probe session 
suggesting that there was not a distinguishable difference in the rats in respect to 
locomotor activity. 
 
 
 
 
 
 
Learning and Memory Assessment 
 Animals were first trained to reach the platform for three days in the presence of 
a conspicuous cue hanging above the partially submerged platform. During cue training 
(Figure 6.7), there was no discernable difference between the treatment groups with 
respect to their ability to see the cue and find the platform suggesting that the animals had 
sufficient visual acuity to see the hanging spatial cues used to find the submerged 
platform during training sessions. 
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Figure 6.6: Locomotor assessment after 9 months of statin treatment using the 
rotorod task. There were no discernable difference between the treatment groups 
in their ability to learn the (A) rotorod task over time or their performance during 
the (B) probe session (n=11/group).  
 
A. B. 
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 Seventy-two hours after the cue training on day 6, the groups began four days of 
training (3trials/day) absent the cue. There was a significant effect of SIMVA with 
respect to performance during the third trial of a given training session as measured by 
both latency and distance to the platform over the four days of training as shown in 
Figure 6.7B&C (repeated measure ANOVA; Fisher’s PLSD post hoc; p<0.05).  
 During the probe session there was an effect of SIMVA treatment on 
performance. The percentage of time spent in the goal quadrant during the first thirty 
seconds of the probe free swim as well as the number of times the animals entered the 
goal quadrant was significantly decreased in SIMVA-treated animals compared to CON 
groups (Figure 6.8). 
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Figure 6.7:  MWM - Visual acuity and training assessment in rats treated for 9 
months with statins.  A. There was no significant difference between groups 
(n=11/group) during the three cue training sessions indicative of similar visual acuity 
across the three treatment groups with all animals showing a reduction in the latency 
to the platform over the course of cue training.  B. SIMVA rats had a significantly 
greater latency to the platform during the third trial of the respective training sessions 
over the four days as compared to both control animals and those treated with 
atorvastatin (F(2,84) = 3.9; p<0.05 repeated measure ANOVA, Fisher PLSD p<0.05). C. 
There was a SIMVA effect on the distance to the platform during the same trial 
(repeated measure 2-way ANOVA F(2,75) = 4.5; p<0.05, Fisher PLSD p<0.05).  
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Figure 6.8:  MWM - Memory retention during probe session in rats treated for 9 
months with statins.  A. Percentage of time during the first thirty seconds spent in 
each quadrant by the respective treatment groups (n=11/group).  The dotted line is set 
at 25%, the percentage of time that would be spent in each quadrant by chance.  B. 
SIMVA-treated animals spent a greater percentage of time during the first thirty 
seconds of the probe trial within the goal quadrant compared to controls (Kruskal-
Wallis, Dunn’s post hoc ** p<0.01).  C. SIMVA-treated rats entered the goal 
quandrant significantly less than did controls during  the probe  (one-way ANOVA, 
Tukey post hoc test **p<0.01).  
 
A. 
B. C. 
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Brain Cholesterol Levels 
  Cholesterol levels were measured from cortical tissue from all the animals in the 
study using LC-MS.  Cholesterol levels were significantly reduced after 9 months of 
treatment, with the majority of measured cholesterol being of the unesterified species as 
has been previously found (Dietschy and Turley, 2004).  Cholesteryl esters species were 
negligible after saponification.  Cholesterol was reduced by about 30% by ATORVA 
(Figure 6.9).  The results reported here are  quantitatively comparable to those levels 
previously reported in the literature (Dietschy and Turley, 2004).  Quantities are reported 
at mg/gram of weight tissue.  
 
 
 
 
 
Figure  6.9: Quantitative analysis of cholesterol levels in cortical tissue from rats 
treated with statins for 9 months using LC-MS. There was a significant effect of drug 
on cholesterol levels in the brain (n=11/group; one-way ANOVA). Atorvastatin 
significantly reduced cholesterol levels as compared to controls (Tukey post hoc; 
**p<0.01). 
 
** 
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Microarray Analysis 
Long-term statin treatment with SIMVA and ATORVA upregulated 21 different 
genes and downregulated 31 and 25 different genes respectively.  SIMVA and ATORVA 
mutually upregulated 23 genes and downregulated 17 genes.  Supplemental tables listing 
all modulated genes can be found here: D:\Long-
term_Statin_microarray_supplement_table.pdf.   
The numbers of genes that are listed in Table 6.2 were exceptionally low and 
were selected based on a very stringent p-value (0.005) to insure a median false discovery 
rate (FDR) of 0.29.  As a result, the list of functional pathways modulated by statin 
treatment revealed by the original DAVID analysis was similarly brief.  To provide a 
larger pool of genes to use in a second DAVID analysis, the p-value cutoff was loosened 
to 0.015, which generated a gene list with a median FDR of 0.34.  The pathways 
described in Tables 6.3-6.4 represent those pathways found to be overrepresented by 
those genes with a p-value of 0.015 and a median FDR of 0.34. DAVID functional 
analysis (Table 6.3) revealed that SIMVA and ATORVA modulated distinctly different 
functional pathways, with SIMVA significantly upregulating genes involved in lipid 
biosynthetic pathways whereas ATORVA did not.   
 
 
 
 
Group Upregulated Downregulated 
Simvastatin 21 31 
Atorvastatin 21 25 
Modulated by Both 23 17 
 
 
 
Table 6.2:  Microarray analysis – number of genes found to be significantly 
modulated by 9 months of statin treatment.  A.   Number of genes significantly 
upregulated and downregulated at a p-value of 0.005, median FDR of 0.29 by both 
SIMVA and ATORVA after 9 months of treatment.   
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Upregulated by Simvastatin # p-value 
Sterol biosynthetic process (cytochrome P450-51, farnesyl diphosphate 
farnesyl transferase 1, sterol-C4-methyl oxidase-like, mevalonate decarboxylase, 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1, farnesyl diphosphate synthetase) 
8 2.23E-09 
Lipid metabolic process (acyl-coA synthetase short-chain family member 2, 
hydroxyacyl-CoA dehydrogenase trifunctional protein subunit A, thyroid hormone 
responsive) 
11 0.001341 
proteolysis (protease 26S subunit-ATPase 5, matrix metallopeptidase 9, ubiquitin 
specific peptidase 36, calpain 7) 
8 0.022094 
positive regulation of cellular metabolic process (cholecystokinin, 
activating transcription factor 4, RAR-related orphan receptor beta) 
6 0.033624 
Downregulated by Simvastatin # p-value 
Nervous system development (fasciculation and elongation protein zeta 2, 
ciliary neurotrophic factor, glutamate receptor-metabotropic 5) 
7 0.034699 
 
 
 
Upregulated by Atorvastatin # p-value 
Intracellular organelle part/Mitochondrial Part (sterol regulatory binding 
transcription factor, ATP-binding cassette, AC8, survival motor neuron, NADH 
dehydrogenase, mitochondrial ribosomal protein) 
20 0.001826 
Calcium ion binding/voltage-gated calcium channel complex   (calcium 
channel-voltage dependent, L type, alpha 1C subunit, cadherin 23, ninein, 
phospholipase, calcium channel, voltage-dependent, gamma subunit 5) 
7 0.045125 
Downregulated by Atorvastatin # p-value 
Response to chemical stimulus (solute carrier family 18 (vesicular monoamine) 
member 1, interleukin 6 receptor (alpha), adipose differentiation related protein, signal 
transducer and activator of transcription 5B, parkin) 
8 0.007404 
neurotransmitter transport (syntaxin 4A, parkin) 3 0.021786 
 
 
Table 6.4:  DAVID functional analysis – functional pathways significantly 
modulated by 9 months of atorvastatin  treatment.     
Table 6.3:  DAVID functional analysis – functional pathways significantly 
modulated by 9 months of simvastatin treatment.   
150 
 
Discussion 
Long-term treatment of mid-aged rats for 9 months with two statins which differ 
in lipid solubility (simvastatin being more lipophilic than atorvastatin) revealed very 
distinct effects on the brain (discussed below).  Statin-specific effects were also observed 
with short-term statin treatment (1-2 months).  These initial studies showed a significant 
enhancement of LTP only in simvastatin-treated animals.  Yet both statins reduced the 
duration of the AHP (afterhyperpolarization).  The AHP is associated with cognitive 
processes and aged animals with impaired memory also have larger AHPs (Landfield, 
Pitler, 1984; Tombaugh et la., 2005; Gant et al., 2006).  The link between hippocampal-
dependent memory and the size of the AHP was demonstrated in a series of studies by 
Disterhoft and colleagues (Disterhoft et al., 1986; Moyer et al., 1990; Power et al., 1997).  
Typically, a reduction in the AHP would be associated with an increase in excitability 
and neuronal firing and, thus, would be expected to facilitate LTP.  In the present studies, 
such results were seen only with simvastatin, with atorvastatin only reducing the AHP, 
suggesting that statins may not have mutual effects on pathways that modulate the AHP 
and LTP.  It is important to note that the AHP represents an electrophysiological response 
of an individual neuron.  LTP, on the other hand, represents a synaptic response of a 
population of neurons and is dependent on the integration of multiple signaling pathways 
which control and fine-tune plasticity.  Thus, it may not be surprising that occasionally 
changes in the AHP are not associated with corresponding changes in LTP.  These results 
raise the question of what might be the basis for the statin-specific effects on LTP. One 
potential mechanism may be found in the different pattern of hippocampal gene 
expression observed in the animals that were treated with the long-term statins (see 
below).  Alternatively, there may be a selective effect of statins on membrane cholesterol.   
Long-Term Statins and Reductions in Brain Cholesterol.  We found that very 
long-term treatment (9 months) with simvastatin and atorvastatin reduced brain 
cholesterol by ~15% and 30%, respectively (Figure 6.9).  However, the reduction in brain 
cholesterol was significant only with atorvastatin.  Long-term statin treatment may reduce 
brain cholesterol by two different mechanisms.  A statin (e.g., simvastatin) that crosses 
the blood brain barrier (BBB) more readily could potentially have a greater effect on 
inhibiting cholesterol synthesis in the brain than another that is less lipophilic (e.g., 
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atorvastatin).  Alternatively, even though it may be against conventional thought, brain 
cholesterol may be affected by peripheral cholesterol levels.  Thus, independent of its 
lipophilicity, any statin could possibly cause cholesterol depletion of the brain, indirectly, 
by significantly reducing peripheral cholesterol levels.  Such a reduction in peripheral 
levels could create a significant cholesterol concentration gradient across the BBB, 
thereby, facilitating efflux of cholesterol from the brain.  Our microarray results suggest 
that the two statins have very different effects on hippocampal gene expression and that 
both of the mechanisms mentioned above may be playing a role in modulating brain 
cholesterol concentrations.  Simvastatin, but not atorvastatin, significantly upregulated 
genes in the cholesterol biosynthesis pathway, perhaps in an attempt to compensate for 
the chronic inhibition of HmG-CoA reductase (Figure 6.13).  The microarray results, 
along with measures of brain and serum peripheral cholesterol, would seem to indicate 
that two statins are depleting cholesterol in different ways.  In addition to inhibiting 
peripheral cholesterol synthesis, the more lipophilic simvastatin crosses the BBB and 
directly inhibits cholesterol synthesis. Comparatively, brain cholesterol synthesis would 
be inhibited to a lesser degree with the less lipophilic atorvastatin, perhaps reflected by a 
lack of upregulation of cholesterol biosynthesis genes.  Like simvastatin, atorvastatin 
lowers serum cholesterol levels (and triglycerides) significantly (Table 6.1 and Figure 
6.5), creating a cholesterol sink in the periphery. Together, these results may provide an 
explanation for the significant decrease in brain cholesterol in the atorvastatin animals 
(Figure 6.9).  In these animals, cholesterol synthesis is not upregulated in the brain as it is 
with simvastatin and, therefore, the brain is unable to compensate for the cholesterol loss 
to the periphery. The low levels of triglycerides in the periphery could also be acting to 
pull triglycerides from the brain as well, reducing available acetyl-CoA precursor needed 
for cholesterol synthesis.  
Effects on LTP.  These differences may also help to explain the different effects 
seen with short-term treatment (1-2 months) on LTP where simvastatin, but not 
atorvastatin, increased LTP (Figure 6.1).  A prior study has shown that isoprenoids,  
byproducts of cholesterol synthesis via the mevalonate pathway, play an important role in 
the induction and maintenance of LTP (Kotti et al., 2006).  Inhibition of hippocampal 
LTP, following acute treatment of slices with a statin, was found to be due to a reduction 
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in levels of geranlygeraniol, an isoprenoid in the mevalonate pathway.  In addition to an 
upregulation of cholesterol synthesis, our microarray results also show that simvastatin, 
but not atorvastatin, upregulated genes involved in the formation of the isoprenoids 
essential for LTP (Figure 6.10).  Thus, this action of simvastatin, observed with long-
term treatment, may be the underlying basis for the robust effect on LTP. 
 
 
Effects on Behavior.  Yet, these results on LTP after short-term treatment are 
seemingly at odds with those observed in animals treated with long-term statins.  After 9 
months of treatment, animals treated chronically with simvastatin performed more poorly 
on the MWM.  As LTP was not measured at 9 months, it is not known whether the 
positive effects of simvastatin on LTP are still present.  If effects on LTP were still 
maintained at 9 months, then there would appear to be an apparent dissociation between 
the LTP results and the impaired memory as reflected by behavior in the MWM at 9 
months.  These results may reflect a competing process induced by chronic cholesterol 
depletion and the activation of an astrocyte/myelinogenic pathway known to correlate 
with cognitive impairment in brain aging (Blalock et al., 2003; Rowe et al., 2007; Kadish 
et al., 2009). This is supported by recently obtained IHC results indicating that 
simvastatin treated rats had activated,  hypertrophic astrocytes in the stratum radiatum of 
the hippocampus as indicated by significantly greater GFAP staining (Figure 6.11).  
Furthermore, simvastatin appeared to selectively increase a myelin marker, CNPase, in 
the same brain region (Figure 6.12).  An integrative model taking into consideration the 
effects on behavior, plasticity and gene expression is shown in Figure 6.14.     
Figure 6.10.  Simvastatin induced increase in genes involved in isoprenoid 
production.  Upregulated genes are shown in red. 
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 Statin Effects in Humans.  The compensatory mechanisms seen in the present 
studies may also be present in humans. A small pilot study in hypercholesterolemic 
patients at risk for AD showed that treatment with either simvastatin or atorvastatin 
reduces serum cholesterol and also results in a corresponding decrease in CSF cholesterol 
levels (reflecting brain cholesterol) during the initial 6 months of treatment.  However, 
after this initial treatment period, the CSF levels return to nearly baseline levels.  The 
same decrease followed by a return to baseline is seen with measures of CSF lathosterol 
and 24S-hydroxycholesterol, representing markers of cholesterol synthesis and 
degradation, respectively (Evans et al., 2009).  Similar results have been observed in 
subjects with normal cholesterol levels following statin treatment (Fassbinder et al., 
2002).  These results are consistent with a turnover rate for brain cholesterol estimated to 
be ~6 months, the time frame during which a return to baseline levels was seen in the 
CSF.  The parallel drop in 24S-hydroxycholesterol levels suggest that the CNS is 
compensating for a reduction in synthesis by decreasing cholesterol breakdown, thus 
allowing it to maintain some level of brain cholesterol. However, as the effects of 
turnover are gradually experienced by the brain, the brain attempts to compensate by 
increasing synthesis, thus overriding the effects of chronic statin treatment on the brain.  
The degree to which such processes occur may depend on duration of treatment as well 
as the type of statin.   
The implications of the results of the present study need to be considered within 
the context of human brain aging and associated neurodegenerative disorders such as AD.  
Recent calls urge more aggressive and earlier treatment of hypercholesterolemia with 
statins in order to reduce age-related cardiovascular risk factors (Steinberg et al., 2008).  
This approach would appear to have a beneficial effect on the brain as well, given a 
recent study showing that high serum cholesterol levels at mid-life increases risk for AD 
as well as vascular dementia (Solomon et al., 2009).  However, this aggressive approach 
must also take into consideration another recent report showing that lower serum 
cholesterol levels after the age of 65 seem to be predictive of impaired cognitive 
functioning (van den Kommer et al., 2009).  Our results, coupled with those in the 
literature, would suggest that more caution be exercised when prescribing statins to the 
elderly and that reports of cognitive impairment on a statin be taken seriously.  The 
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results presented here suggest that chronic use of a lipophilic statin that can more readily 
penetrate the BBB may be more deleterious to cognition than a less lipophilic statin. 
There are, undoubtedly, many beneficial effects of statins in the periphery and the present 
studies also show potentially beneficial effects in the brain (e.g., increased LTP).  Reports 
showing that lower cholesterol levels later in life may increase risk of cognitive decline 
may indicate that statins should not be given for very long periods (e.g., years) , but 
rather intermittingly for shorter periods during mid-life.  This type of more limited 
treatment could potentially confer reduced risk of heart attack and stroke and potentially 
reduce the risk of developing AD later in life.  
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Figure 6.11: GFAP staining in the stratum radiatum of rats treated for nine months 
with atorvastatin or simvastatin.  IHC images reveal activated hypertrophic astrocytes 
within the stratum radiatum of SIMVA-treated rats.  Semiquantitative analysis of the 
optical density measures within the hippocampi of SIMVA-treated animals revealed 
significantly higher levels of GFAP (one-way ANOVA, Tukey post hoc; p<0.05).   
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Figure 6.12: CNPase staining in the stratum radiatum of rats treated for nine 
months with atorvastatin or simvastatin.  IHC Semiquantitative analysis of the 
optical density measures within the hippocampi of SIMVA-treated animals revealed 
significantly higher levels of CNPase indicative of myelogenesis (one-way ANOVA, 
Tukey post hoc; p<0.05).   
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Figure 6.13:  Specific effect of simvastatin on genes within the cholesterol 
biosynthetic pathway. Genes labeled in red and green are significantly 
upregulated or downregulated respectively at a p<0.005 with median FDR of 0.29.  
Genes shaded in pink were significant at a p<0.015, but with a median FDR at 
0.34. David functional analysis also indicated a significant modulation in the 
cholesterol biosynthetic pathway by SIMVA treatment.  This indicates perhaps a 
compensatory upregulation of genes involved in cholesterol synthesis upon 
inhibition of HmG-CoA reductase both upstream and downstream of the targeted 
site of drug action. 
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Figure 6.14: Speculative model of the effects of long-term statin treatment on the 
aging brain.  Brain cholesterol depletion leads to the simvastatin-selective increase in 
cholesterol synthesis pathways in the brain, which can potentially improve early LTP, 
but also increases astrocytic activation, mimicking processes observed in the normal 
aging brain, thus acting to increase the  rate of cognitive decline.  
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Overall Conclusions 
 
We originally proposed to elucidate the role lipid metabolism plays in normal and 
pathological brain aging.   The work was driven by two main hypotheses: 1). Chronically 
activating the liver X receptor (LXR), which in turn drives the expression of genes 
involved in cholesterol metabolism, transport, and efflux will reduce pathology and 
cognitive deficits associated with AD as modeled in mice, and 2). Chronically inhibiting 
cholesterol synthesis in mid-aged rats, at an age when signs of brain aging begin to 
appear, will attenuate cognitive deficits and electrophysiological correlates in the aging 
brain.   
 The studies were, by design, two-pronged in nature.  To test the first hypothesis, a 
potent LXR agonist was administered chronically to two different transgenic AD mouse 
models, which were then assessed using a battery of measures, including memory 
paradigms, electrophysiological  measures of synaptic plasticity (LTP) and neuronal 
excitability (AHP), brain pathology assessment, and extensive microarray analysis.  To 
test the second hypothesis, we chronically treated mid-aged Fischer 344 rats with two 
different HMG-CoA reductase inhibitors (statins) and used similar techniques and 
outcome measures 
 Besides providing insight into the role that cholesterol metabolism plays in aging 
and neurodegenerative disease, the results from these studies, also have far-reaching 
clinical implications with respect to both interventions.  LXR agonists have been 
considered as a possible therapy for atherosclerosis as well as AD (Repa and 
Mangelsdorf, 2002; Bruemmer and Law, 2005; Geyeregger et al., 2006; Zelcer et al., 
2007), yet, there have been few studies that have treated animal models for the length of 
time presented here and they typically do not report any peripheral side effects. Statins 
are among the most widely prescribed drugs in the United States and simvastatin is 
available over-the-counter in much of Europe.  Even with prescriptions in the millions, 
very few studies, especially long-term intervention studies, as the one described here, 
have been completed which focus on effects on the brains.   
 The LXR agonist used in both the 3xTg- and 2xTg-AD models is very potent but 
has very reliable effects on gene expression which likely underlie decreases in AD-
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associated pathologies and apparent improvements in cognition in AD mouse models 
(Sun et al., 2003; Koldamova et al., 2005; Riddell et al., 2007).  Also consistent with 
some of the gene pathways targeted in the brain (e.g.,  fatty acid synthase), is the 
observation of severe peripheral side effects including liver steatosis and cardiac 
hypertrophy.  These effects likely represent actions  of the LXR agonist at the same target 
pathways in the periphery.  Despite some potentially beneficial effects in the brain (e.g., 
the positive effect on behavior), the peripheral side effects raise doubts as to whether this 
drug could ever be used clinically.  Interestingly, much of what LXR agonist treatment 
does in the brain mirrors many of the molecular changes that occur in the brain at midlife. 
As stated before, LXR-β is upregulated at midlife in rats along with cholesterol 
trafficking perhaps as a compensatory mechanism (Rowe et al., 2007; Kadish et al., 
2009).  Therefore, by chronically activating LXR a situation is created in the brain that 
mimics many of the molecular alterations seen at midlife.  This includes upregulation of 
Apoe and Srebf as well as genes associated with acyltransferase activity (possessing 
similar cholesterol storage promoting properties as SOAT1), which were found to be 
present at higher levels in the brains of aging rats.  Normally, the LXR pathway is 
upregulated in response to higher concentrations of cholesterol, which as noted above, 
may be the case for the aging brain.  In the aging brain, such an upregulation of this 
pathway may be compensatory, yet the effects of such an upregulation may contribute to 
age-related deficits; thus chronic activation of this pathway may have the unintended 
effect of creating a premature aging effect.  
 Similarly, statins present with their own set of potential problems with long-term 
use.  The study design reflects circumstances in which statins are prescribed in a patient 
population which are typically initiated at midlife and maintained for a chronic (often 
indefinite) period. Such a study has not been carried out in rodents, and because of this, 
several of our findings appear compelling as well as novel. First, unlike prior 
observations showing no change in serum  cholesterol levels with in vivo statin treatment, 
decreases in peripheral cholesterol levels were detected following chronic  treatment in 
aged rats. Secondly, statins were able to reduce brain cholesterol concentrations. Finally, 
statins with differing lipophilicities had different effects on the brain in relation to both 
cholesterol levels as well as on cognition. But, where many epidemiological studies have 
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suggested that a more lipophilic statin, like simvastatin would confer greater benefit on 
cognition and reduce AD risk, it was found that in fact simvastatin, after very long-term 
chronic treatment, appeared to be detrimental to the brain.  Animals treated with 
simvastatin performed worse on the memory recall components of the MWM, had greater 
GFAP staining in the hippocampus indicative of astrocyte reactivity (and a marker of 
brain aging) and had greater CNPase staining in the hippocampus suggestive of increased 
myelinogenesis. Simvastatin also had a selective effect on the upregulation of cholesterol 
synthesis pathways as well. Again, we see similarities between a select drug effect and 
normal aging. Thus, the effects of simvastatin are similar to  those of aging including the 
associated decrease in memory, increase in astrocyte reactivity, and increase in 
myelinogenesis.  In  fact, in some respects, it appeared to produce an accelerated aging  
phenotype.  Neither statin, simvastatin nor atorvastatin conferred any detectable benefit 
to the aging brain, but atorvastatin failed to exacerbate deficits.   
 With both the LXR agonist and the statins, two different aspects of cholesterol 
metabolism were modulated, cholesterol trafficking (transport and efflux) and synthesis.  
Interestingly, both treatments appeared to potentiate some aspects of brain aging.  
Perhaps both approaches are affecting cholesterol trafficking and myelinogenesis, 
suggesting that cognitive deficits first appearing at mid-age may be attributed to the 
dysregulation of the movement and deposition of cholesterol within the brain, which in 
turn affects myelinogenic processes.  As the brain ages, the degradation of myelin about 
axons along with remyelination of these axons continues.  This can lead to the re-
myelination of already myelinated fibers along with changes in nodal size and proximity, 
both of which can reduce signaling efficiency along the fiber (Peters 2009).  
 It is possible that as the brain ages, and cholesterol levels become excessive, that 
some of this brain cholesterol is stored as myelin.  This would require the efflux of 
cholesterol from astrocytes to oligodendrocytes ensheathing axons using mechanisms 
enabled by activation of the LXR pathway.  In the case of chronic simvastatin use, we see 
a compensatory upregulation of genes involved in cholesterol synthesis which likely 
takes place in brain astrocytes.   This upregulation of cholesterol biosynthesis, in the 
context of an aging brain, may result in a  reactive astrocyte phenotype and upregulated 
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myelinogenesis, which may potentially occur in response to the presence of excess free 
cholesterol.   
 Accordingly, these results do not support the long-term use of either an LXR 
agonist or a lipophilic statin for brain aging.  The risks involved in using the potent LXR 
agonist TO901317 outweigh any perceived benefit, but the role that the LXR pathway 
plays in reducing AD-associated pathologies is still interesting and is worthy of further 
exploration. Perhaps more selective targeting of specific mechanistic components within 
its target pathways would prove to confer the benefits without the peripheral side effects.  
The known benefits of statins in the reduction of cardiovascular disease cannot be 
ignored or denied.  Further, it would be unwise to disregard the potential benefits of an 
increase in brain perfusion due to reduced atherosclerosis occurring with statin therapy.  
Improved perfusion may be contributing to the observed statin-associated reduced risk of 
AD later in life.  Nevertheless, our studies do suggest that long-term treatment with a 
lipophilic statin could be detrimental within the context of normal aging.  Perhaps the use 
of a less lipophilic statin, one that is able to confer lipid-lowering effects in the periphery 
without promoting some aspects of brain aging, would be preferred.   
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